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1 Introduction 
1.1 Alkyl Groups in Natural Products and Pharmaceuticals 
 
Compounds bearing alkyl groups have received significant attention in various fields of 
organic chemistry. This is due to their abundance in natural compounds, such as steroids, 
alkaloids, polyketides, lipids, as well as in the side-chain of peptides (Scheme 1).1 Estradiol 
(1), for example, is not only relevant for regulation of the ovarian cycle, but is also, along 
with other estrogenes, linked to breast and ovarian cancer growth. Erythromycin (2) and 
derivatives thereof have shown anti-biotic activity. Vitamin E (4) inactivates reactive oxygen 
species, in order to avoid cell damages, such as oxidation of unsaturated membrane lipids. 
 
Scheme 1: Selection of natural compounds containing aliphatic groups. 
Therefore, aliphatic chains and cycles with various substitution patterns and functional 
groups can be commonly found in a wide range of top-selling drugs and pharmaceuticals 
(Scheme 2).2 
                                                          
1
 (a) Berg, J. M.; Tymoczko, J. L.; Stryer, L. Biochemistry, 7th int. ed., E. H. Freeman and Company, New York, 
2012. (b) Leeper, F. J.; Vederas, J. C. Biosynthesis: Polyketides and Vitamins, Springer Verlag, Berlin, 2000. (c) 
Kibwage, I. O.; Hoogmartens, J.; Roets, E.; Vanderhaeghe, H.; Verbist, L.; Dubost, M.; Pascal, C.; Petitjean, P.; 
Levol, G. Antimicrob Agents Chemother. 1985, 28, 630–633. (d) Kittakoop, P.; Mahidol, C.; Ruchirawat, S. Curr 
Top. Med. Chem. 14, 2, 239–252. (e) Ricketts M. L.; Boekschoten M. V.; Kreeft A. J.; Hooiveld G. J.; Moen C. J.; 
Müller M.; Frants R. R.; Kasanmoentalib S.; Post S. M.; Princen H. M.; Porter J. G.; Katan M. B.; Hofker M. H.; 
Moore D. D. Mol. Endocrin. 2007, 21 , 1603–1616. 
2
 (a) McGrath, N. A.; Brichacek, M.; Njardarson, J. T. J. Chem. Ed. 2010, 87, 1348–1349. (b) Aggarwal, R. K.; 
Showkathali, R. Expert Opin. Pharmacother. 2013, 14, 1–13. (c) Sanford, M. Drugs 2014, 74, 1411–1433. (d) 
Chen, M.-J.; Cheng, C.-Y.; Chen, Y.-C.; Chou, C.-K.; Hsu, W.-M. J. Ocul. Pharmacol. Ther. 2006, 22, 188–193. 
1 Introduction 
- 2 - 
 
 
Scheme 2: Selection of marketed drugs containing aliphatic moieties. 
One particularly noteworthy effect of alkyl groups within medicinal chemistry is the so-called 
“magic methyl” effect. .3Usually, when a methyl group is added to a compound, an increase 
of biological potency of up to tenfold can be expected. This can usually be attributed to 
hydrophobic and desolvation effects. However, in some cases, the potency increase can be 
as high as two orders of magnitude, which is then labeled as the aforementioned “magic 
methyl” effect (Scheme 3). Such an extreme effect usually occurs, when the introduction of 
the methyl group causes the unbound compound to assume a shape complementary to the 
bound form in the target’s active site. Thus, the conformational change to achieve binding in 
the active site is minimised. 
 
 
Scheme 3: Boost in potency by introduction of a methyl group. 
In addition to this effect there is also a particular interest within pharmaceutical research for 
developing fluorinated analogues of bioactive compounds. Such compounds may show 
significantly altered chemical reactivity, but it has also been shown that the introduction of 
fluorine atoms into biologically active molecules has a profound and complex impact on 
their metabolic behaviour. Special interest has been given in medicinal chemistry to the 
introduction of trifluoromethyl groups. However, fluorinated, marketed drugs are still rather 
                                                          
3
 Schönherr, H.; Cernak, T. Angew. Chem. Int. Ed. 2013, 52, 12256–12267, and references cited therein. 
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scarce, as suitable methodologies for the introduction of fluorinated groups are still being 
developed.4 A selection of fluorine-containing, marketed drugs is shown in Scheme 4.5 
 
Scheme 4: Selection of fluorine-containing, marketed drugs. 
 
 
1.2 Alkylations through traditional Cross-Coupling Reactions 
 
As mentioned in the previous chapter, C–C bond forming reactions for the synthesis of 
alkylated scaffolds have always been of highest importance within organic synthesis. In the 
last few decades focus has been particularly on transition metal-catalyzed cross-coupling 
reactions. Early examples for cross-coupling reactions include the Glaser coupling6 and the 
Ullman coupling7 (Scheme 5). These reactions, however, apart from being limited to aryl and 
                                                          
4
 Zhu, W.; Wang, J.; Wang, S.; Gu, Z.; Acena, J. L.; Izawa, K.; Liu, H.; Soloshonok, V. A. J. Fluorine Chem. 2014, 
167, 37–54. 
5
 (a) Sanders, S.; Harsidangkul, V. Am. J. Med. Sci. 2002, 323, 190–193. (b) Cespedes, M. S.; Aberg, J. A. Drug Saf. 
2006, 29, 865–874. (c) Gadsby, R. Clin. Med. Ther. 2009, 1, 53–62. (d) Hargreaves, R.; Ferreira, J. C. A.; Hughes, 
D.; Brands, J.; Hale, J.; Mattson, B.; Mills, S. Ann. N. Y. Acad. Sci. 2011, 1222, 40–48. (e) Behm, B. W.; Peura, D. A. 
Expert Rev. Gastroenterol. Hepatol. 2011, 5, 439–445. (f) Field, S. K. Expert Opin. Investig. Drugs 2008, 17, 811–
818. (g) Hakimian, S.; Cheng-Hakimian, A.; Anderson, G. D.; Miller, J. W. Expert Opin. Pharmacother. 2007, 8, 
1931–1940. 
6
 Glaser, C. Justus Liebigs Ann. Chem. 1870, 154, 137–171. 
7
 (a) Ullman, F.; Bielecki, J. Ber. Dtsch. Chem. Ges. 1901, 34, 2174–2185.; A review: (b) Hassan, J.; Sevignon, M.; 
Gozzi, C.; Schulz, E.; Lemaire, M. Chem. Rev. 2002, 102, 1359–1469. 
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alkyne moieties, could originally only proceed by utilisation of stoichiometric amounts of 
transition metals. 
 
Scheme 5: General reaction equation for (a) the Glaser coupling and (b) the Ullman coupling. 
The first step towards catalyzed reactions was first achieved by Job in the early 1920s. 8 He 
found that a solution of phenyl magnesium bromide does not react with ethylene gas, unless 
anhydrous nickel dichloride is introduced. Furthermore, he showed that the uptake of 
ethylene gas in the reaction is solely dependent on the amount of Grignard reagent and not 
on the amount of nickel dichloride. Although this yielded a mixture of ethylbenzene, styrene, 
biphenyl and other hydrocarbons, Job thus proved that nickel dichloride could be used for 
such reactions in catalytic quantities. Two decades later, Kharasch conducted investigations 
on the cobalt-catalyzed C–C bond formation of aryl Grignard reagents with both aryl 
bromides and vinyl bromides to yield the corresponding biphenyls and styrenes.9 Significant 
advancements in this type of reaction were achieved in the 1970s with the extension of 
cross-coupling reactions towards the use of palladium- and nickel-catalysis. The most 
commonly employed catalytic cross-coupling reactions include the Kumada-Corriu coupling, 
Negishi coupling, Suzuki-Miyaura coupling, Migita-Kosugi-Stille coupling, Hiyama coupling, 
Mizoroki-Heck reaction and Sonogashira-Hagihara coupling (Scheme 6).10 The importance of 
these advancements were significant enough so that in 2010 professors Akira Suzuki, Ei-ichi 
Negishi and Richard Frederick Heck were honoured with the Nobel prize in Chemistry for 
their contributions to the field of palladium-catalyzed cross-coupling chemistry.11 
 
                                                          
8
 Job, A.; Reich, R. C. R. Hebd. Seances Acad. Sci. 1924, 179, 330–332. 
9
 (a) Kharasch, M. S.; Fields, E. K. J. Am. Chem. Soc. 1941, 63, 2316–2320. (b) Kharasch, M. S.; Fuchs, C. F. J. Am. 
Chem. Soc. 1943, 65, 504–507. 
10
 Selected review: Johansson Seechurn, C. C. C.; Kitching, M. O.; Colacot, T. J.; Snieckus, V. Angew. Chem. Int. 
Ed. 2012, 51, 5062–5085. 
11
 http://www.nobelprize.org/nobel_prizes/chemistry/laureates/2010 (accessed December 6th, 2015). 
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Scheme 6: General equations for transition metal catalysed cross couplings reactions. 
The widely accepted catalytic cycle for most of cross-coupling reactions consist of an 
oxidative addition of the organic halide to the catalyst, transmetalation with an 
organometallic reagent, followed by a reductive elimination (Scheme 7a). In the case of the 
Mizoroki-Heck reaction, the oxidative addition is followed by a syn-addition to the olefin, 
syn--hydride elimination and reductive elimination (Scheme 7b).12 
 
Scheme 7: Catalytic cycles for (a) cross coupling and (b) Heck reactions. 
                                                          
12
 Kürti, L.; Czakó, B. Strategic Applications of Named Reactions in Organic Synthesis, Elsevier Inc., London, 2005. 
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Initially, these transformations were limited to the coupling of sp2- or sp-hybridized-carbon 
centres, with the exception of the nickel-catalysed Kumada-Corriu coupling. The 
corresponding alkylation coupling reactions proved more challenging due to the tendency of 
the alkylated intermediates to undergo -hydride elimination, thus forming undesired 
olefinic side products.13 In subsequent years, many new protocols for alkylation coupling 
reactions have been developed.14 These cross-coupling reactions have found numerous 
applications in total synthesis,15 as well as in industrial settings.16 
 
 
1.3 Transition-metal catalyzed C–H functionalization 
 
Despite the enormous advances achieved by the previously discussed cross-coupling 
reactions, limitations still need to be addressed. For traditional cross-coupling reactions 
organic halides, as well as a organometallic reagents, are required. Therefore pre-
functionalisation of substrates was necessary. These pre-functionalisation steps, along with 
the cross-coupling itself, are each accompanied with the generation of stoichiometric 
amounts of by-products and metal waste.  
Due to spiralling costs and dwindling resources sustainability has become a major focus in 
both industry and society in general.17 Nonetheless, the goal of more efficient, atom-
economical strategies were already pointed out in the early 1990s by Barry Trost.18 Among 
possible solutions were the development of C–H functionalisation reactions via 
organometallic C–H bond activation. These type of reactions can be divided into three 
categories (Scheme 8).19 
                                                          
13
 Ackermann, L. Chem. Commun. 2010, 46, 4866–4877. 
14
 (a) Tollefson, E. J.; Hanna, L. E.; Jarvo, E. R. Acc. Chem. Res. 2015, 48, 2344–235. (b) Cherney, A. H.; Kadunce, 
N. T.; Reisman, S. E. Chem. Rev. 2015, 115, 9587–9652. (c) Netherton, M. R.; Fu, G. C. Adv. Synth. Catal. 2004, 
346, 1525–1532. 
15
 (a) Hong, A. Y.; Stoltz, B. M. Eur. J. Org. Chem. 2013, 2745–2759. (b) Majumdar, K. C.; Sinha, B. Synthesis 2013, 
45, 1271–1299. (c) Sasaki, M. Bull. Chem. Soc. Jpn. 2007, 80, 856–871. 
16
 (a) Xu, S.; Kim, E. H.; Wei, A.; Negishi, E. Sci. Technol. Adv. Mater. 2014, 15, 044201. (b) Corbet, J.-P.; Mignani, 
G. Chem. Rev. 2006, 106, 2651–2710. (c) Dumrath, A.; Lübbe, C.;Beller, M. Palladium-Catalyzed Cross-Coupling 
Reactions – Industrial Applications, in Palladium-Catalyzed Coupling Reactions: Practical Aspects and Future 
Developments, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2013. (d) Torborg, C.; Beller, M. Adv. Synth. 
Catal. 2009, 351, 3027–3043. 
17
 Sheldon, R. A. Chem. Soc. Rev. 2012, 41, 1437–1451. 
18
 Trost, B. M. Science 1991, 254, 1471–1477. 
19
 Ackermann, L; Vicente, R.; Kapdi, A. R. Angew. Chem. Int. Ed. 2009, 48, 9792–9826. 
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Scheme 8: Comparison of C–H functionalisation strategies. 
Friedel-Crafts-alkylation represents an early example of the synthesis of alkylated arenes 
(Scheme 9).20 
 
Scheme 9: General equation for the Friedel-Crafts-Alkylation. 
It is, however, not considered as C–H activation, because C–H activations rely on 
organometallic intermediates. The term C–H activation is commonly applied to reactions, in 
which the active metal catalyst performs a direct C–H metalation.21  For these C–H 
metalations, five mechanistic scenarios have so far been widely accepted (Scheme 10).22 
                                                          
20
 Bandini, M.; Umani-Ronchi, A. Catalytic Asymmetric Friedel-Crafts Alkylations, Wiley-VCH Verlag GmbH & Co. 
KGaA, Weinheim, 2009. 
21
 (a) Sezen, B.; Sames, D. What is C–H bond activation, in Handbook of C—H transformations, Wiley-VCH 
Verlag GmbH & Co. KGaA, Weinheim, 2005. (b) Shilov, A. E.; Shul’pin, G. B. Chem. Rev. 1997, 97, 2879–2932. 
22
 (a) Ackermann, L. Chem. Rev. 2011, 111, 1315–1345. (b) Balcells, D.; Clot, E.; Eisenstein, E. Chem. Rev. 2010, 
110, 749–823. (c) Boutlada, Y.; Davies, D. L.; Macgregor, S. A.; Poblador-Bahamonde, A. I. Dalton Trans. 2009, 
5820–5831. 
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Scheme 10: Mechanistic pathways for C–H activation. 
The oxidative addition mechanism usually occurs in the case of electron-rich, low-valent late-
transition metal catalysts, such as iridium, platinum and ruthenium. For the σ–bond 
metathesis pathway early transition metals and lanthanoids are typically employed. 
Somewhat similar mechanistically is the 1,2 addition, where a heteroatom is a hydrogen 
acceptor, is implemented by early or mid transition metals. For electrophilic substitution 
processes the metal catalyst reacts as a Lewis acid, most commonly with a hydroxy or alkoxy 
ligand.22b The base-assisted deprotonation, for example, uses secondary phsphine oxides or 
carboxylates, acting as an internal base. This pathway has been called either concerted 
metalation-deprotonation pathway or ambiphilic metal ligand activation.22a The latter two 
mechanistic pathways have also been investigated and illuminated in detail through DFT 
studies.22a,c 
Selectivity is of key importance in C–H activation chemistry. The organic compounds of 
interest possess many C–H bonds of comparable dissociation energy and therefore achieving 
chemo- and regioselectivity is challenging. In order to differentiate between various 
chemically similar C–H bonds several strategies have been developed. These include 
differentiation through assistance of a Lewis-basic directing group within the substrate, 
differently electronically activated C–H bonds and sterical bulk in combination with catalyst 
control (Scheme 11).23 
                                                          
23
 Neufeldt, S. R.; Sanford, M. S. Acc. Chem. Res. 2012, 45, 936–946. 
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Scheme 11: Strategies for site-selectivity in C–H functionalisation via (a) lewis-basic directing group (b) electronic bias 
and (c) steric bulk with catalyst based control. 
Considering these various approaches a wide variety of catalytic C–H functionalisation 
reactions have been developed with transition metals employed including, for example, 
ruthenium, 24  rhodium, 25  palladium, 26  manganese, 27  iron, 28  cobalt 29  and nickel. 30 The 
transformations facilitated by these catalysts include alkenylations (Scheme 12a+b) and 
arylations (Scheme 12c).31 One of the earliest examples for an alkenylation reaction is the 
Fujiwara-Moritani reaction (Scheme 12a).32 However, in this case the arene (36) was 
required in large excess. Further development took advantage of directing groups to give 
rise to a variety of protocols for such transformations (Scheme 12b).33 Remarkably, using an 
                                                          
24
 Seminal works:(a) Lewis, L. N.; Smith, J. F. J. Am. Chem. Soc. 1986, 108, 2728–2735. (b) Murai, S.; Kakiuchi, F.; 
Sekine, S.; Tanaka, Y.; Kamatani, A.; Sonoda, M.; Chatani, N. Nature 1993, 366, 529–531. ;for recent reviews 
see: (a) Ackermann, L. Acc. Chem. Res. 2014, 47, 281–295. (b) De Sarkar, S.; Liu, W.; Kozhushkov, S. I.; 
Ackermann, L. Adv. Synth. Catal. 2014, 356, 1461–1479. (c) Kozhushkov, S. I.; Ackermann, L. Chem. Sci. 2013, 4, 
886–896. (d) Arockiam, P. B.; Bruneau, C.; Dixneuf, P. H. Chem. Rev. 2012, 112, 5879–5918. (f) Ackermann, L.; 
Vicente, R. Top. Curr. Chem. 2010, 292, 211–229. 
25
 (a) Ye, B.; Cramer, N. Acc. Chem. Res. 2015, 48, 1308–1318. (b) Song, G.; Li, X. Chem. Soc. Rev. 2012, 41, 
3651–3678. (c) Satoh, T.; Miura, M. Chem. Eur. J. 2010, 16, 11212–11222. (d) Colby, D. A.; Bergman, R. G.; 
Ellman, J. A. Chem. Rev. 2010, 110, 624–655. 
26
 (a) Qiu, G.; Wu, J. Org. Chem. Front. 2015, 2, 169–178. (b) Engle, K. M.; Yu, J.-Q. J. Org. Chem. 2013, 78, 8927–
8955. (c) Wencel-Delord, J.; Dröge, T.; Liu, F.; Glorius, F. Chem. Soc. Rev. 2011, 40, 4740–4761. (d) Yeung, C. S.; 
Dong, V. M. Chem. Rev. 2011, 111, 1215–1292. 
27
 (a) Liu, W.; Ackermann, L. ACS Catal. 2016, 6, 3743–3752 (b) Liu, W.; Zell, D.; John, M.; Ackermann, L. Angew. 
Chem. Int. 2015, 54, 4092–4096. (c) Liu, W.; Bang, J.; Zhang, Y.; Ackermann, L. Angew. Chem. Int. Ed. 2015, 54, 
14137–14140. (d) Liu, W.; Groves, J. T. Acc. Chem. Res. 2015, 48, 1727–1735. (e) Wang, C. Synlett 2013, 24, 
1606–1613. 
28
 (a) Mihovilovic, M. D.; Schnürch, M. ChemCatChem 2014, 6, 2194–2196. (b) Sun, X.; Li, J.; Huang, X.; Sun, C. 
Curr. Inorg. Chem. 2012, 2, 64–85. (c) Nakamura, E.; Yoshikai, N. J. Org. Chem. 2010, 75, 6061–6067. 
29
 (a) Moselage, M.; Li, J.; Ackermann, L. ACS Catal. 2016, 6, 498–525 (b) Gao, K.; Yoshikai, N. Acc. Chem. Res. 
2014, 47, 1208–1219. (c) Ackermann, L. J. Org. Chem. 2014, 79, 8948–8954. (d) Yoshikai, N. J. Synth. Org. Chem. 
2014, 72, 1198–1206. 
30
 (a) Castro, L. C. M.; Chatani, N. Chem. Lett. 2015, 44, 410–421. (b) Johnson, S. A. Dalton Trans. 2015, 44, 
10905–10913. 
31
 Selected examples: (a) Li, J.; Ackermann, L. Chem. Eur. J. 2015, 21, 5718–5722. (b) Diers, E.; Kumar, N. Y. P.; 
Mejuch, T.; Marek, I.; Ackermann, L. Tetrahedron 2013, 69, 4445–4453. (c) Yoshikai, N.; Matsumoto, A.; 
Norinder, J.; Nakamura, E. Angew. Chem. Int. Ed. 2009, 48, 2925–2928. (d) Satoh, T.; Kametani, Y.; Terao, Y.; 
Miura, M.; Nomura, M. Tetrahedron Lett. 1999, 40, 5345–5348.  
32
 (a) Moritani, I.; Fujiwara, Y. Tetrahedron Lett. 1967, 8, 1119–1122. (b) Fujiawara, Y.; Moritani, I.; Danno, S.; 
Asano, R.; Teranishi, S. J. Am. Chem. Soc. 1969, 91, 7166–7169. 
33
 Selected examples: (a) Wang, Y.; Li, C.; Li, Y.; Yin, F.; Wang, X.-S. Adv. Synth. Catal. 2013, 355, 1724–1728. (b) 
Ackermann, L.; Wang, L.; Wolfram, R. ; Lygin, A. V. Org. Lett. 2012, 14, 728–731. (c) Cai, G.; Fu, Y.; Li, Y.; Wan, 
X.; Shi, Z. J. Am. Chem. Soc. 2007, 129, 7666–7673. (b) Boele, M. D. K.; van Strijdonck, G. P. F.; de Vries, A. H. 
M.; Kamer, P. C. J.; de Vries, J. G.; van Leeuwen, P. W. N. M. J. Am. Chem. Soc. 2002, 124, 1586–1587. 
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appropriate directing group, alkenylation could also be achieved with meta-selectivity with 
regard to the directing group.34 
 
 
Scheme 12: (a) Fujiwara-Moritani reaction and (b) selected examples of directed C–H olefination and (c) arylation. 
A broad range of heterocycles have been accessed using C–H functionalisation via oxidative 
annulation reactions (Scheme 13). The stoichiometric oxidant in these reactions can either 
be another metal, such as copper,35 internal oxidants in the form of hetero-hetero-bonds36 
                                                          
34
 (a) Wang, X.-C.; Gong, W.; Fang, L.-Z.; Zhu, R.-Y.; Li, S.; Engle, K. M.; Yu, J.-Q. Nature 2015, 519, 334–338. (b) 
Tang, R.-Y.; Li, G.; Yu, J.-Q. Nature 2014, 507, 215–220. (c) Leow, D.; Li, G.; Mei, T.-S.; Yu, J-Q. Nature 2012, 486, 
518–522. 
35
 (a) Ackermann, L. Acc. Chem. Res. 2014, 47,281–295. (b) Pham, M. V.; Ye, B.; Cramer, N. Angew. Chem. Int. Ed. 
2012, 51, 10610–10614. (c) Satoh, T.; Miura, M. Chem. Eur. J. 2010, 16, 11212–11222. (d) Pham, M. V.; Ye, B.; 
Cramer, N. Angew. Chem. Int. Ed. 2012, 51, 10610–10614. (e) Song, G.; Chen, D.; Pan, C.-L.; Crabtree, R. H.; Li, X. 
J. Org. Chem. 2010, 75, 7487–7490. (f) Su, Y.; Zhao, M.; Han, K.; Song, G.; Li, X. Org. Lett. 2010, 12, 5462–5465. 
(g) Hyster, T. K.; Rovis, T. J. Am. Chem. Soc. 2010, 132, 10565–10569. (h) Guimond, N.; Fagnou, K. J. Am. Chem. 
Soc. 2009, 131, 12050–12051. (i) Ueura, K.; Satoh, T.; Miura, M. Org. Lett. 2007, 9, 1707–1409. 
36
 (a) Koornhaaß, C.; Kuper, C.; Ackermann, L. Adv. Synth. Catal. 2014, 356, 1619–1624. (b) Guimond, N.; 
Gorelsky, S. I.; Fagnou, K. J. Am. Chem. Soc. 2011, 133, 6449–6457. (c) Ackermann, L.; Fenner, S. Org. Lett. 2011, 
13, 6548–6551. (d) Guimond, N.; Gouliaras, C.; Fagnou, K. J. Am. Chem. Soc. 2010, 132, 6908–6909. 
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or, ideally, aerial oxygen.37 Apart from the relatively common annulation reactions towards 
six-membered heterocycles, it should be noted that the synthesis of compounds with other 
ring sizes through C–H functionalisation have also been achieved.38 
 
 
Scheme 13: General examples for oxidative annulations through C–H functionalisation. 
For direct C–H alkylations two approaches have been very common. One is the 
hydroarylation of olefins (Scheme 14a).24b,39 The use of electrophilic alkyl halides directly has 
also been demonstrated (Scheme 14b).13,40 
                                                          
37
 (a) Warratz, S.; Koornhaaß, C.; Cajaraville, A.; Niepötter, B.; Stalke, D. Ackermann, L. Angew. Chem. Int. Ed. 
2015, 54, 5513–5517. (b) Liegault, B.; Fagnou, K. Organometallics 2008, 27, 4841–4843. (c) Liegault, B.; Lee, D.; 
Huestis, M. P.; Stuart, D. R.; Fagnou, K. J. Org. Chem. 2008, 72, 5022—5028. (d) Stahl, S. S. Angew. Chem. Int. Ed. 
2004, 43, 3400–3420. 
38
 (a) Burns, D. J.; Lam, H. W. Angew. Chem. Int. Ed. 2014, 53, 9931–9935.(b) Seoane, A.; Casanova, N.; 
Quin͂ones, N.; Mascaren͂as, J. L.; Gulías, M. J. Am. Chem. Soc. 2014, 136, 834–837. (c) Stuart, D. R.; Alsabeh, P.; 
Kuhn, M.; Fagnou, K. J. Am. Chem. Soc. 2010, 132, 18326–18339. (d) Rakshit, S. Patureau, F. W.; Glorius, F. J. 
Am. Chem. Soc. 2010, 132, 8585–9587. (e) Stuart, D. R.; Bertrand-Laperle, M.; Burgess, K. M. N.; Fagnou, K. J. 
Am. Chem. Soc 2008, 130, 16474–16475. 
39
 (a) Schinkel, M.; Marek, I.; Ackermann, L. Angew. Chem Int. Ed. 2013, 52, 3977–3980. (b) Kozhushkov, S. I.; 
Yufit, D. S.; Ackermann, L. Org. Lett. 2008, 10, 3409–3412. (c) Kakiuchi, F.; Murai, S. Acc. Chem. Res. 2002, 35, 
826–834. 
40
 Selected examples: (a) Graczyk, K.; Haven, T.; Ackermann, L. Chem. Eur. J. 2015, 21, 8812–8815. (b) Zhu, R.-Y-
; He, J.; Wang, X.-C.; Yu, J.-Q. J. Am. Chem. Soc. 2014, 136, 13194–13197. (c) Fruchey, E. R.; Monks, B. M.; Cook, 
S. P. J. Am. Chem. Soc. 2014, 136, 13130–13133. (d) Ilies, L.; Matsubara, T.; Ichikawa, S.; Asako, S.; Nakamura, E. 
J. Am. Chem. Soc. 2014, 136, 13126–13129. (e) Gao, K.; Yoshikai, N. J. Am. Chem. Soc. 2013, 135, 9279–9282. (f) 
Punji, B.; Song, W.; Shevchenko, G. A.; Ackermann, L. Chem Eur. J. 2013, 19, 10605–10610. (g) Ackermann, L.; 
Hofmann, N.; Vicente, R. Org. Lett. 2011, 13, 1875–1877. (h) Ackermann, L.; Novák, P.; Vicente, R.; Hofmann, N. 
Angew. Chem. Int. Ed. 2009, 48, 6045–6048. 
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Scheme 14: Strategies for direct alkylations via C–H functionalisation. 
Beyond these C–C bond forming reactions it should be noted that C–X bond forming 
reactions have been thoroughly investigated, as well. These include C–H aminations,41 
oxygenations,42 halogenations43 and thiolations.44 
Given this plethora of procedures, C–H functionalisation reactions have become viable for 
implementation within the total synthesis of natural products. This is demonstrated in the 
synthesis of dragmacidin F (45) and hydratoaustamide (48) (Scheme 15).45  
                                                          
41
 Selected examples: (a) Minovilovic, M. D.; Schnürch, M. ChemCatChem 2014, 6, 2194–2196. (b) Gephart, R. 
T.; Warren, T. H. Organometallics 2012, 31, 7728–7752. 
42
 Selected examples: (a) Yang, W.; Chen, H.; Li, J.; Li, C.; Wu, W.; Jiang, H. Chem. Commun. 2015, 51, 9575–
9578. (b) Thirunavukkarasu, V. S.; Kozhushkov, S. I.; Ackermann, L. Chem. Commun. 2014, 50, 29–39. (c) Gary, J. 
B.; Cook, A. K.; Sanford, M. S. ACS Catal. 2013, 3, 700–703. (d) Gulevich, A. V.; Melkonyan, F. S.; Sarkar, D.; 
Gevorgyan, V. J. Am. Chem. Soc. 2012, 134, 5528–5531. 
43
 Selected examples: (a) Miao, J.; Yang, K.; Kurek, M.; Ge, H. Org. Lett. 2015, 17, 3738–3741. (b) Wang, L.; 
Ackermann, L. Chem. Commun. 2014, 50, 1083–1085. (c) Wang, X.-C.; Hu, Y.; Bonacorsi, S.; Hong, Y.; Burrell, R.; 
Yu, J.-Q. J. Am. Chem. Soc. 2013, 135, 10326–10329. (c) Whitfield, S. R.; Sanford, M. S. J. Am. Chem. Soc. 2007, 
129, 15142–15143. 
44
 Selected examples: (a) Vásques-Céspedes, S.; Ferry, A.; Candish, L.; Glorius, F. Angew. Chem. Int. Ed. 2015, 54, 
5772–5776. (b) Zhou, A.-X.; Liu, X.-Y.; Yang, K.; Zhao, S.-C.; Liang, Y.-M. Org. Biomol. Chem. 2011, 9, 5456–5462. 
45
 (a) Gark, N. K.; Caspi, D. D.; Stoltz, B. M. J. Am. Chem. Soc. 2004, 126, 9552–9553. (b) Baran, P. S.; Corey, E. J. J. 
Am. Chem. Soc. 2002, 124, 7904–7905. 
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Scheme 15: Total syntheses with C–H functionalization steps shown. 
 
1.4 Nickel-catalyzed C–H functionalization 
 
As highlighted a wide array of C–H functionalisation reactions are possible with a range of 
transition metals24–30 and nickel has been featured relatively early. Indeed, in 1963 a 
stoichiometric direct C–H nickelation of azobenzene was reported by Dubeck and Kleiman 
(Scheme 16).46 
 
Scheme 16: Nickel-mediated C–H activation of azobenzene. 
Early examples of such catalytic reactions were investigated by the groups of Miura, Hu and 
Ackermann.47,48 These reports originally focused on C–H functionalisation of electronically-
biased azoles and included arylation47 and alkylation48 reactions as depicted in Scheme 17. 
                                                          
46
 Kleiman, J. P.; Dubeck, M. J. Am. Chem. Soc. 1963, 85, 1544–1545. 
47
 (a) Muto, K.; Yamaguchi, J.; Itami, K. J. Am. Chem. Soc. 2012, 134, 169–172. (b) Hachiya, H.; Hirano, K.; Satoh, 
T.; Miura, M. Org. Lett. 2009, 11, 1737–1740. (c) Canivet, J.; Yamaguchi, J.; Ban, I.; Itami, K. Org. Lett. 2009, 11, 
1733–1736. (d) Ackermann, L.; Althammer, A.; Fenner, S. Angew. Chem. Int. Ed. 2009, 48, 201–204. 
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Scheme 17: Nickel-catalyzed C–H (a) arylation and (b) alkylation of azoles. 
The utilisation of a Lewis-basic directing group for site-selective nickel-catalyzed C–H 
functionalization was achieved after the conception of bidentate auxiliaries was introduced 
by the group of Daugulis for palladium-catalysed C–H functionalisations. 49 They found that 
otherwise inert C–H bonds, could be functionalised, if a bidentate directing group was 
employed. Based on these findings the group of Chatani developed corresponding nickel-
catalysed annulation,50 arylation51 and primary alkylation52 reactions (Scheme 18). 
 
Scheme 18: Nickel-catalyzed direct C–H (a) annulation, (b) arylation and (c) primary alkylation under bidentate assistance. 
Taking advantage of this enhanced reactivities towards C–H bonds it was recently rendered 
possible to activate C(sp3)-C–H bonds in a similar fashion (Scheme 19).53 
                                                                                                                                                                                     
48
 (a) Ackermann, L.; Punji, B.; Song, W. Adv. Synth. Catal. 2011, 353, 3325–3329. (b) Vechorkin, O.; Proust, V.; 
Hu, X. Angew. Chem. Int. Ed. 2010, 49, 3061–3064. 
49
 Daugulis, O.; Roane, J.; Tran, L. D. Acc. Chem. Res. 2015, 48, 1053–1064. 
50
 Shiota, H.; Ano, Y.; Aihara, Y.; Fukumoto, Y.; Chatani, N. J. Am. Chem. Soc. 2011, 133, 14952–14955. 
51
 Yokota, A.; Aihara, Y.; Chatani, N. J. Org. Chem. 2014, 79, 11922–11932. 
52
 Aihara, N.; Chatani, N. J. Am. Chem. Soc. 2013, 135, 5308–5311. 
53
 (a) Aihara, Y.; Chatani, N. J. Am. Chem. Soc. 2014, 136, 898–901. (b) Iyanaga, M.; Aihara, Y.; Chatani, N. J. Org. 
Chem. 2014, 79, 11933–11939. (c) Wu, X.; Zhao, Y.; Ge, H. J. Am. Chem. Soc. 2014, 136, 1789–1792. 
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Scheme 19: Examples of C(sp
3
)-C–H functionalisation through Nickel-catalysis. 
The bidentate approach has remained most commonly used within directed nickel-catalyzed 
C–H functionalization. However, monodentate strategies have been less prevalent. One 
instance is the nickel-catalysed oxidative annulation of oximes developed by Matsubara 
(Scheme 20a). 54  Another are two annulation reactions reported by Hiyama 55  and 
Ackermann56 respectively (Scheme 20b and c). 
 
Scheme 20: Nickel-catalyzed C–H functionalisations with monodentate auxiliaries. 
                                                          
54
 Yoshida, Y.; Kurahashi, T.; Matsubara, S. Chem. Lett. 2011, 40, 1140–1142. 
55
 Nakao, Y.; Morita, E.; Idei, H.; Hiyama, T. J. Am. Chem. Soc. 2011, 133, 3264–3267. 
56
 Song, W.; Ackermann, L. Chem. Commun. 2013, 49, 6638–6640. 
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In addition, just as for other transition metals, protocols for the formation of C–X bonds 
through C–H bond functionalisation with nickel catalysts have recently been developed. 
These include borylation, 57  sulfonylation, 58  thiolation, 59  amination 60  and oxygenation 
reactions, 61  although the latter example still being a nickel-mediated process. New 
heterogenous nickel-catalysts, such as the reusable, metal organic framework 
Ni2(BDC)2(DABCO), have emerged, as well.
62 
Nickel catalysis usually follows the previously mentioned modes for C–H activation (vide 
supra Scheme 10).22 Oxidative addition pathways are often thought to be operative. 
However, the oxidation manifold has generally been unclear. In nickel-catalyzed alkylation 
chemistry three sets of probable oxidation states need to be considered for 2-electron 
changes, these being Ni(0)/Ni(II), Ni(I)/Ni(III) and Ni(II)/Ni(IV). 
A typical example involving a catalytic cycle proposed for Ni(0)/Ni(II) intermediates involves 
the reaction of azoles. 63 In some cases the homocoupled azole 71 has been isolated, through 
which a Ni(0) species is proposed to be generated (Scheme 21). 
 
Scheme 21: Pathway for generation of nickel(0) species in the direct C–H arylation of azoles. 
The Ni(I)/Ni(III) manifold is commonly invoked within alkylation reactions. 64 However, such 
conclusions are largely based on analogy to traditional cross coupling reactions, where 
isolated organonickel complexes were used for studies of the oxidative addition of 
unactivated alkyl halides. It has been established that the oxidative addition occurs through 
a single-electron-transfer, in which the alkyl halide is first bound to the nickel center and 
then a free organic radical is generated. Next, a rebound of the free organic radical occurs to 
form the new nickel-carbon bond. The initial Ni(I) species is often assumed to be only 
seemingly in this oxidation state, as the ligand may become redox-active. This however is 
mostly presumed for pyridine- and imin-based ligands (Scheme 22). Additional EPR 
                                                          
57
 Furukawa, T.; Tobisu, M.; Chatani, N. Chem. Commun. 2015, 51, 6508–6511. 
58
 Yokota, A.; Chatani, N. Chem. Lett. 2015, 44, 902–904. 
59
 (a) Zhu, J.; Chen, Y.; Lin, F.; Wang, B.; Chen, Z.; Liu, L. Org. Biomol. Chem. 2015, 13, 3711–3720. (b) Lin, C.; Yu, 
W.; Yao, J.; Wang, B.; Liu, Z.; Zhang, Y. Org. Lett. 2015, 17, 1340–1343. 
60
 Yan, Q.; Chen, Z.; Yu, W.; Yin, H.; Liu, Z.; Zhang, Y. Org. Lett. 2015, 17, 2482–2485. 
61
 Pattanayak, P.; Pratihar, J. L.; Patra, D.; Burrows, A.; Mohan, M.; Chattopadhyay Eur. J. Inorg. Chem. 2007, 
4263–4271. 
62
 Phan, N. T. S.; Nguyen, C. K.; Nguyen, T. T.; Truong, T. Catal. Sci. Technol. 2014, 4, 369–377. 
63
 Yamamoto, T.; Muto, K.; Komiyama, M.; Canivet, J.; Yamaguchi, J.; Itami, K. Chem. Eur. J. 2011, 17, 10113–
10122. 
64
 Hu, X. Chem. Sci. 2011, 2, 1867–1886, and references cited therein. 
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measurements conducted by Fu et al. confirmed the generation and importance nickel(I) 
intermediates.65  
 
Scheme 22: Proposed intermediates for oxidative addition involving Ni(I)/Ni(III) oxidation states. 
Furthermore, it could be considered that a Ni(IV) species could still be generated in these 
reactions, as a handful of Ni(IV)-alkyl-complexes have been isolated. 66 In case of complex 73 
this was achieved by C–H functionalization (Scheme 23). However, these are typically formed 
under strongly oxidizing reaction conditions. 
 
 
Scheme 23: Selected examples of nickel(IV)-alkyl-complexes. 
 
                                                          
65
 Schley, N. D.; Fu, G. C. J. Am. Chem. Soc. 2014, 136, 16588–16593. 
66
 (a) Camasso, N. M.; Sanford, M. S. Science 2015, 347, 1218–1220. (b) Carnes, M.; Buccella, D.; Chen, J. Y.-C.; 
Ramirez, A. P.; Turro, N. J.; Nuckolls, C.; Steigerwald, M. Angew. Chem. Int. Ed. 2009, 48, 290–294. (c) Klein, H-
F.; Bickelhaupt, A.; Lemke, M.; Sun, H.; Brand, A.; Jung, T.; Röhr, C.; Flörke, U.; Haupt, H.-J. Organometallics 
1997, 16, 668–676. 
2 Objectives 




Efficient and selective alkylation and fluoroalkylation reactions are of key importance for 
numerous applied areas. Ongoing research within the group of Prof. Ackermann and the 
groups of others have developed a limited number of direct C–H alkylations with various 
transition metals.13,40,48,52,53 
At the outset of this thesis, a novel direct secondary alkylation, as well as trifluoroethylation, 
of benzamides under bidentate assistance was developed by the co-worker Dr. Weifeng 
Song.67 Based on this further expansion of the utilized secondary alkyl halides 80 was to be 
investigated (Scheme 24).  
 
Scheme 24: Nickel-catalyzed bidentate-assisted secondary C–H alkylation. 
Additionally, the applicability of the direct trifluoroethylation and perfluoroalkylation of 
variously decorated arenes was to be probed (Scheme 25). Furthermore, more detailed 
studies to elucidate the details of the mechanism for these catalytic reactions was to be 
carried out. 
 
Scheme 25: Nickel-catalysed bidentate-assisted fluoroalkylation. 
A noticeable disadvantage of these bidentate auxiliaries, however, is their relative large size, 
which effectively lowers their atom economy for possible applications within industry and 
total synthesis.49 Therefore, the development of simpler or biologically useful directing 
groups is of high interest. Based on previous findings for the efficient nickel-catalyzed 
synthesis of indoles from 2-pyrimidyl-anilines, the possibility to apply this useful directing 
group to the nickel-catalyzed alkylation and fluoroalkylation transformations was to be 
investigated. If successful, detailed mechanistic studies, particularly regarding the type of 
nickelacycle, were to be carried out. Further development of additional directing groups 
derived from the 2-pyrimidyl-anilines was also to be attempted (Scheme 26). 
                                                          
67
 Song, W. Cobalt- and Nickel- Catalyzed Functionalization of Unactivated C–Hal, C–O and C–H bonds. PhD 
Thesis, Georg-August-University, Göttingen, 2014. 
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Scheme 26: Nickel-catalysed secondary C–H alkylations and fluoroalkylations of 2-pyrimidyl-anilines 69. 
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3 Results and Discussion 
3.1 Direct C–H secondary Alkylation under Bidentate Assistance 
 
As indicated in the introduction, direct C–H alkylations with unreactive alkyl halides 80 are of 
high relevance. In this context a nickel-catalyzed secondary alkylation of benzamides 59 with 
bidentate auxiliaries, a catalytic system has been previously developed by our co-worker Dr. 
Weifeng Song (Scheme 27).67  
 
Scheme 27: System for nickel-catalyzed secondary alkylation of benzamides 59. 
Mechanistic studies conducted by Dr. Weifeng Song revealed a reversible C–H metalation 
with the C–H acidity being of relevance.  
 
3.1.1 Scope and Limitations 
 
Initially, cyclic alkyl bromides 80 were investigated (Scheme 28). Apart from cyclopropyl 
bromide 80a, a wide range of alkyl halides with various ring sizes was well tolerated. It is also 
noteworthy that exo-bromo norbornane 80f furnished the corresponding alkylated 
benzamide 81af with retention of configuration. Only in the case of the bulkier 2-bromo 
adamantine 80g did the conversion drop significantly. 
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Scheme 28: Scope of secondary C–H alkylation of benzamide 59a with cyclic alkyl bromides 80. 
For acyclic alkyl bromides 80 moderate yields were generally be obtained (Scheme 29). 
However, the trend of decreasing yields with increasing sterical demand of the alkyl chain 
was observed. In regards to functional groups, a protected amine in substrate 80p was well 
tolerated. Additional halides or unsaturated bonds, however, were not feasible.  
 
Scheme 29: Scope of secondary C–H alkylation of benzamide 59a with acyclic bromides 80. 
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As the use of bidentate auxiliaries has proven to be impeccable, further possible variations 
of this basic principle were investigated (Scheme 30). These, however, proved to be 
incompatible with the optimized procedure. 
 
Scheme 30: Scope of alternative auxiliaries 90a–92a. 
In an effort to achieve an enantioselective process a small selection of chiral ligands were 
probed next (Table 1). An enantiomeric excess could, however, not be observed. Based on 
previous protocols and findings from asymmetric nickel-catalysed cross-coupling reactions it 
can be reasoned that at temperatures significantly exceeding ambient temperature only low, 
if any, enantiomeric excess can be expected.68 Therefore, no further studies were conducted. 
Table 1: Screening of ligands for asymmetric C–H alkylation.
[a] 
 
Entry ligand Yield [%] ee [%] 
1 (-)-pseudoephedrin (96) 3 0 
2 (L)-valinol (97) 2 0 
3 
 (98) 
(trace) n. d. 
4 
(99) 
(trace) n. d. 
5 (R)-BINOL (100) 56 0 
a Reactions conditions: 59a (1.0 mmol), 80k (2.0 mmol), LiOtBu (2.0 mmol), ligand, PhMe (2 mL), 
130 °C, 20 h, yields of isolated products. 
                                                          
68
 Liang, Y.; Fu, G. C. J. Am. Chem. Soc. 2014, 136, 5520–5524. 
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In addition to the direct C(sp2)–H alkylation, the applicability of the optimized system 
towards C(sp3)–H alkylation was preliminarily tested. Although the yield was low, it could be 
shown that the reaction was in principle feasible (Scheme 31). 
 
Scheme 31: Direct C(sp
3
)–H alkylation of amide 62a with 80d. 
 
3.2.2 Mechanistic Studies 
 
As to the reaction mechanism it could be shown that the conditions for primary alkylation, 
previously reported by Chatani et al,52 were completely ineffective for challenging secondary 
C–H alkylation (Scheme 32). 
 
Scheme 32: Secondary C–H alkylation under conditions for primary alkylation. 
Additionally, it was found that the reaction conditions for primary alkylation and the 
procedure for secondary alkylation were fully chemo-selective (Scheme 33). 
 
Scheme 33: Competition experiment between primary and secondary alkyl halide. 
A competition experiment between 2-bromo hexane 80k and 3-bromo hexane 80m revealed 
that less sterically bulky substrates were significantly favoured (Scheme 34). 
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Scheme 34: Competition experiment between 2-bromo and 3-bromo hexane. 
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3.2 Direct C–H Trifluoroethylation under Bidentate Assistance 
 
Fluorinated compounds have a significant role in medicinal chemistry (vide supra). Therefore, 
based on the catalytic system for direct secondary alkylations it was found that the first 
trifluoroethylation using trifluoroethyl iodide 82 was accessable by the nickel catalyst. 
Without further optimisation a representative set of substrates 59 were tested (Scheme 35). 
While the yields were rather moderate, the feasibility of this novel transformation could be 
shown as a proof of concept study. 
 
Scheme 35: Scope of Trifluoroethylation for benzamides 59. 
Furthermore, based on a recently reported cross coupling transformation, 69 the related 
direct fluoromethylation was investigated as well (Scheme 36). However, without any 
optimization this attempt did not yield the desired product 101a. 
 
Scheme 36: Attempted fluoromethylation of benzamide 59a. 
  
                                                          
69
 An, L.; Xiao, Y.-L.; Min, Q.-Q.; Zhang, X. Angew. Chem. Int. Ed. 2015, 54, 9079–9083. 
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3.3 Direct Secondary C–H Alkylation of N-Pyrimidyl-Anilines 
 
Mono-dentate directing groups are severely underrepresented within nickel-catalysed C–H 
activation (vide supra). Therefore, based on the previously reported nickel-catalysed 
synthesis of indoles,56 a direct C–H alkylation reaction utilising N-(2-pyrimidyl)-anilines 69 
was envisioned. These are particularly interesting targets for alkylation reactions, as various 
important pharmaceuticals contain the 2-amino-pyrimidine motif.70 Two examples of such 
drugs are Gleevec 104 and Tasigna 105, both of which marketed by Novartis (Scheme 37).71 
 
Scheme 37: Selected examples for marketed pharmaceuticals containing N-(2-pyrimidyl)-anilines. 
 
3.3.1 Synthesis of Starting Materials 
 
For the aniline substrates 69 an additional pathway for their synthesis was developed. Based 
on the known literature, usually three synthetic pathways are used. First, transition metal-
catalyzed amination reactions, most commonly using palladium or copper as the transition 
metal, can be utilised.72 This option can be rendered impractical, however, as trace amounts 
of the used transition metal need to be fully removed. This is typically achieved by 
distillation, which is often problematic due to the very high boiling point of these types of 
anilines 69. Second, an acid-catalyzed aromatic substitution can be achieved by using 2-
chloro-pyrimidine 106.73 This methodology, however, often gives low yields when employing 
                                                          
70
 (a) Kumar, S.; Deep, A.; Narasimhan, B. Cent. Nerv. Syst. Agents Med. Chem. 2015, 15, 5–10. (b) Kaur, R.; Kaur, 
P.; Sharma, S.; Singh, G.; Mehndiratta, S.; Bedi, P. M. S.; Nepali, K. Recent Pat. Anticancer Drug Discov. 2015, 10, 
23–71. (c) Dongre, R. S.; Bhat, A. R.; Meshram, J. S. Am. J. PharmTech Res. 2014, 4, 138–155. (d) Rawat, B.; 
Rawat, D. S. Med. Res. Rev. 2013, 33, 693–764. (d) Selvam, T. P.; James, C. R.; Dniandev, P. V.; Valzita, S. K. Res. 
in Phar. 2012, 2, 1–9. (e) Weisberg, E.; Manley, P.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. Br. J. Cancer 
2006, 94, 1765–1769. 
71
 (a) Breccia, M.; Alimena, G Leuk. Res. 2010, 34, 129–134. (b) McGrath, N. A.; Brichacek, M.; Njardarson, J. T. J. 
Chem. Ed. 2010, 87, 1348–1349. 
72
 (a) Yin, J.; Zhao, M. M.; Huffman, M. A.; McNamara, J. M. Org. Lett. 2002, 4, 3481–3484. (b) Liu, Y.; Bai, Y.; 
Zhang, J.; Li, Y.; Jiao, J.; Qi, X. Eur. J. Org. Chem. 2007, 6084–6088. 
73
 Ackermann, L.; Lygin, A. V. Org. Lett. 2012, 14, 764–767. 
3 Results and Discussion 
- 27 - 
 
anilines, which are electron-deficient or contain sterically demanding substituents in the 
ortho-position. The typically employed protic solvent can also react with the 2-chloro-
pyrimidine 106 to give undesired side products. Last, a three-step synthesis via a 
guanidinium moiety reacting with a corresponding Michael acceptor is also possible.74 This 
approach, however, involves three steps with typically moderate yields. Also the scope of 
the substitution pattern in the 6-position of the pyrimidine is very narrow. 
Hence, a more generally applicable methodology was needed and developed. Thus the 
nucleophilic aromatic substitution was employed without further optimisation (Scheme 38). 
Although the yields were generally rather moderate, otherwise unreactive anilines, such as 
1-naphthylamine (107g), could be used here as well. 
 
 
Scheme 38: Scope of basic synthesis of 2-pyrimidyl anilines 69. 
A Lewis acid-mediated method was also tested, in which the typically protic solvents or co-
solvents were avoided (Scheme 39). Possibly due to the high reactivity of aluminium chloride 
the yields were low. 
 
Scheme 39: Lewis acid-mediated synthesis of 2-pyrimidyl aniline 69b. 
 
                                                          
74
 Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; 
Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S.-Y.; McInees, C.; Zheleva, D.; Walkinshaw, M. 
D.; Fischer, P. M. J. Med. Chem. 2004, 47, 1662–1675. 
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3.3.2 Optimisation Studies 
 
At the outset of our studies, an initial test without additional ligand was performed and 
already furnished a low yield of desired product 83ad (Table 2, entry 1). Adding the 
previously established ligand BDMAE or TMEDA significantly improved the performance 
(Table 2, entries 2—3). Secondary amines were also found to be suitable ligands for this 
transformation (Table 2, entries 4—6, 9—10). Among these, secondary amine DtBEDA 
proved to be ideal, allowing a lowering of the catalyst loading to 2.5 mol % (Table 2, entries 
6—8). Surprisingly, 12-crown-4 facilitated the reaction as well (Table 2 , entry 12). While 
nickel complexes with related crown ether moieties are known,75 it is unclear what type of 
coordination to nickel ions can occur during these type of reactions. Additionally, employing 
both, DtBEDA and 12-crown-4, together gives an intermediary yield (Table 2, entry 13). This 
may indicate a separate and possibly conflicting mode of action. Variation of the base 
showed that LiOtBu was the best choice. Changing the metal cation lead to a severe 
decrease in conversion (Table 2, entries 13—16). Conversely, a change towards weaker 
lithium bases also gave no conversion. This may indicate that either certain solubility 
properties are crucial or that the lithium cation itself may be involved in the catalytic 
reaction. The latter case might be possible, if the lithium precoordinates to the directing 
group, effectively changing its electronic properties. Such cases have been studied for 
cesium bases in palladium-catalyzed C–H functionalisation.76  Only lithium bases were 
therefore used in further studies. Additional lowering of the catalyst loading lead to trace 
conversion (Table 2, entries 18—19). Without catalyst no conversion towards the desired 
product was observed (Table 2, entry 20). 
 
Table 2: Optimisation studies for secondary alkylation of anilines.
[a] 
 
entry Ni [mol %] solvent ligand (mol %) base yield [%] 
1 10 PhMe – LiOtBu 24 
2 10 PhMe BDMAE (86) (40) LiOtBu 94 (86[b]) 
                                                          
75
 (a) Korybut-Daszkiewicz, B.; Taraszewska, J.; Zieba, K.; Makal, A.; Wozniak, K. Eur. J. Inorg. Chem. 2004, 3335–
3344. (b) Jarrin, J.; Dawans, F.; Robert, F.; Jeannin, Y. Polyhedron 1982, 1, 409–412. 
76
 Musaev, D. G.; Figg, T. M.; Kaledin, A. L. Chem. Soc. Rev. 2014, 43, 5009–5031. 
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3 10 PhMe TMEDA (108) (40) LiOtBu 55 
4 2.5 PhMe   
(109) (40) 
LiOtBu 39 
5 10 PhMe  (110) (20) LiOtBu 15 
6 10 PhMe  (111) (20) LiOtBu 97 
7 5 PhMe  (111) (10) LiOtBu 96 
8 2.5 PhMe  (111) (5) LiOtBu 81 
9 2.5 PhMe HNiPr2 (112) (10) LiOtBu 24 
10 2.5 PhMe TMP (113) (10) LiOtBu 15 
11 2.5 1,4-dioxane  (111) (5) LiOtBu 97 (95
[b]) 
12 2.5 1,4-dioxane 12-crown-4 (114) (5) LiOtBu 73 
13 2.5 1,4-dioxane 
12-crown-4 (114) (5) + 
 (111) (5) 
LiOtBu 91 
14 2.5 1,4-dioxane  (111) (5) NaOtBu 2 
15 2.5 1,4-dioxane  (111) (5) KOtBu 4 
16 2.5 1,4-dioxane  (111) (5) Mg(OtBu)2 0 
17 2.5 1,4-dioxane  (111) (5) Li3PO4 0 
18 1 1,4-dioxane  (111) (2) LiOtBu 2 
19 0.5 1,4-dioxane  (111) (1) LiOtBu 1 
3 Results and Discussion 
- 30 - 
 
20 0 1,4-dioxane  (111) (5) LiOtBu 0 
[a] Reaction conditions: 69a (1.0 mmol), 80d (2.0 mmol), base (2.0 mmol), [(DME)NiCl2], ligand, 




The catalytic system utilising DtBEDA as the ligand appeared to perform best at reaction 
temperatures lowered to 100-120 °C with 80 °C only giving low conversion (Table 3, entries 
1—3). At these reduced reaction temperatures weaker lithium bases were still not viable for 
this transformation. Additional ligands consisting of bis-alcohols, oxazolines and primary 
amines gave no product formation (Table 3, entries 6, 8—9). N-heterocyclic carbene IPr, 
however, gave a moderate yield (Table 3, entry 7). Replacing the tert-butyl in DtBEDA with 
an adamantyl moiety significantly decreased the yield (Table 3, entry 10). The previously 
reported system for primary alkylations with bidentate auxiliaries proved to be ineffective, 
as well (Table 3, entry 12). Palladium dichloride was tested as the catalyst in order to exclude 
the possibility of catalytically active trace amount of palladium (Table 3, entry 13). Under 
these conditions neither the desired product nor other side-products were detected. 
 
Table 3: Optimisation of reaction temperature, base and ligand.
[a] 
 
entry T [°C] ligand base yield [%] 
1 120  (111) LiOtBu 96 
2 100  (111) LiOtBu 98 
3 80  (111) LiOtBu 9 
4 100  (111) Li3PO4 0 
3 Results and Discussion 
- 31 - 
 








9 100 Ethylene diamine (118) LiOtBu 0 
10 100  (119) LiOtBu 18 
11 100  (111) LiOtBu 99
[b] 
12 100 PPh3 (120) LiOtBu 5
[c] 
13 100  (111) LiOtBu 0
[d] 
[a] Reaction conditions: 69a (1.0 mmol), 80d (2.0 mmol), LiOtBu (2.0 mmol), [(DME)NiCl2] (2.5 mol %), 
ligand (5.0 mol %), 1,4-dioxane (2 mL), 16 h, yields based on crude 19F-NMR with C6F6 as internal 




3.3.3 Scope of C–H Alkylation of anilines 
 
Due to the novelty of the employed directing group different variations of the basic pattern 
were examined with the optimised conditions (Scheme 40). Adding an arene substituent on 
the pyrimidine moiety did not significantly inhibit the reaction to product 129. However, a 
sideproduct 129’ was observed. This observation clearly showed that alternative 
arrangements of 2-amino-pyrimidines can serve as directing groups as well. Replacing the 
acidic N-H- with a N-Me moiety as in compound 130 completely shut down the reaction. A 
change of the pyrimidine-moiety to pyridine substrate 123 caused a significant decrease in 
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conversion, thereby giving product 131 in trace amounts only. Spatially separating the acidic 
proton and the directing pyrimidyl group by using O-(2-pyrimidyl)-resorcinol 124 led to no 
conversion. Further, a simpler thiourea-derivative 125 did not give the desired product 133, 
but instead the S-alkylated product 133’. 
Additionally, the catalytic system proved ineffective for N-(2-pyrimidyl)-indole derivatives, 
which have been previously employed in various C–H functionalisations.77 Azobenzene 126, 
which was used by Dubeck and Kleimann very early for the synthesis of the corresponding 
nickelacycle, was not viable to synthesise 134.46 
 
Scheme 40: Scope of C–H alkylations with different directing groups. 
                                                          
77
 Selected examples: (a) Sauermann, N.; Gonzalez, M. J.; Ackermann, L. Org. Lett. 2015, 17, 5316–5319. (b) 
Yoshino, T.; Ikemoto, H.; Matsunaga, S.; Kanai, M. Eur. J. Org. Chem. 2013, 19, 9142–9146. (c) Ackermann, L.; 
Lygin, A. V. Org. Lett. 2011, 13, 3332–3335. 
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With the optimised system at hand, a variety of cyclic alkyl bromides 80 were tested. This 
was initially done at a reaction temperature of 150 °C (Scheme 41), as increased 
temperature usually provided improved efficacy for less reactive halides 80. 
 
 
Scheme 41: Scope of C–H alkylation of aniline 69a with cyclic alkyl bromides 80 at 150 °C. 
During further investigation it was found, however, that at reduced reaction temperatures 
the yields for corresponding cyclic alkyl bromides 80 was either identical or even better 
(Scheme 42). Under these reaction conditions a wide range of cyclic alkyl bromides 80 was 
well tolerated, with the exception of cyclopropyl bromide 80a. Of particular interest was the 
use of exo-bromo norbornane 80f, which reacted under retention of configuration to give 
product 86af. The related exo-2-bromo-camphor 80u on, however, was unreactive, 
presumably due to the additional keto group. In addition, the bulky 2-bromo adamantane 
gave 86ag in excellent yields, as well. 
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Scheme 42: Scope for C–H alkylation of aniline 69a with cyclic alkyl bromides 80 at 100 °C. 
The catalytic system was not limited to cyclic alkyl bromides 80. Acyclic bromides 80 were 
also viable substrates (Scheme 43). Alkyl chains containing phthalimide moieties gave 
excellent yields as well. Esters within the alkyl chain however only led to poor yields of 
transesterified product 86au’. This is presumably caused by the formation and side reactions 
of the corresponding ester enolate. 
 
Scheme 43: Scope for C–H alkylation aniline 69a with acyclic alkyl bromides 80 at 100 °C. 
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Additionally, several differently decorated arenes 69 were investigated (Scheme 44). With 
substrates 69h-j, in which the ortho-position is unsubstituted, good selectivity for the mono-
alkylated products with moderate yields can be achieved by lowering the amount of alkyl 
bromide 80 to 1.1 equivalents. For substrates 69i-j bearing a fluoro-substituent in the meta-
position yields decreased significantly. This might be attributed to either additional 
coordination of the fluoro-group towards the nickel-catalyst or potential C–F activation by 
the nickel-catalyst. 
 
Scheme 44: Scope for C–H alkylation of anilines 69 with alkyl bromides 80 at 120 °C. 
It was shown during the previous optimisation studies (Table 3, entry 11), that the bench-
stable Nickel dichloride hexahydrate appeared to be an efficient catalyst also. Therefore, a 
small selection of substrates was tested for these conditions (Scheme 45). It was found that 
for most substrates the conversion was lower, yet still acceptable. 
 
Scheme 45: Scope for C–H secondary alkylation with [NiCl2(H2O)6] as the catalyst. 
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In case of benzylic bromides 80o/v a change in chemo-selectivity to N-alkylation was 
observed (Scheme 46). 
 
 
Scheme 46: N-Benzylation with alkyl bromides 80v/o. 
 
In addition to alkyl halides the more easily accessible cyclohexyl acetate (137) was probed 
(Scheme 47). However, the current catalytic system proved inefficient for this type of 
substrates. 
 
Scheme 47: Attempted C–H alkylation of aniline 68a with cyclohexyl acetate (137). 
 
3.3.4 Mechanistic Studies 
 
Intrigued by this unusual, new transformation a variety of mechanistic studies was 
conducted. First, isotopically labelled substrate D5-69h was subjected to the reaction 
conditions with only the standard ligand DtBEDA as a proton source, giving significant H/D-
exchange (Scheme 48).This result shows that in the absence of alkyl halides 80 the C–H 
metalation is facile. 
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Scheme 48: H/D-exchange for substrate D5-69d with DtBEDA as proton source. 
The reverse process, using 69h in the presence of D4-methanol led to no H/D-exchange 
(Scheme 49). This, however, may be attributed to the significantly more acidic deuterium 
donor, thus changing the reaction conditions greatly, thus making them incompatible with 
the catalytic system. 
 
Scheme 49: Attempted H/D-exchange for 69h with D4-MeOH as deuterium source. 
The reaction of labelled substrate D5-69h with alkyl halide 80d showed significant H/D 
scrambling (Scheme 50). Considering these findings it can be assumed that the C–H-
metalation is reversible. 
 
Scheme 50: H/D-exchange under standard reaction conditions. 
Independent experiments with substrates 69h and D5-69h with alkylation 80d revealed a 
kinetic isotope effect (KIE) of kH/kD = 1.7 (Scheme 51). A kinetic isotope effect (KIE) of this 
magnitude might indicate that the C–H metalation is not the rate determining step.  
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Scheme 51: Kinetic isotope effect studies. 
Considering that the alkyl halides 80 may undergo elimination to the corresponding olefins, 
the actual alkylation agent should be identified. For this the standard reaction was 
attempted with cyclohexene 138 under otherwise identical reaction conditions (Scheme 52). 
 
Scheme 52: Attempted alkylation of substrate 69a with cyclohexene 138. 
Likewise, the more reactive styrene 139 (Scheme 53) did not yield any alkylated products. It 
can therefore be concluded that the alkyl halides 80 are the active alkylating agents. 
 
Scheme 53: Attempted alkylation of substrate 69a with styrene 139. 
y = 19,943x - 29,01 
R² = 0,9804 
y = 11,886x - 17,686 
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To probe the mode of the alkyl bromide activation a reaction was performed in the presence 
of the radical scavenger TEMPO (Scheme 54). This led to a shutdown of the catalytic 
reactivity, indicating formation of radical intermediates. 
 
Scheme 54: Standard reaction in presence of radical scavenger TEMPO.
78 
 
The enantiopure alkyl halide (S)-80k lead to full racemization in the product 86ak, further 
indicating a planar, radical intermediate (Scheme 55). 
 
Scheme 55: Standard reaction with enantiopure (S)-2-bromo-octane ((S)-80k). 
In order to elucidate electronic effects on the C–H alkylation, a Hammett plot was done 
(Scheme 56). Here, a clear positive inclination towards high sigma-values was observed, 
albeit a possibly unusual change in steepness at values near 0. This result can indicate for the 
reductive elimination to be rate determining. A few additional factors, however, should be 
taken into account. The most basic fact is that the Hammott correlation was developed for 
reactions that undergo a clean reaction not creating side-products, while also using 
substrates whose substituents do not cause secondary effects on the reaction kinetics.79 
These criteria may not fully apply in the case given here. For one, substrates containing C–F 
and C–Cl bonds may, to some degree, undergo side reactions involving these bonds. This 
may influence the rate of the corresponding reaction. Another secondary effect to be 
regarded here is the acidity of the N-H group. This moiety has previously been shown to be 
vital. The acidity should increase towards more positive sigma-values. Therefore, if said 
acidity may become relevant for the rate of the reaction, it may explain the observed change 
in inclination. Thus, for a more clear answer a significantly larger set of data points or a 
separate correlation between acidity and reaction rate will be required. 
                                                          
78
 Experiment performed by Zhixiong Ruan. 
79
 (a) Hansch, C.; Leo, A.; Taft, R. W. Chem. Rev. 1991, 91, 165–195. (b) Hammett, L. P. J. Am. Chem. Soc. 1937, 
59, 96–103. 
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Scheme 56: Hammett plot for C–H secondary alkylation of anilines 69. 
 
Considering the novelty of the employed directing group, studies regarding the nickelacycle 
were conducted. The assumed cycle is six-membered based on previous findings for 
palladium,80 ruthenium81 and gold complexes.82 Initially an oxidative addition of Ni(0) with 
ortho-Bromo-substrate 69q was attempted (Scheme 57). While the crude analysis indicated 
formation of traces of several new compounds, the assumed nickelacycle 140 could not be 
identified via crude NMR analysis or isolated. 
 
Scheme 57: Attempted synthesis of nickelacycle 140 through oxidative addition. 
Another approach was simply applying the reported procedure for the palladacycle (Scheme 
58). Crude NMR analysis indicated only simple coordination of the lewis basic nitrogen of the 
directing group to the nickel ion. 
                                                          
80
 Nonoyama, M. Transition Met. Chem. 1982, 7, 281–284. 
81
 Nonoyama, M. Polyhedron 1985, 4, 765–768. 
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Scheme 58: Attempted formation of nickelacycle through C–H metalation. 
Based on our mechanistic studies a catalytic cycle can be proposed (Scheme 59). The 
catalytic cycle is initiated by deprotonation of substrate 69, followed by C–H-metallation by 
the nickel catalyst. Based on the mechanisms previously discussed (Scheme 10) and the 
electron-rich nature of the aniline substrates used, it can be considered for a intramolecular 
electrophilic substitution (IES) mechanism to be most probable. However, a ambiphilic metal 
ligand activation (AMLA) pathway should also be considered. The following oxidative 
addition occurs in two steps through an SET-pathway. In this the bromide reacts first with 
the metal centre, followed by a rebound of the organic radical to generate nickel species 140. 
Last, reductive elimination leads to the desired product 86 and regeneration of the nickel 
catalyst. 
 
Scheme 59: Proposed catalytic cycle for the direct secondary alkylation of anilines 69. 
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3.4 Direct C–H Fluoroalkylation of N-Pyrimidyl-Anilines 
 
Introducing fluorine or fluorine-containing functional groups into organic compounds is 
crucial within medicinal chemistry. In connection with the importance of the 2-amino-
pyrimidine moiety in anti-cancer drugs, trifluoroethylation was attempted with the N-(2-
pyrimidyl)-aniline substrate 69 as well. 
 
3.4.1 Synthesis of Starting Materials 
 
For substrate 146 a novel synthesis was developed. This became necessary due to the only 
reported procedures either requiring expensive reagents or special autoclave techniques.83 
Therefore, derived from these procedures, a synthesis starting from commercially available 
trifluoroethanol 144 was devised (Scheme 60). After tosylation of the alcohol to give 
trifluoroethyltosylate 145, substitution with sodium bromide at high temperatures gave the 
desired reagent 146. 
 
Scheme 60: Synthesis of trifluoroethyl bromide 146. 
 
3.4.2 Optimisation Studies 
 
At the outset, the envisioned C–H trifluoroethylation for standard substrate 69b and 
commercially available trifluoroethyl iodide 82 were tested without ligand and these 
conditions furnished minor amounts of the desired product 87b (Table 4, entry 1). Employing 
the BDMAE ligand, which has previously been used for the analogous trifluoroethylation 
reaction under bidentate assistance, a significant improvement was observed (Table 4, entry 
2). Lowering the reaction temperature reduced the conversion notably (Table 4, entries 3—
5). Similar to previous finding, use of weaker bases completely shut down the efficacy of the 
catalytic system (Table 4, entries 6—10). 
 
 
                                                          
83
 (a) Mathey, F. 2001, Molybdenum(VI) Fluoride. e-EROS Encyclopedia of Reagents for Organic Synthesis. (b) 
Kashutina, E. V.; Lavrent’ev, A. N. Zhurnal Obshchei Khimii 2000, 70, 1814. 
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Table 4: Screening of solvents and bases for C–H trifluoroethylation of aniline 69b.
[a] 
 
entry [Ni] ligand [mol %] solvent base yield [%] 
1 [(DME)NiCl2] – PhMe LiOtBu <10 
2 [(DME)NiCl2] BDMAE (89) (40) PhMe LiOtBu 83 
3 [(DME)NiCl2] BDMAE (89) (40) PhMe LiOtBu – (<30
[b,c]) 
4 [(DME)NiCl2] BDMAE (89) (40) PhH LiOtBu 53
[c] 
5 [(DME)NiCl2] BDMAE (89) (40) PhMe LiOtBu 69
[d] 












9 [(diglyme)NiBr2] BDMAE (89) (40) PhMe Na2CO3 0 
10 [(diglyme)NiBr2] BDMAE (89) (40) PhMe NaOAc 0 
[a] Reactions conditions: 69b (1.0 mmol), 82 (2.0 mmol), base (2.0 mmol), [Ni] (10 mol %), ligand (40 
mol %), solvent (2 mL), 150 °C, 16 h, yields based on crude 19F-NMR with C6F6 as internal standard. 
[b] 
Isolated yield. [c] 120 °C. [d] 130 °C. 
 
Further screening of ligands revealed that other tertiary amines 108 or pyridine 147 
derivatives are not viable for this transformation (Table 5, entries 1 and 2). Similarily, 
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Table 5: Screening of ligands for the trifluoroethylation of aniline 69b.
[a] 
 
entry ligand [mol %] yield [%] 
1 BDMAE (89) (40) 83 
2 TMEDA (108) (40) 14 
3 2,2’-bipyridine (147) (10) 11 
4 (R)-BINOL (100) (10) <5 
5 PPh3 (120) (40) <10 
6 XantPhos (148) (20) 21 
7 IPr*HCl (116) (10) <5 
8 LiCp* (149) (10) <5 
[a] Reactions conditions: 69b (1.0 mmol), 82 (2.0 mmol), LiOtBu (2.0 mmol), PhMe (2 mL), 150 °C, 16 h, 
yields based on crude 19F-NMR with C6F6 as internal standard. 
[b] Isolated yield. 
 
Considering the high efficacy of the DtBEDA ligand in the secondary alkylation of anilines 69, 
this system was also tested for the C–H trifluoroethylation (Table 6). Initially, only moderate 
yields were achieved, however at significantly lower reaction temperatures (Table 6, entries 
1—3). Changing the solvent to arenes gave either lower or, at best, identical yields (Table 6, 
entries 4—7). When a wider variety of ether solvents was tested, 2-methyl-tetrahydrofuran 
was found to be optimal (Table 6, entries 10—16). 
 
Table 6: Solvent effect for C–H trifluoroethylation with DtBEDA ligand.
[a] 
 
entry T [°C] solvent yield [%] 
1 140 1,4-dioxane 38 
2 120 1,4-dioxane 44 
3 100 1,4-dioxane 26 
4 120 PhMe 19 
5 120 PhtBu 26 
6 120 PhCl 43 
7 120 PhCF3 18 
8 120 1,4-dioxane 11[b] 
9 120 1,4-dioxane 3[c] 
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10 120 DME 14 
11 120 (nBu)2O 0 
12 120 THF 39 
13 120 PhOMe 15 
14 120 Ph2O 9 
15 120 CPME 4 
16 120 2-Me-THF 47 
[a] Reactions conditions: 69b (1.0 mmol), 82 (2.0 mmol), LiOtBu (2.0 mmol), solvent (2 mL), 150 °C, 16 
h, yields based on crude 19F-NMR with C6F6 as internal standard. 
[b] LiBr (2.0 equiv). [c] DMEDA (20 
mol %) as ligand. 
 
Further investigation revealed that trifluoroethyl bromide (146) appeared to be a more 
effective reagent (Table 7, entry 1). Further screening of reaction temperature and 
concentration showed that at 120 °C and at lower concentrations optimal results were 
achieved (Table 7, entries 4—7). With no nickel catalyst or palladium dichloride as the 
catalyst no conversion was observed (Table 7, entries 12—13). Re-evaluating the previous 
conditions with BDMAE at 150 °C with trifluoroethyl bromide (143) showed improved 
conversion, as well (Table 7, entry 14). 
 
Table 7: C–H trifluoroethylation with trifluoroethyl bromide (146).
[a] 
 
entry ligand T [°C] solvent [M] yield [%] 
1 DtBEDA 120 2-Me-THF (0.5) 55 




120 2-Me-THF (0.5) 14 
4 DtBEDA 100 2-Me-THF (0.5) 35 
5 DtBEDA 100 2-Me-THF (0.25) 45 
6 DtBEDA 120 2-Me-THF (1.0) 27 
7 DtBEDA 120 2-Me-THF (0.25) 67 (64[b]) 
8 DtBEDA 120 2-Me-THF (0.5) 61[c] 
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10 DtBEDA 120 2-Me-THF (0.25) 76 (68[b,c]) 
11 – 120 2-Me-THF (0.5) 38 
12 DtBEDA 120 2-Me-THF (0.5) 0[d] 
13 DtBEDA 120 2-Me-THF (0.5) 0[e] 
14 BDMAE 150 PhMe (0.5) 78[f] (66[b]) 
[a] Reactions conditions: 69b (1 mmol), 146 (2 mmol), LiOtBu (2 mmol), solvent, 150 °C, 16 h, yields 
based on crude 19F-NMR with C6F6 as internal standard. 
[b] isolated yield. [c] 146 (3 equiv). [d] No 
catalyst. [e] PdCl2 as catalyst. 
[f] ligand (40 mol %). 
 
3.4.3 Scope of Trifluoroethylation 
 
Initially, the catalytic system utilising DtBEDA as the ligand was probed, specifically for 
functional group tolerance (Scheme 61). However, both electron-rich and -deficient 
substrates gave only low to moderate yields. Chloro- and ester-substituents furnished no 
desired products 87o and 87r. 
 
Scheme 61: Scope for trifluoroethylation with DtBEDA as ligand. 
Therefore, the study of substrates was continued with the BDMAE ligand system at 150 °C 
(Scheme 62). Both electron-deficient and –rich ortho-substituents were tolerated with 
moderate to high yields. meta-Substituted substrates 69l-n, however, gave low conversion 
with site-selectivity favoring the sterically less hindered position. Unsubstituted or electron-
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rich para-substituted substrates 69h/k-l gave moderate yields. For these substrates the 
selectivity was mainly towards the mono-trifluoroethylated products 87h/k-l, with either 
none or only small amounts of bis-trifluoroethylated products 87h’ and 87l’ being isolated. 
 
Scheme 62: Scope for C–H trifluoroethylation with BDMAE as ligand. 
Identically to the secondary alkylation of anilines, the reaction does not proceed if the acidic 
N-H group is removed (Scheme 63). 
 
Scheme 63: Screening of directing groups for trifluoroethylation. 
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While trifluoroethyl bromide 146 was identified as an effective reagent, it also contains 
possible drawbacks. One issue is the relatively high volatility of the reagent with a boiling 
point of 28 °C. Additionally, the reagent is currently not commercially available and only few 
syntheses have been reported. Therefore, the viability of the more easily accessible and non-
volatile tosylate derivative 145 was tested (Scheme 64). Albeit formation of only trace 
amounts with lithium bromide as additive, it could be shown that trifluoroethyl toslyate may 
be used for this type of transformation. 
 
Scheme 64: Attempted C–H trifluoroethylation utilising trifluoroethyl tosylate (145). 
 
3.4.4 Mechanistic Studies 
 
Due to the novelty of this type of transformation several mechanistic experiments were 
conducted. In an H/D-exchange-experiment full scrambling was found, indicating a facile C–
H-metallation (Scheme 65). 
 
Scheme 65: H/D-exchange experiment for C-H trifluoroethylation. 
 
Further, a direct competition between 69h and D5-69h revealed a KIE of kH/kD = 1.1 (Scheme 
66), indicating the C–H-metallation not to being rate determining. 
 
Scheme 66: Kinetic isotope effect. 
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The reaction was shut down by the addition of one equivalent of the radical scavenger 
TEMPO (Scheme 67). The formation of radical intermediates can therefore be assumed. 
 
Scheme 67: Attempted trifluoroethylation with TEMPO. 
 
A competition experiment between electron-rich and -deficient substrates revealed the 
electron-richer substrate to react preferentially (Scheme 68). This may point towards the 
oxidative addition being rate determining. 
 
Scheme 68: Competition experiment for trifluoroethylation under standard conditions. 
Based on these findings a plausible catalytic cycle is proposed in Scheme 69. After the initial, 
facile C–H nickelation, the oxidative addition occurs through a SET-type pathway. This is 
followed by the reductive elimination to give the desired product and regenerate the active 
catalyst. 
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Scheme 69: Proposed catalytic cycle for the C-H trifluoroethylation. 
 
 
3.4.5 Further Fluoroalkylations 
 
Based on the novelty of the trifluoroethylation, further variations of fluoroalkylation 
reactions were probed. These were particularly focused on fluoroalkylation reagents 
containing alpha-fluoro-groups. Based on a previous report of nickel-catalysed cross coupling 
with iodofluoromethane (102),69 an analogous reaction was tested (Scheme 70). This, 
however, did not lead to the desired product 154. 
 
Scheme 70: Attempted C–H fluoromethylation of aniline 69b. 
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Additionally, the Langlois’ reagent (155) was tested for a direct trifluoromethylation (Scheme 
71). This led only to a low conversion to side-product 153a. 
 
Scheme 71: Attempted trifluoromethylation of aniline 69a utilising Langlois' reagent. 
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4 Summary and Outlook 
 
The focus within this thesis was on the development of atom- and step- economic nickel-
catalyzed alkylation reactions utilising challenging, unactivated alkyl halides with -
hydrogens or  -fluorines. 
In the first part, a protocol for the direct C–H secondary alkylation under bidentate 
assistance was devised for a variety of alkyl bromides 80 (Scheme 72).84 This was achieved 
using [(DME)NiCl2] as the catalyst with BDMAE as a commercially available ligand. A series of 
products 81 were obtained in good to excellent yields. 
 
Scheme 72: C–H Secondary alkylation of benzamides under bidentate assistance. 
 
Second, investigations on the first trifluoroethylation were conducted (Scheme 73).84 Albeit 
in low to moderate yields, the corresponding trifluoroethylated benzamides 84 were made 
accessible. 
 
Scheme 73: C–H trifluoroethylation of benzamides 59 under bidentate assistance. 
The research was then focused on utilising simpler and biologically relevant directing groups 
for direct C–H secondary alkylation. For this a simple catalytic system consisting of 
                                                          
84
 Song, W.; Lackner, S.; Ackermann, L. Angew. Chemie Int. Ed. 2014, 53, 2477–2480. 
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[(DME)NiCl2] and ligand DtBEDA was developed (Scheme 74).
85 The system showed broad 
applicability of substrates. Mechanistic studies revealed a reversible C–H nickelation and a 
formal oxidative addition through an SET-type pathway. The involved nickelacycle is 
presumed to be an unusual 6-membered metallacycle 141. 
 
Scheme 74: C–H Secondary alkylation of aniline derivatives 69. 
 
Finally, the C–H trifluoroethylation was applied to aniline derivatives 69. The protocol was 
amenable to a variety of substrates 69. Mechanistic studies revealed a reversible C–H 




Scheme 75: C–H Trifluoroethylation of aniline derivatives 69. 
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 Ruan, Z.; Lackner, S.; Ackermann, L. Angew. Chem. Int. Ed. 2016, 55, 3153–3157. 
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Further research should focus on enabling tertiary alkylation and fluoroalkylations for the 
established substrates. The latter case being of particular interest, as novel palladium-
catalyzed C–H trifluoroethylation reactions have been reported after publication of results 
presented herein.86 New development of additional monodentate directing groups for 
nickel-catalysed C–H functionalisation based on the 2-amino-pyrimidine moiety is also of 
importance. Moreover, if a catalytic system with higher efficacy at lower temperatures can 
be found, direct C–H alkylation reactions in an enantioselective fashion may become feasible. 
 
                                                          
86
 (a) Toth, B. L.; Kovacs, S.; Salyi, G.; Novak, Z. Angew. Chem. Int. Ed. 2016, 55, 1988–1992. (b) Zhang, H.; Chen, 
P.; Liu, G. Angew. Chem. Int. Ed. 2014, 53, 10174–10178. 
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5.1 General Remarks 
 
All reactions involving moisture- or air-sensitive reagents or products were performed under 
an argon atmosphere using pre-dried glassware and standard Schlenk techniques. Syringes 
for handling of dry solvents were flushed with dry argon threefold prior to their use. 
 
Solvents 
All solvents for reactions involving moisture-sensitive reagents were dried, distilled and 
stored under inert atmosphere (argon or nitrogen) according to the following standard 
procedures. 
 
solvent   drying method 
CH2Cl2  was purified using an solvent purification system (SPS) from 
MBRAUN. 
N,N-Dimethylformamide  was dried over CaH2 for 8 h, degassed and distilled under 
reduced pressure. 
N-Methyl-2-pyrrolidone  was stirred for 4 h at 150 °C over CaH2 and subsequently 
distilled under reduced pressure. 
Methanol    was stirred over Mg chips for 3 h at 65 °C prior to distillation.  
Tetrahydrofuran  was purified using an SPS solvent purification system from 
MBRAUN. 
Toluene  was either predried over KH followed by distillation from 
sodium benzophenone ketyl or purified using a solvent 
purification system from MBRAUN.  
1,4-Dioxane   was dried by distillation from sodium benzophenone ketyl. 
nOctane   was dried by addition of predried 4Å molecular sieve. 
Diphenylether   was dried by addition of predried 4Å molecular sieve. 
Chlorobenzene  was dried by addition of predried 4Å molecular sieve. 
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tert-Butylbenzene  was dried by addition of predried 4Å molecular sieve. 
Trifluoromethylbenzene was dried by addition of predried 4Å molecular sieve. 
Anisole was dried by stirring over Na at 135 °C prior to disitillation at 
1 mbar. 
Dimethoxyethane  was dried by distillation from sodium benzophenone ketyl. 
Di-(n-butyl)-ether  was dried by distillation from sodium benzophenone ketyl. 
CPME    was dried by stirring over sodium at 120 °C prior to disitillation. 
tert-Butanol   was dried by distillation from sodium. 
2-Methyl-tetrahydrofuran was dried by distillation from sodium. 
 
Vacuum 
The following pressures were measured on the used vacuum pump and were not corrected: 
membrane pump vacuum (MPV): 0.5 mbar, oil pump vacuum (OPV): 0.1 mbar. 
 
Melting Points 
Melting points were measured using a Stuart® Melting Point Apparatus SMP3 from 
BARLOWORLD SCIENTIFIC. Reported values are not corrected.  
 
Chromatography 
Analytical thin layer chromatography (TLC) was performed on 0.25 mm silica gel 60F-plate 
(MACHEREY-NAGEL) with 254 nm fluorescent indicator from MERCK. Plates were either 
visualized under ultraviolet light or developed by treatment with a potassium permanganate 
or a cerium ammonium molybdate solution followed by careful warming with a heat gun. 
Chromatographic purification of products was accomplished by flash column 
chromatography on MERCK silica gel, grade 60 (40–63 µm and 63–200 µm, 70–230 mesh 
ASTM). 
 
High Performance Liquid Chromatography 
Preparative and analytical separations were performed on an HPLC-System from Agilent. 
Separation column ChiralPak IC (4.6 × 250 mm) from DAICEL CHEM. IND. (LTD) was used. 
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Organic solvents of HPLC grade were employed. All samples were filtered through 




Monitoring of reaction processes via coupled gas chromatography-mass spectrometry was 
performed using G1800C GCDplus with mass detector HP 5971, 5890 Series II with mass 
detector HP 5972 from HEWLETT-PACKARD and 7890A GC-System with mass detector 5975C 
(Triplex-Axis-Detector ) from AGILENT TECHNOLOGIES. HP-5MS columns (30 m × 0.25 mm, 
film 0.25 µm) were used. 
 
Gel permeation chromatography 
Preparative and analytical separations were performed on an GPC-System from Japan 
Analytical Industry, Co. Separation column JAIGEL-1HH was used. HPLC grade chloroform 
stabilized with 0.6% ethanol was employed. All samples were filtered through 




Infrared spectra were recorded using a BRUKER Alpha-P ATR spectrometer. Liquid samples 
were measured as film and solid samples neat. Analysis of the spectral data was carried out 
using OPUS 6. Absorption is given in wave numbers (cm−1). Spectra were recorded in the 
range from 4000 to 400 cm−1. 
 
Mass Spectrometry 
EI- and EI-HR-MS spectra were measured on a Time-of-Flight mass spectrometer AccuTOF 
from JOEL. ESI-mass spectra were recorded on an Ion-Trap mass spectrometer LCQ from 
FINNIGAN or on a Time-of-Flight mass spectrometer microTOF from BRUKER. ESI-HR-MS 
spectra were recorded on a BRUKER APEX IV (7T, Transform Ion Cyclotron Resonance 
(FTICR)) mass spectrometer. The ratios of mass to charge are indicated, intensities relative to 
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Nuclear Magnetic Resonance Spectroscopy (NMR) 
Nuclear magnetic resonance (NMR) spectra were recorded at 300 or 600 MHz (1H NMR), 75 
or 125 MHz (13C NMR and APT) and 282 MHz (19F NMR) on VARIAN Unity-300, AMX 300, 
Inova-500 and Inova-600 instruments. Chemical shifts are reported as δ-values in ppm 
relative to the residual proton peak or the carbon peak of the deuterated solvent. 
1H NMR   13C NMR 
CDCl3   7.26 ppm  77.2 ppm 
DMSO-d6  2.54 ppm  40.5 ppm 
benzene-d6   7.16 ppm  128.1 ppm 
For characterization of the observed resonance multiplicities the following abbrevations 
were applied: s (singlet), d (doublet), t (triplet), q (quartet), pent (pentet), hept (heptet), m 
(multiplet) or analogous representations. The coupling constants J are reported in Hertz (Hz). 
Analysis of the recorded spectra were carried out using MestReNova 10.0 software. 
 
Optical Rotatory Power 
Optical rotations were measured with digital polarimeters PERKIN-ELMER 241 or JASCO P-




Chemicals obtained from commercial sources with purity above 95% were used without 
further purification. 
The following compounds were synthesised according to known literature procedures and 
were pure by comparison with the published analytical data: 
(3-bromobutyl)benzene (80n), 87  2-(4-Bromopentyl)isoindoline-1,3-dione (80p), 88  (6S)-8-
Bromo-2,6-dimethylnon-2-ene (80r),87 4-Methyl-N-(pyridin-2-ylmethyl)benzamide (80a),89 4-
methyl-N-(thiophen-2-ylmethyl)benzamide (95a),89 (L)-Valinol (97),90 (S)-4-Methyl-2-(pyridin-
2-yl)-4,5-dihydrooxazole (98),91 N-(Quinolin-8-yl)pivalamide (62a),92 N-(2-pyrimidyl)-anilines 
                                                          
87
 Gonzalez-Bobes, F.; Fu, G. C. J. Am. Chem. Soc. 2006, 128, 5360–5361. 
88
 Bothmann, H.; Roncarati, R.; Bettinetti, L.; Quinn, J.; Varrone, M.; Valacchi, M.; Nencini, A.; Micco, I.; Ghiron, 
C.; Haydar, S. PCT Int. Appl. 2007, WO 2007098826 A2 Sep 07, 2007. 
89
 Inoue, S.; Shiota, H.; Fukumoto, Y.; Chatani, N. J. Am. Chem. Soc. 2009, 131, 6898–6899. 
90
 Hsiao, Y.; Hegedus, L. S. J. Org. Chem 1997, 62, 3586–3591. 
91
 Binder, J. T.; Cordier, C. J.; Fu, G. C. J. Am. Chem. Soc. 2012, 134, 17003–17006. 
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(69h/i/j/q), 93  cyclododecylbromide (80t), 94  methyl 5-bromohexanoate (80u), 95  (S)-2-
bromooctane ((S)-80k),96 N-(2-fluorophenyl)pyridin-2-amine (123),97 2,4-dichloropyrimidine 
(157), 98  N-Phenylmorpholine-4-carbothioamide (125), 99  N-methyl-N-phenylpyrimidin-2-
amine (122), 100  cyclohexylacetate (137), 101  N-(phenyl-d5)pyrimidin-2-amine (D5-69h),
102 
2,2,2-trifluoroethyl 4-methylbenzenesulfonate (145).103 
 
The following compounds were obtained by the generous courtesy of the following persons: 
Dr. Weifeng Song: N-(quinolin-8-yl)benzamides (59a-g), 
Dr. Jie Li: N-Methylbenzamide (92a), 1,3-Bis((S)-1-phenylethyl)-1H-imidazol-3-ium chloride 
(99) 
Dr. Xu Tian: (S)-4-Isopropyl-2-(pyridin-2-yl)-4,5-dihydrooxazole (117) 
M. Sc. Zhixiong Ruan: N-(2-Pyrimidyl)-anilines (69l-p/r) 
M. Sc. Marc Moselage: 3-Methyl-1-(pyrimidin-2-yl)-1H-indole (127), 1,3-Dimethyl-3,4,5,6-
tetrahydro-2(1H)-pyrimidinone (dry) 
M. Sc. Alexandra Schischko: Methyl N’-acetyl-1-(pyrimidin-2-yl)tryptophanate (128) 
M. Sc. Thomas Müller: N-(2-Pyrimidyl)-anilines (69s) 
 
5.3 General Procedures 
 
General Procedure A 
 
To solution of aniline 107 (2.0 equiv) in dry THF (1.5 mL/mmol) was added n-butyllithium 
(2.0 equiv) under stirring at -78 °C. The reaction was stirred for 15 min at ambient 
temperature, cooled to -78 °C and 2-chloropyrimidin (106) was slowly added as a suspension 
                                                                                                                                                                                     
92
 Zhu, L.; Qiu, R.; Cao, X.; Xiao, S.; Xu, X.; Au, C.-T.; Yin, S.-F. Org. Lett. 2015, 17, 5528–5531. 
93
 Ackermann, L.; Lygin, A. V. Org. Lett. 2012, 14, 764–767. 
94
 Masson, E.; Leroux, F. Helvetica Chimica Acta 2005, 88, 1375–1386. 
95
 Schmidt, V. A.; Quinn, R. K.; Brusoe, A. T.; Alexanian, E. J. J. Am. Chem. Soc. 2014, 136, 14389–14392. 
96
 Liang, Y.; Fu, G. C. J. Am. Chem. Soc. 2015, 137, 9523–9526. 
97
 Qian, G.; Liu, B.; Tan, Q.; Zhang, S.; Xu, B. Eur. J. Org. Chem. 2014, 22, 4837–4843. 
98
 Whittaker, N.; Jones, T. S. G. J. Chem. Soc. 1951, 1565–1570. 
99
 Biswas, K.; Greaney, M. F. Org. Lett. 2011, 13, 4946–4949. 
100
 Johansson Seechurn, C. C. C.; Parisel, S. L.; Colacot, T. J. J. Org. Chem. 2011, 76, 7918–7932. 
101
 Ranu, B. C., Dey, S. S.; Hajra, A. Green Chemistry 2003, 5, 44–46. 
102
 Liu, Y.; Bai, Y.; Zhang, J.; Li, Y.; Jiao, J.; Qi, X. Eur. J. Org. Chem. 2007, 6084–6088. 
103
 Li, L.; Huang, M.; Liu, C.; Xiao, J.-C.; Chen, Q.-Y.; Guo, Y.; Zhao, Z.-G. Org. Lett. 2015, 17, 4714–4717. 
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in THF (0.5 mL). The reaction mixture was slowly warmed to ambient temperature and 
stirred for 16 h. The reaction was stopped by addition of saturated, aqueous Na2CO3 solution. 
After extraction with EtOAc, the organic phase was dried over Na2SO4 and concentrated in 
vacuo. The crude product was purified by flash column chromatography, followed by 
recrystallization from hot toluene to yield 69. 
 
General Procedure B: 
To a mixture of benzamide 59 (0.50 mmol), alkylbromide 80 (1.00 mmol), [(DME)NiCl2] 
(11 mg, 10.0 mol %), BDMAE (32 mg, 40 mol %) and LiOtBu (80 mg, 1.00 mmol) was added 
PhMe (1.0 mL). Thereafter, the reaction mixture was stirred under Ar at 160 °C for 20 h. 
After cooling to ambient temperature, the crude product was purified by column 
chromatography on silica gel to yield product 81. 
 
General Procedure C: 
To a mixture of benzamide 59 (0.50 mmol), trifluoroethyl iodide (82) (1.00 mmol), 
[(DME)NiCl2] (11 mg, 10.0 mol %), BDMAE (32 mg, 40 mol %) and LiOtBu (80 mg, 1.00 mmol) 
was added dry PhMe (1.0 mL). Thereafter, the reaction mixture was stirred under Ar at 
160 °C for 20 h.After cooling to ambient temperature, the crude product was purified by 
column chromatography on silica gel to yield product 84. 
 
General Procedure D1 
Anilines 69 (1.0 mmol), [(DME)NiCl2] (5.5 mg, 2.5 mol %) and LiOtBu (160 mg, 2.0 mmol) 
were placed in a 25 mL Schlenk tube. The tube was evacuated and purged with Ar three 
times. DtBEDA (11.0 µL, 5.0 mol %), alkyl bromides 80 (2.0 mmol) and 1,4-dioxane (2.0 mL) 
were then added, and the mixture was stirred at 100 °C for 16 h. At ambient temperature, 
CH2Cl2 (2.0 mL) was added, concentrated under reduced pressure and purified by flash 
column chromatography on silica gel to afford the product 86. 
 
General Procedure D2 
Anilines 69 (1.0 mmol), [(DME)NiCl2] (11 mg, 5.0 mol %) and LiOtBu (160 mg, 2.0 mmol) were 
placed in a 25 mL Schlenk tube. The tube was evacuated and purged with Ar three times. 
DtBEDA (22.0 µL, 10 mol %), alkyl bromides 80 (2.0 mmol) and 1,4-dioxane (2.0 mL) were 
then added, and the mixture was stirred at 120 °C for 16 h. At ambient temperature, CH2Cl2 
(2.0 mL) was added, concentrated under reduced pressure and purified by flash column 
chromatography on silica gel to afford the products 86. 
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General Procedure D3 
Anilines 69 (1.0 mmol), [NiCl2(H2O)6] (6 mg, 2.5 mol %) and LiOtBu (160 mg, 2.0 mmol) were 
placed in a 25 mL Schlenk tube. The tube was evacuated and purged with Ar three times. 
DtBEDA (11.0 µL, 10 mol %), alkyl bromides 80 (2.0 mmol) and 1,4-dioxane (2.0 mL) were 
then added, and the mixture was stirred at 120 °C for 16 h. At ambient temperature, CH2Cl2 
(2.0 mL) was added, concentrated under reduced pressure and purified by flash column 
chromatography on silica gel to afford the products 86. 
 
General Procedure E1 
Anilines 69 (1.0 mmol), [(DME)NiCl2] (22 mg, 10 mol %) and LiOtBu (160 mg, 2.0 mmol) were 
placed in a 25 mL sealed tube. The tube was evacuated and purged with Ar three times. 
DtBEDA (42.0 µL, 20 mol %) and 2-Me-THF (2.0 mL) were then added. The reaction was 
cooled to -78 °C, trifluoroethylbromide (146) (489 mg, 3.0 mmol) was added and the mixture 
was stirred at 120 °C for 16 h. At ambient temperature, CH2Cl2 (2.0 mL) was added, the 
mixture was concentrated under reduced pressure and purified by flash column 
chromatography on silica gel to afford the products 87. 
 
General Procedure E2 
Anilines 69 (1.0 mmol), [(DME)NiCl2] (22 mg, 10 mol %) and LiOtBu (160 mg, 2.0 mmol) were 
placed in a 25 mL sealed tube. The tube was evacuated and purged with Ar three times. 
BDMAE (76.0 µL, 40 mol %) and PhMe (2.0 mL) were then added. The reaction was cooled to 
-78 °C, trifluoroethylbromide (146) (489 mg, 3.0 mmol) was added and the mixture was 
stirred at 150 °C for 16 h. At ambient temperature, CH2Cl2 (2.0 mL) was added, the mixture 
was concentrated under reduced pressure and purified by flash column chromatography on 
silica gel to afford the products 87. 
 
General Procedure E3 
Anilines 69 (1.0 mmol), [(DME)NiCl2] (22 mg, 10 mol %) and LiOtBu (160 mg, 2.0 mmol) were 
placed in a 25 mL sealed tube. The tube was evacuated and purged with Ar three times. 
BDMAE (76.0 µL, 40 mol %), trifluoroethyliodide (82) (420 mg, 2.0 mmol) and PhMe (2.0 mL) 
were then added, and the mixture was stirred at 100 °C for 16 h. At ambient temperature, 
CH2Cl2 (2.0 mL) was added, the mixture was concentrated under reduced pressure and 
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5.4 Experimental and Analytical Data 
 
5.4.1 Analytical Data for Substrates 
 
Synthesis of N-(2-fluorophenyl)pyrimidin-2-amine (69a) 
 
The general procedure A was followed using 107a (6.83 g, 61.5 mmol) and 106 (3.44 g, 
30.0 mmol). After purification by column chromatography (n-hexane/EtOAc 95:5) and 
recrystallisation 69a (3.47 g, 61%) was obtained as a white solid. Analytical data was 
identical to that previously reported.104  
M.p.: 114-115 °C 
1H NMR (300 MHz, CDCl3): δ = 8.45 (d, J = 4.8 Hz, 2H), 8.43 (ddd, J = 8.5, 8.3, 1.7 Hz, 1H), 7.59 
(s, 1H), 7.19 – 7.06 (m, 2H), 6.98 (dddd, J = 8.3, 7.3, 5.1, 1.7 Hz, 1H), 6.76 (t, J = 4.8 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ = 159.9 (Cq), 158.0 (CH), 152.8 (Cq, d, 
1JC–F = 240.3 Hz), 128.0 (Cq, 
d, 2JC–F = 9.9 Hz), 124.3 (CH, d, 
4JC–F = 3.3 Hz), 122.6 (CH, d, 
3JC–F = 7.8 Hz), 121.0 (CH), 114.9 
(CH, d, 2JC–F = 19.3 Hz), 113.1 (CH). 
19F NMR (283 MHz, CDCl3): δ = -130.91 – -131.03 (m). 
IR (neat): ν͂ = 3231, 3165, 3005, 1576, 1440, 1409, 1251, 1179, 754, 640 cm-1. 
MS (ESI): m/z (relative intensity) 381 (24), 190 (100) [M+H+], 170 (13). 
HR-MS (ESI): m/z calcd for C10H9FN3 [M+H
+] 190.0780, found 190.0777. 
 
Synthesis of N-(o-Tolyl)pyrimidin-2-amine (69b) 
 
Under basic conditions: 
The general procedure A was followed using 107b (6.59 g, 61.50 mmol) and 106 (3.44 g, 
30.0 mmol). After purification by column chromatography (n-hexane/EtOAc 95:5) and 
                                                          
104
 Shaw, J. W.; Grayson, D. H.; Rozas, I. ARKIVOC 2014, 2, 161–174. 
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recrystallisation 69b (3.81 g, 69%) was obtained as a white solid. Analytical data was 
identical to that previously reported.93 
 
Under acidic conditions: 
A Schlenk flask was charged with AlCl3 (4.00 g, 30 mmol) and evacuated and purged with Ar 
three times. THF (30 mL), aniline 107b and 106 (3.44 g, 30 mmol) were added successively at 
0 °C. The reaction was stirred for 48 h at ambient temperature. The reaction was stopped 
with H2O (20 mL), basified with K2CO3 and extracted with EtOAc (100 mL). The organic phase 
was washed with brine (100 mL), dried over Na2SO4 and concentrated in vacuo. After 
purification by column chromatography (n-hexane/EtOAc 95:5) 69b (1.42 g, 26%) was 
obtained as a white solid. Analytical data was identical to that previously reported. 
M.p.: 88-89 °C 
1H NMR (300 MHz, CDCl3): δ = 8.39 (d, J = 4.8 Hz, 2H), 7.92 (d, J = 7.8 Hz, 1H), 7.29 – 7.20 (m, 
2H), 7.10 – 7.01 (m, 2H), 6.69 (t, J = 4.8 Hz, 1H), 2.32 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 160.8 (Cq), 158.2 (CH), 137.3 (Cq), 130.7 (CH), 129.6 (Cq), 126.8 
(CH), 124.3 (CH), 122.6 (CH), 112.4 (CH), 18.2 (CH3). 
IR (neat): ν͂ = 3228, 3031, 2927, 1579, 1441, 1406, 1187, 797, 751, 719 cm-1. 
MS (ESI): m/z (relative intensity) 208 (6), 186 (100) [M+H+], 170 (4). 
HR-MS (ESI): m/z calcd for C11H11N3 [M+H
+] 186.1031, found 186.1030. 
 
Synthesis of N-(2-methoxyphenyl)pyrimidin-2-amine (69c) 
 
The general procedure A was followed using 107c (4.93 g, 40.0 mmol) and 106 (2.29 g, 
20.0 mmol). After purification by column chromatography (n-hexane/EtOAc 85:15) and 
recrystallisation 69c (1.45 g, 37%) was obtained as a white solid. Analytical data was identical 
to that previously reported.104  
M.p.: 119–120 °C 
1H NMR (300 MHz, CDCl3): δ = 8.53 – 8.48 (m, 1H), 8.43 (d, J = 4.8 Hz, 2H), 7.78 (s, 1H), 7.04 – 
6.95 (m, 2H), 6.92 – 6.87 (m, 1H), 6.70 (t, J = 4.8 Hz, 1H), 3.90 (s, 3H). 
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13C NMR (75 MHz, CDCl3): δ = 160.2 (Cq), 158.0 (CH), 148.0 (Cq), 129.3 (Cq), 121.9 (CH), 121.0 
(CH), 118.6 (CH), 112.5 (CH), 110.1 (CH), 55.8 (CH3). 
IR (neat): ν͂ = 3382, 2998, 2836, 1569, 1520, 1432, 1405, 1241, 721, 566 cm-1. 
MS (ESI): m/z (relative intensity) 224 (12), 202 (100) [M+H+], 187 (7), 170 (18). 
HR-MS (ESI): m/z calcd for C11H11N3O [M+H
+] 202.0980, found 202.0979. 
 
Synthesis of N-[2-(tert-Butyl)phenyl]pyrimidin-2-amine (69d) 
 
The general procedure A was followed using 107d (2.98 g, 20.0 mmol) and 106 (1.14 g, 
10.0 mmol). After purification by column chromatography (n-hexane/EtOAc 95:5) and 
recrystallisation 69d (1.12 g, 50%) was obtained as a white solid.  
M.p.: 95-96 °C 
1H NMR (300 MHz, CDCl3): δ =
 8.35 (d, J = 4.8 Hz, 2H), 7.58 (dd, J = 7.9, 1.5 Hz, 1H), 7.45 (dd, J 
= 7.9, 1.6 Hz, 1H), 7.27 (ddd, J = 7.5, 7.5, 1.6 Hz, 1H), 7.17 (ddd, J = 7.5, 7.5, 1.6 Hz, 1H), 6.89 
(br s, 1H), 6.64 (t, J = 4.8 Hz, 1H), 1.44 (s, 9H). 
13C NMR (75 MHz, CDCl3): δ =
 161.5 (Cq), 158.4 (CH), 143.8 (Cq), 136.9 (Cq), 128.4 (CH), 127.0 
(CH), 126.9 (CH), 125.9 (CH), 112.1 (CH), 35.0 (Cq), 30.8 (CH3). 
IR (neat): ν͂ = 3211, 3004, 2958, 2936, 1570, 1440, 1407, 1257, 1088, 773 cm-1. 
MS (ESI): m/z (relative intensity) 250 (23), 228 (100) [M+H+], 172 (57). 
HR-MS (ESI): m/z calcd for C14H18N3 [M+H
+] 228.15004, found 228.1498. 
 
Synthesis of N-([1,1'-Biphenyl]-2-yl)pyrimidin-2-amine (69e) 
 
The general procedure A was followed using 107e (3.48 g, 20.5 mmol) and 106 (1.14 g, 
10.0 mmol). After purification by column chromatography (n-hexane/EtOAc 9:1) and 
recrystallisation 69e (0.91 g, 37%) was obtained as a white solid. Analytical data was 
identical to that previously reported.  
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M.p.: 165–166 °C 
1H NMR (300 MHz, CDCl3): δ =
 8.40 (dd, J = 8.1, 0.9 Hz, 1H), 8.38 (d, J = 4.8 Hz, 2H), 7.50 – 
7.35 (m, 6H), 7.27 (d, J = 8.3, 1.6 Hz, 1H), 7.13 (dd, J = 7.5, 7.5, 1.2 Hz, 1H), 7.08 (br s, 1H), 
6.69 (t, J = 4.8 Hz, 1H). 
13C NMR (75 MHz, CDCl3): δ = 160.3 (Cq), 158.1 (CH), 138.8 (Cq), 136.4 (Cq), 130.5 (Cq), 129.6 
(CH), 129.2 (CH), 128.3 (CH), 127.9 (CH), 123.0 (CH), 120.6 (CH), 112.7 (CH). 
IR (neat): ν͂ = 3268, 3225, 3018, 1575, 1519, 1433, 1407, 1267, 738, 698 cm-1. 
MS (ESI): m/z (relative intensity) 381 (5), 270 (7), 248 (100) [M+H+], 195 (1), 178 (3). 
HR-MS (ESI): m/z calcd for C16H14N3 [M+H
+] 248.1187, found 248.1185. 
 
Synthesis of N-[3-(Trifluoromethyl)phenyl]pyrimidin-2-amine (69f) 
 
The general procedure A was followed using 107f (13.2 g, 82. 0 mmol) and 106 (5.58 g, 
40.0 mmol). After purification by column chromatography (n-hexane/EtOAc 9:1) and 
recrystallisation 69f (3.54 g, 37%) was obtained as a white solid.  
M.p.: 123-124 °C 
1H NMR (300 MHz, CDCl3): δ = 8.47 (d, J = 4.8 Hz, 2H), 8.20 (br s, 1H), 8.02 (s, 1H), 7.79 (dd, J 
= 8.4, 1.7 Hz, 1H), 7.43 (dd, J = 8.4, 7.7 Hz, 1H), 7.29 (ddd, J = 7.7, 1.5, 0.8 Hz, 1H), 6.79 (t, J = 
4.8 Hz, 1H). 
13C NMR (126 MHz, CDCl3): δ =
 159.9 (Cq), 158.0 (CH), 140.2 (Cq), 131.3 (Cq, q, 
2JC–F = 32.4 Hz), 
129.4 (CH), 124.2 (Cq, q, 
1JC–F = 272.6 Hz), 122.3 (CH, q, 
4JC–F = 1.2 Hz), 119.0 (CH, q, 
3JC–F = 
3.7 Hz), 116.0 (CH, q, 3JC–F = 3.9 Hz), 113.3 (CH). 
19F NMR (283 MHz, CDCl3): δ = -62.68 (s). 
IR (neat): ν͂ = 3294, 3119, 1580, 1318, 1152, 1102, 1072, 872, 792, 765 cm-1. 
MS (ESI): m/z (relative intensity) 381 (22), 240 (100) [M+H+], 220 (10), 185 (3). 
HR-MS (ESI): m/z calcd for C11H8F3N3 [M+H
+] 240.0748, found 240.0745. 
 
Synthesis of N-(Naphthalen-2-yl)pyrimidin-2-amine (69g) 
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The general procedure A was followed using 107g (2.94 g, 20.5 mmol) and 106 (1.14 g, 
10.0 mmol). After purification by column chromatography (n-hexane/EtOAc 9:1) and 
recrystallisation 69g (0.93 g, 42%) was obtained as a white solid. Analytical data was 
identical to that previously reported.93 
M.p.: 147-148 °C 
1H NMR (300 MHz, CDCl3): δ = 8.59 (br s, 1H), 8.32 (d, J = 4.8 Hz, 2H), 8.16 – 8.09 (m, 1H), 
7.99 (d, J = 7.5 Hz, 1H), 7.95 – 7.86 (m, 1H), 7.73 (d, J = 8.2 Hz, 1H), 7.60 – 7.45 (m, 3H), 6.63 
(t, J = 4.8 Hz, 1H). 
13C NMR (75 MHz, CDCl3): δ = 161.6 (Cq), 158.2 (CH), 134.5 (2Cq), 128.6 (CH), 128.3 (Cq), 
126.0 (CH), 126.0 (CH), 125.9 (CH), 125.1 (CH), 121.9 (CH), 120.6 (CH), 112.2 (CH). 
IR (neat): ν͂ = 3230, 3045, 2914, 1572, 1529, 1443, 1392, 1271, 777, 511 cm-1. 
MS (ESI): m/z (relative intensity) 244 (8), 222 (100) [M+H+]. 
HR-MS (ESI): m/z calcd for C14H11N3 [M+H
+] 222.1031, found 222.1024. 
 
Synthesis of 2-Chloro-4-(p-tolyl)pyrimidine (160) 
 
Following the reported procedure, 105  2,4-dichloropyrimidine (2.2 g, 15 mmol) and p-
tolylboronic acid (1.4 g, 10 mmol) were reacted. After purification by flash column 
chromatography (n-hexane/EtOAc 96:4) and Kugelrohr distilliation (1 mbar, 170 °C) 160 
(1.4 g, 69%) was obtained as a white solid. 
M.p.: 102-103 °C 
1H NMR (300 MHz, CDCl3): δ = 8.59 (d, J = 5.3 Hz, 1H), 7.99 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 
5.3 Hz, 1H), 7.31 (d, J = 8.2 Hz, 2H), 2.43 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 167.3 (CH), 161.9 (Cq), 159.7 (Cq), 142.7 (CH), 132.4 (Cq), 130.0 
(CH), 127.5 (CH), 114.9 (CH), 21.7 (CH3). 
                                                          
105
 Peng, Z.-H.; Journet, M.; Humphrey, G. Org. Lett. 2008, 8, 395–398. 
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IR (neat): ν͂ = 1566, 1532, 1424, 1346, 1176, 1066, 817, 770, 687, 483 cm-1. 
MS (ESI): m/z (relative intensity) 227 (7), 205 (100) [M+H+], 177 (4), 149 (5), 117 (46), 103 
(14). 
HR-MS (ESI): m/z calcd for C11H10ClN2 [M+H
+] 205.0532, found 205.0531. 
 
Synthesis of N-(2-Fluorophenyl)-4-(p-tolyl)pyrimidin-2-amine (121) 
 
A round-bottom flask was charged with 2-chloro-4-(p-tolyl)pyrimidine (160) (819 mg, 
4.0 mmol), 1,4-dioxane (12 mL), 2-fluoroaniline (0.58 mL, 6.0 mmol) and trifluoroacetic acid 
(3.06 mL, 40 mmol). The reaction was stirred at 80 °C for 16 h. The reaction was cooled to 
ambient temperature, solvents evaporated in vacuo, residue basified with K2CO3 and 
extracted with EtOAc threefold. The organic phases were dried over Na2SO4 and evaporated 
in vacuo. After purification by flash column chromatography (n-hexane/EtOAc 9:1) 121 
(703 mg, 63%) was obtained as a white solid. 
M.p.: 120-121 °C 
1H NMR (600 MHz, CDCl3): δ = 8.63 (ddd, J = 8.4, 8.2, 1.5 Hz, 1H), 8.47 (d, J = 5.2 Hz, 1H), 7.99 
(d, J = 7.9 Hz, 2H), 7.52 (s, 1H), 7.31 (d, J = 7.9 Hz, 2H), 7.20 (dd, J = 7.9, 7.9 Hz, 1H), 7.17 (d, J 
= 5.2 Hz, 1H), 7.13 (ddd, J = 11.4, 8.2, 1.3 Hz, 1H), 7.02 – 6.96 (m, 1H), 2.44 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 165.1 (Cq), 160.1 (Cq), 158.5 (CH), 152.5 (Cq, d, 
1JC–F = 
242.8 Hz), 141.3 (Cq), 134.3 (Cq), 129.7 (CH), 128.5 (Cq, d, 
2JC–F = 10.1 Hz), 127.2 (CH), 124.4 
(CH, d, 4JC–F = 3.1 Hz), 122.1 (CH, d, 
3JC–F = 7.0 Hz), 120.7 (CH), 114.8 (CH, d, 
2JC–F = 18.7 Hz), 
108.7 (CH), 21.6 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -131.55 (ddd, J = 9.7, 7.2, 4.0 Hz). 
IR (neat): ν͂ = 3264, 3015, 1537, 1438, 1410, 1254, 1181, 809, 748, 509 cm-1. 
MS (EI): m/z (relative intensity) 279 (37) [M+], 260 (100), 138 (4), 115 (8), 91 (5). 
HR-MS (EI): m/z calcd for C17H14FN3 [M
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Synthesis of 3-(Pyrimidin-2-yloxy)phenol (124) 
 
A round-bottom flask was charged with THF (40 mL), resorcinol (11.0 g, 100 mmol), 2-
chloropyrimidine (106) (2.29 g, 20 mmol) and K2CO3 (5.52 g, 40 mmol). The reaction was 
stirred at 50 °C for 36 h. The crude reaction mixture was filtered through a paper filter, 
washed with EtOAc and solvent evaporated in vacuo. After purification by flash column 
chromatography (n-hexane/EtOAc 1:2) 124 (382 mg , 10%) was isolated as a pale brown solid. 
M.p.: 205-206 °C 
1H NMR (600 MHz, DMSO-d6): δ = 9.61 (s, 1H), 8.63 (d, J = 4.8 Hz, 2H), 7.23 (t, J = 4.8 Hz, 1H), 
7.20 (dd, J = 8.1, 8.1 Hz, 1H), 6.66 (ddd, J = 8.1, 2.3, 0.8 Hz, 1H), 6.59 (ddd, J = 8.1, 2.3, 0.8 Hz, 
1H), 6.56 (dd, J = 2.2, 2.2 Hz, 1H). 
13C NMR (125 MHz, DMSO-d6): δ = 164.5 (Cq), 159.7 (CH), 158.3 (Cq), 153.6 (Cq), 129.8 (CH), 
116.7 (CH), 112.1 (CH), 111.8 (CH), 108.6 (CH). 
IR (neat): ν͂ = 3204, 2963, 2925, 1579, 1410, 1246, 1136, 1074, 787, 638 cm-1. 
MS (EI): m/z (relative intensity) 188 (100) [M+], 160 (32), 146 (10), 133 (11), 117 (38), 93 (15). 
HR-MS (EI): m/z calcd for C10H7N2O2 [M
 +] 188.0586, found 188.0587. 
 
Synthesis of Trifluoroethylbromide (146) 
 
A round-bottom flask was charged with DMPU (50 mL), 2,2,2-trifluoroethyl 4-
methylbenzenesulfonate (145) (50.8 g, 200 mmol) and NaBr (61.7 g, 600 mmol). A distillation 
bridge with a two-necked collection flask was attached to the round flask and the reaction 
was stirred at 170 °C for 1.5 h. The pure product 146 (18.3 g, 56%) distilled directly into the 
collection flask. The analytical data was identical to that reported in the literature.106 
1H NMR (300 MHz, CDCl3): δ = 3.67 (q, J = 9.0 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 123.2 (Cq, q, 
1JC–F = 274.7 Hz), 26.0 (CH2, q, 
2JC–F = 37.7 Hz). 
19F NMR (283 MHz, CDCl3): δ = -68.76 (t, J = 9.0 Hz). 
                                                          
106
 Sigma-Aldrich Co. , http://www.sigmaaldrich.com/spectra/fnmr/FNMR003857.PDF, (accessed 22
nd
 of April 
2016) 
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IR (neat): ν͂ = 3051, 2991, 1431, 1310, 1263, 1235, 1125, 1065, 719, 629 cm-1. 
MS (EI): m/z (relative intensity) 162 (100) [M+], 143 (22), 123 (11), 93 (26), 83 (95), 79 (10), 
64 (39). 
HR-MS (ESI): [not available] 
 
5.4.2 Analytical Data for C–H Secondary Alkylation of Benzamides 59 
 
Synthesis of 2-Cyclobutyl-4-methyl-N-(quinolin-8-yl)benzamide (81ab) 
 
The general procedure B was followed using 59a (131 mg, 0.50 mmol) and 80b (67.5 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 96:4) 81ab 
(132 mg, 83%) was obtained as a white solid. 
M.p.: 136-137 °C 
1H NMR (600 MHz, CDCl3): δ = 10.10 (s, 1H), 8.94 (d, J = 7.5 Hz, 1H), 8.76 (dd, J = 4.2, 1.6 Hz, 
1H), 8.18 (dd, J = 8.2, 1.6 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 7.54 (dd, J = 8.2, 1.1 Hz, 1H), 7.51 (d, 
J = 7.9 Hz, 1H), 7.45 (dd, J = 8.2, 4.2 Hz, 1H), 7.27 (s, 1H), 7.12 (d, J = 7.7 Hz, 1H), 4.09 (pent, J 
= 8.9 Hz, 1H), 2.44 (s, 3H), 2.41–2.35(m, 2H), 2.23–2.15(m, 2H), 2.00–1.90 (m, 1H), 1.81–1.74 
(m, 1H). 
13C NMR (126 MHz, CDCl3): δ = 168.8 (Cq), 148.3 (CH), 144.3 (Cq), 140.4 (Cq), 138.7 (Cq), 136.5 
(CH), 135.0 (Cq), 133.4 (Cq), 128.2 (Cq), 127.9 (CH), 127.6 (CH), 127.4 (CH), 126.6 (CH), 121.8 
(CH), 121.8 (CH), 116.6 (CH), 38.0 (CH), 30.0 (CH2), 21.7 (CH3), 18.4 (CH2).  
IR (ATR): ν͂ = 3350, 2970, 2860, 1668, 1517, 1481, 1324, 1258, 827, 678, 598 cm-1. 
MS (EI): m/z (relative intensity) 316 (46) [M+], 287 (14), 172 (86), 157 (77), 145 (100), 115 
(40), 91 (20), 43 (14). 
HR-MS (EI): m/z calcd for C21H20N2O [M
+] 316.1576, found 316.1583. 
 
Synthesis of 2-Cyclopentyl-4-methyl-N-(quinolin-8-yl)benzamide (81ac) 
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The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80c (298 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 97:3) 81ac 
(235 mg, 71%) was obtained as a white solid. 
M.p.: 121-122 °C 
1H NMR (600 MHz, CDCl3): δ = 10.13 (s, 1H), 8.95 (d, J = 7.8 Hz, 1H), 8.76 (dd, J = 4.2, 1.7 Hz, 
1H), 8.18 (dd, J = 8.3, 1.7 Hz, 1H), 7.60 (t, J = 7.8 Hz, 1H), 7.55 (dd, J = 7.8, 1.3 Hz, 1H), 7.50 (d, 
J = 7.6 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 7.26 (s, 1H), 7.10 (ddd, J = 7.6, 1.6, 0.8 Hz, 1H), 
3.54 (tt, J = 9.2, 7.3 Hz, 1H), 2.41 (s, 3H), 2.21–2.14 (m, 2H), 1.83–1.78 (m, 2H), 1.70–1.61 (m, 
4H). 
13C NMR (126 MHz, CDCl3): δ = 169.2 (Cq), 148.3 (CH), 145.1 (Cq), 140.4 (Cq), 138.7 (Cq), 136.5 
(CH), 135.0 (Cq), 134.7 (Cq), 128.2 (Cq), 127.7 (CH), 127.6 (CH), 127.2 (CH), 126.6 (CH), 121.8 
(CH), 121.7 (CH), 116.7 (CH), 42.0 (CH), 35.6 (CH2), 26.1 (CH2), 21.8 (CH3). 
IR (ATR): ν͂ = 3352, 2955, 2865, 1667, 1515, 1480, 1322, 825, 761, 593 cm-1. 
MS (EI): m/z (relative intensity) 330 (35) [M+], 186 (100), 169 (55), 158 (86), 143 (48), 129 
(22), 115 (30), 105 (15), 91 (16).  
HR-MS (ESI): m/z calcd for C22H23N2O [M+H
+] 331.1805, found 331.1804. 
 
 Synthesis of 2-Cyclohexyl-4-methyl-N-(quinolin-8-yl)benzamide (81ad) 
 
The general procedure B was followed using 59a (131 mg, 0.50 mmol) and 80d (163 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 81ad 
(148 mg, 86%) was obtained as a white solid. 
M.p.: 177–178 °C. 
1H NMR (300 MHz, CDCl3): δ = 10.12 (s, 1H), 8.94 (dd, J = 7.3, 1.1 Hz, 1H), 8.73 (dd, J = 4.3, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.63–7.47 (m, 3H), 7.42 (dd, J = 8.3, 4.3 Hz, 1H), 
5 Experimental 
- 71 - 
 
7.23 (s, 1H), 7.09 (dd, J = 7.8, 1.1 Hz, 1H), 3.14 (tt, J = 11.7, 3.3 Hz, 1H), 2.40 (s, 3H),1.99 (d, J 
= 12.8 Hz, 2H), 1.83–1.70 (m, 2H), 1.67–1.15 (m, 6H). 
13C NMR (75 MHz, CDCl3): δ = 168.8 (Cq), 148.1 (CH), 146.1 (Cq), 140.2 (Cq), 138.5 (Cq), 136.3 
(CH), 134.9 (Cq), 133.7(Cq), 128.0 (Cq), 127.7 (CH), 127.4 (CH), 127.3 (CH), 126.5 (CH), 121.6 
(CH), 121.6 (CH), 116.4 (CH), 40.3 (CH), 34.7 (CH2), 26.7 (CH2), 26.1 (CH2), 21.6 (CH3). 
IR (neat): ν͂ = 3339, 2935, 2849, 1665, 1609, 1264, 828, 691 cm-1. 
MS (EI): m/z (relative intensity) 344 (43) [M+], 200 (100), 183 (83), 144 (79), 105 (35), 43 (20). 
HR-MS (EI): m/z calcd for C23H24N2O [M
+] 344.1889, found 344.1888. 
 
Synthesis of 2-Cycloheptyl-4-methyl-N-(quinolin-8-yl)benzamide (81ae) 
 
The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80e (354 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 97:3) 81ae 
(196 mg, 55%) was obtained as a white solid. 
M.p.: 157-158 °C 
1H NMR (600 MHz, CDCl3): δ = 10.12 (s, 1H), 8.96 (d, J = 7.5 Hz, 1H), 8.75 (dd, J = 4.3, 1.5 Hz, 
1H), 8.18 (dd, J = 8.3, 1.7 Hz, 1H), 7.61 (t, J = 7.5 Hz, 1H), 7.55 (dd, J = 8.3, 1.5 Hz, 1H), 7.49 (d, 
J = 7.7 Hz, 1H), 7.45 (dd, J = 8.3, 4.3 Hz, 1H), 7.22 (s, 1H), 7.09 (d, J = 7.7 Hz, 1H), 3.26 (tt, J = 
10.4, 3.4 Hz, 1H), 2.40 (s, 3H), 2.07–2.01 (m, 2H), 1.78–1.67 (m, 4H), 1.65–1.59 (m, 2H), 1.58–
1.48 (m, 4H). 
13C NMR (126 MHz, CDCl3): δ = 169.0 (Cq), 148.4 (Cq), 148.3 (CH), 140.5 (Cq), 138.7 (Cq), 136.5 
(CH), 135.1 (Cq), 133.2 (Cq), 128.2 (Cq), 128.1 (CH), 127.6 (CH), 127.3 (CH), 126.5 (CH), 121.7 
(CH), 121.7 (CH), 116.7 (CH), 42.5 (CH), 37.2 (CH2), 28.0 (CH2), 27.5 (CH2), 21.8 (CH3). 
IR (ATR): ν͂ = 3342, 2920, 2858, 1667, 1518, 1478, 1257, 1133, 829, 689, 576 cm-1. 
MS (EI): m/z (relative intensity) 358 (43) [M+], 214 (100), 196 (44), 171 (46), 155 (52), 144 
(75), 130 (30), 105 (26), 91 (16). 
HR-MS (EI): m/z calcd for C24H26N2O [M
+] 358.2045, found 358.2055. 
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Synthesis of 2-(exo-norborn-2-yl)-4-methyl-N-(quinolin-8-yl)benzamide (81af) 
 
The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80f (350 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 97:3) 81af 
(231 mg, 65%) was obtained as a white solid. 
M.p.: 158-160 °C 
1H NMR (600 MHz, CDCl3): δ = 10.11 (s, 1H), 8.95 (d, J = 7.6 Hz, 1H), 8.75 (dd, J = 4.2, 1.5 Hz, 
1H), 8.19 (dd, J = 8.3, 1.6 Hz, 1H), 7.61 (t, J = 7.9 Hz, 1H), 7.55 (dd, J = 8.3, 1.5 Hz, 1H), 7.50 (d, 
J = 7.6 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 7.25 (s, 1H), 7.11–7.08 (m, 1H), 3.30 (dd, J = 8.8, 
6.0 Hz, 1H), 2.51 (d, J = 3.2 Hz, 1H), 2.42 (s, 3H), 2.30 (d, J = 4.2 Hz, 1H), 1.84 (ddd, J = 11.9, 
9.1, 2.3 Hz, 1H), 1.68–1.62 (m, 2H), 1.53–1.47 (m, 2H), 1.31 (ddd, J = 10.6, 6.9, 2.4 Hz, 1H), 
1.26–1.23 (m, 1H), 1.21–1.17 (m, 1H). 
13C NMR (126 MHz, CDCl3): δ = 169.3 (Cq), 148.2 (CH), 145.9 (Cq), 140.1 (Cq), 138.6 (Cq), 136.6 
(CH), 135.0 (Cq), 134.6 (Cq), 128.2 (Cq), 127.7 (CH), 127.5 (CH), 127.1 (CH), 126.2 (CH), 121.8 
(CH), 121.7 (CH), 116.8 (CH), 43.7 (CH), 42.8 (CH), 40.3 (CH2), 37.1 (CH), 36.9 (CH2), 30.7 (CH2), 
28.8 (CH2), 21.9 (CH3). 
IR (ATR): ν͂ = 3335, 2950, 2869, 1672, 1517, 1478, 1324, 826, 688, 596 cm-1. 
MS (EI): m/z (relative intensity) 356 (29) [M+], 212 (100), 184 (32), 171 (25), 144 (31), 115 
(24), 67 (26). 
HR-MS (EI): m/z calcd for C24H24N2O [M
+] 356.1889, found 356.1890. 
 
Synthesis of 2-(2-Adamantyl)-4-methyl-N-(quinolin-8-yl)benzamide (81ag) 
 
The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80g (430 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 96:4) 81ag 
(104 mg, 28%) was obtained as a white solid. 
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M.p.: 169–170 °C 
1H NMR (600 MHz, CDCl3): δ = 10.16 (s, 1H), 8.91 (d, J = 7.4 Hz, 1H), 8.78 (dd, J = 4.2, 1.7 Hz, 
1H), 8.18 (dd, J = 8.3, 1.6 Hz, 1H), 7.59 (dd, J = 7.9, 7.9 Hz, 1H), 7.55 (d, J = 5.2 Hz, 1H), 7.54 
(dd, J = 7.4, 1.5 Hz, 1H), 7.46 (dd, J = 8.2, 4.2 Hz, 1H), 7.40 (s, 1H), 7.12 (d, J = 7.6 Hz, 1H), 3.92 
(s, 1H), 2.43 (s, 3H), 2.30 (s, 2H), 1.95 (d, J = 12.6 Hz, 2H), 1.90 (s, 1H), 1.87 (s, 2H), 1.85 – 
1.81 (m, 3H), 1.70 (s, 2H), 1.59 (d, J = 12.7 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 169.7 (Cq), 148.3 (CH), 144.0 (Cq), 139.8 (Cq), 138.7 (Cq), 136.5 
(CH), 135.2 (Cq), 134.3 (Cq), 129.1 (CH), 128.5 (CH), 128.2 (Cq), 127.7 (CH), 126.2 (CH), 121.8 
(CH), 121.7 (CH), 116.6 (CH), 44.8 (CH), 39.9 (CH2), 38.0 (CH2), 32.7 (CH2), 32.6 (CH), 28.0 (CH), 
27.8 (CH), 22.0 (CH3). 
IR (neat): ν͂ = 3342, 2901, 2848, 1672, 1517, 1480, 1384, 1324, 826, 791 cm-1. 
MS (EI): m/z (relative intensity) 396 (23) [M+], 252 (100), 234 (9), 195 (20), 181 (9), 144 (761). 
HR-MS (EI): m/z calcd for C27H28N2O [M
+] 396.2202, found 396.2212. 
 
Synthesis of 2-iso-Propyl-4-methyl-N-(quinolin-8-yl)benzamide (81ai) 
 
The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80i (163 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 97:3) 81ai 
(200 mg, 66%) was obtained as a white solid. 
M.p.: 118-119 °C 
1H NMR (600 MHz, CDCl3): δ = 10.14 (s, 1H), 8.95 (d, J = 7.5 Hz, 1H), 8.75 (dd, J = 4.2, 1.6 Hz, 
1H), 8.17 (dd, J = 8.3, 1.3 Hz, 1H), 7.60 (t, J = 7.9 Hz, 1H), 7.55 (dd, J = 8.2, 1.3 Hz, 1H), 7.50 (d, 
J = 7.5 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 7.26 (s, 1H), 7.12 (dd, J = 7.9, 0.8 Hz, 1H), 3.54 
(hept, J = 6.9 Hz, 1H), 2.42 (s, 3H), 1.31 (d, J = 6.9 Hz, 6H). 
13C NMR (126 MHz, CDCl3): δ = 169.0 (Cq), 148.3 (CH), 147.4 (Cq), 140.5 (Cq), 138.7 (Cq), 136.5 
(CH), 135.0 (Cq), 133.8 (Cq), 128.1 (Cq), 127.6 (CH), 127.2 (CH), 127.1 (CH), 126.7 (CH), 121.9 
(CH), 121.8 (CH), 116.6 (CH), 30.0 (CH), 24.5 (CH3), 21.8 (CH3). 
IR (ATR): ν͂ = 3338, 2966, 1674, 1518, 1325, 825, 686, 599 cm-1. 
MS (EI): m/z (relative intensity) 304 (36) [M+], 160 (100), 145 (67), 128 (25), 117 (21), 105 
(16), 91 (19). 
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HR-MS (EI): m/z calcd for C20H20N2O [M
+] 304.1576, found 304.1570. 
 
Synthesis of 2-(sec-Butyl)-4-methyl-N-(quinolin-8-yl)benzamide (81aj) 
 
The general procedure B was followed using 59a (131 mg, 0.50 mmol) and 80j (137 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 20:1) 81aj 
(98 mg, 62%) was obtained as a colorless oil. 
1H NMR (300 MHz, CDCl3): δ = 10.10 (s, 1H), 8.94 (dd, J = 7.3, 1.4 Hz, 1H), 8.73 (dd, J = 4.3, 
1.7 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.61–7.51 (m, 2H), 7.49 (d, J = 7.9 Hz, 1H),7.42 (dd, J 
= 8.3, 4.3 Hz, 1H), 7.19 (s, 1H), 7.10 (ddd, J = 7.9, 1.7, 0.7 Hz, 1H), 3.24 (tq, J = 7.2, 6.9 Hz, 1H), 
2.40 (s, 3H), 1.77–1.55 (m, 2H), 1.29 (d, J = 6.7 Hz, 3H), 0.83 (t, J = 7.0 Hz, 3H). 
13C NMR (75 MHz, CDCl3): δ = 168.9 (Cq), 148.2 (CH), 146.0 (Cq), 140.2 (Cq), 138.5(Cq), 136.3 
(CH), 134.9 (Cq), 134.4 (Cq), 127.9 (Cq), 127.4 (CH), 127.2 (CH), 127.0 (CH),126.5 (CH), 121.6 
(CH), 121.5 (CH), 116.4 (CH), 36.8 (CH), 31.1 (CH2), 22.3 (CH3), 21.6 (CH3), 12.3 (CH3). 
IR (ATR): ν͂ = 3350, 2960, 2871, 1671, 1422,  1260, 919, 789 cm-1. 
MS (EI): m/z (relative intensity) 318 (55) [M+], 159 (100), 142 (46), 91 (27), 43 (8). 
HR-MS (EI): m/z calcd for C21H22N2O [M
+] 318.1732, found 318.1730. 
 
Synthesis of 2-(Hexan-2-yl)-4-methyl-N-(quinolin-8-yl)benzamide (81ak) 
 
The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80ak (330 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 96:4) 81ak 
(181 mg, 52%) was obtained as a clear oil. 
1H NMR (300 MHz, CDCl3): δ = 10.10 (s, 1H), 8.94 (d, J = 7.3 Hz, 1H), 8.75 (dd, J = 3.9, 1.8 Hz, 
1H), 8.17 (dd, J = 8.5, 1.1 Hz, 1H), 7.64 – 7.51 (m, 2H), 7.51 – 7.41 (m, 2H), 7.21 (s, 1H), 7.11 
(d, J = 7.7 Hz, 1H), 3.40 – 3.21 (m, 1H), 2.42 (s, 3H), 1.74 – 1.56 (m, 2H), 1.32 – 1.17 (m, 6H), 
0.87 – 0.74 (m, 4H). 
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13C NMR (75 MHz, CDCl3): δ = 169.1 (Cq), 148.4 (CH), 146.4 (CH), 140.4 (Cq), 138.7 (Cq), 136.4 
(Cq), 135.0 (CH), 134.5 (CH), 128.1 (CH), 127.6 (Cq), 127.4 (Cq), 127.2 (Cq), 126.6 (CH), 121.8 
(CH), 121.8 (CH), 116.7 (CH), 61.2 (CH), 38.3 (CH2), 35.4 (CH3), 30.2 (CH2), 23.0 (CH2), 21.8 
(CH3), 14.1 (CH3). 
IR (neat): ν͂ = 3350, 2958, 2926, 2858, 1676, 1521, 1482, 1325, 1261, 825 cm-1. 
MS (ESI): m/z (relative intensity) 715 (64), 369 (100), 347 (76) [M+H+], 236 (8), 203 (20). 
HR-MS (ESI): m/z calcd for C23H27N2O [M+H
+] 347.2123, found 347.2115. 
 
Synthesis of 4-Methyl-2-(pentan-3-yl)-N-(quinolin-8-yl)benzamide (81al) 
 
The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80l (302 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 97:3) 81al 
(126 mg, 38%) was obtained as a white solid. 
M.p.: 80–81 °C 
1H NMR (300 MHz, CDCl3): δ = 10.07 (s, 1H), 8.94 (dd, J = 7.3, 1.7 Hz, 1H), 8.74 (dd, J = 4.2, 
1.7 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.63 – 7.54 (m, 2H), 7.49 (d, J = 7.7 Hz, 1H), 7.44 (dd, 
J = 8.3, 4.2 Hz, 1H), 7.15 (s, 1H), 7.11 (ddd, J = 7.7, 1.7, 0.6 Hz, 1H), 3.06 (tt, J = 8.8, 5.9 Hz, 
1H), 2.42 (s, 3H), 1.80 – 1.60 (m, 4H), 0.83 (t, J = 7.4 Hz, 6H). 
13C NMR (125 MHz, CDCl3): δ = 169.2 (Cq), 148.3 (CH), 144.3 (Cq), 140.2 (Cq), 138.7 (Cq), 136.4 
(CH), 135.8 (Cq), 135.1 (Cq), 128.1 (Cq), 127.6 (CH), 127.5 (CH), 127.0 (CH), 126.7 (CH), 121.7 
(CH), 121.7 (CH), 116.6 (CH), 44.1 (CH), 29.6 (CH2), 21.8 (CH3), 12.3 (CH3). 
IR (neat): ν͂ = 3342, 2959, 2923, 2854, 1667, 1519, 1481, 1383, 1325, 781 cm-1. 
MS (EI): m/z (relative intensity) 332 (46) [M+], 208 (28), 189 (57), 173 (100), 144 (65), 130 
(36). 
HR-MS (EI): m/z calcd for C22H24N2O [M
+] 332.1889, found 332.1880. 
 
Synthesis of 2-(Hexan-3-yl)-4-methyl-N-(quinolin-8-yl)benzamide (81am) 
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The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80m (330 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 96:4) 81am 
(147 mg, 42%) was obtained as a clear oil. 
1H NMR (600 MHz, CDCl3): δ = 10.06 (s, 1H), 8.94 (d, J = 7.7 Hz, 1H), 8.74 (dd, J = 4.2, 1.5 Hz, 
1H), 8.17 (dd, J = 8.2, 1.5 Hz, 1H), 7.59 (dd, J = 7.9, 7.9 Hz, 1H), 7.54 (d, J = 8.2 Hz, 1H), 7.48 (d, 
J = 7.7 Hz, 1H), 7.44 (dd, J = 8.2, 4.2 Hz, 1H), 7.16 (s, 1H), 7.10 (d, J = 7.7 Hz, 1H), 3.13 (ddd, J 
= 14.6, 8.7, 6.0 Hz, 1H), 2.41 (s, 3H), 1.74 – 1.57 (m, 3H), 1.34 – 1.23 (m, 2H), 1.23 – 1.12 (m, 
1H), 0.85 – 0.78 (m, 6H). 
13C NMR (125 MHz, CDCl3): δ = 169.0 (Cq), 148.2 (CH), 144.5 (Cq), 140.1 (Cq), 138.7 (Cq), 136.3 
(CH), 135.6 (Cq), 135.0 (Cq), 128.1 (Cq), 127.5 (CH), 127.4 (CH), 126.9 (CH), 126.6 (CH), 121.7 
(CH), 121.7 (CH), 116.6 (CH), 42.5 (CH), 39.4 (CH2), 30.1 (CH2), 21.9 (CH3), 21.1 (CH2), 14.6 
(CH3), 12.4 (CH3). 
IR (neat): ν͂ = 3352, 2958, 2928, 2870, 1677, 1521, 1482, 1385, 1325, 825 cm-1. 
MS (ESI): m/z (relative intensity) 715 (52), 369 (100), 347 (68) [M+H+], 236 (8), 203 (20). 
HR-MS (ESI): m/z calcd for C23H27N2O [M+H
+] 347.2123, found 347.2119. 
 
Synthesis of 4-Methyl-2-(4-phenylbutan-2-yl)-N-(quinolin-8-yl)benzamide (81an) 
 
The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80n (426 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 97:3) 81an 
(224 mg, 56%) was obtained as a viscous oil.  
1H NMR (600 MHz, CDCl3): δ = 10.15 (s, 1H), 8.96 (d, J = 7.5 Hz, 1H), 8.75 (dd, J = 4.2, 1.6 Hz, 
1H), 8.19 (dd, J = 8.2, 1.4 Hz, 1H), 7.62 (t, J = 7.9 Hz, 1H), 7.57 (dd, J = 8.2, 1.4 Hz, 1H), 7.55 (d, 
J = 7.5 Hz, 1H), 7.45 (dd, J = 8.2, 4.2 Hz, 1H), 7.28 (d, J = 1.6 Hz, 1H), 7.17–7.09 (m, 5H), 7.07–
7.03 (m, 1H), 3.45 (tq, J = 6.9, 6.9 Hz, 1H), 2.65 (ddd, J = 13.7, 11.0, 5.5 Hz, 1H), 2.52 (ddd, J = 
13.7, 11.0, 5.5 Hz, 1H), 2.45 (s, 3H), 2.10–2.03 (m, 1H), 1.98–1.90 (m, 1H), 1.40 (d, J = 6.8 Hz, 
3H). 
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13C NMR (126 MHz, CDCl3): δ = 168.9 (Cq), 148.3 (CH), 145.8 (Cq), 142.7 (Cq), 140.5 (Cq), 138.7 
(Cq), 136.4 (CH), 134.9 (Cq), 134.5 (Cq), 128.4 (CH), 128.2 (CH), 128.1 (Cq), 127.5 (CH), 127.4 
(CH), 127.2 (CH), 126.9 (CH), 125.6 (CH), 121.8 (CH), 121.7 (CH), 116.6 (CH), 40.2 (CH3), 35.2 
(CH), 34.2 (CH3), 23.0 (CH2), 21.8 (CH2). 
IR (ATR): ν͂ = 3350, 3025, 2923, 1672, 1517, 1454, 1260, 824, 696, 594 cm-1. 
MS (EI): m/z (relative intensity) 394 (11) [M+], 303 (76), 159 (100), 145 (36), 117 (15), 91 (76). 
HR-MS (ESI): m/z calcd for C27H27N2O [M+H





The general procedure B was followed using 59a (262 mg, 1.00 mmol) and 80p (592 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 80:20) 81ap 
(178 mg, 37%) was obtained as a white solid. 
M.p.: 136–137 °C 
1H NMR (600 MHz, CDCl3): δ = 10.09 (s, 1H), 8.90 (d, J = 6.8 Hz, 1H), 8.70 (dd, J = 4.2, 1.7 Hz, 
1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.77 (dd, J = 5.4, 3.0 Hz, 2H), 7.66 (dd, J = 5.4, 3.0 Hz, 2H), 
7.57 (dd, J = 7.9, 7.9  Hz, 1H), 7.52 (dd, J = 8.3, 1.3 Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.41 (dd, J 
= 8.2, 4.2 Hz, 1H), 7.18 (s, 1H), 7.10 (ddd, J = 7.8, 1.6, 0.6 Hz, 1H), 3.67 – 3.57 (m, 2H), 3.37 
(tq, J = 7.0, 6.9 Hz, 1H), 2.39 (s, 3H), 1.80 – 1.68 (m, 2H), 1.68 – 1.62 (m, 1H), 1.59 – 1.51 (m, 
1H), 1.30 (d, J = 6.9 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 168.6 (Cq), 168.3 (Cq), 148.2 (CH), 145.5 (Cq), 140.5 (Cq), 138.6 
(Cq), 136.3 (CH), 134.9 (Cq), 134.3 (Cq), 133.8 (CH), 132.2 (Cq), 128.0 (Cq), 127.5 (CH), 127.3 
(CH), 127.1 (CH), 126.8 (CH), 123.1 (CH), 121.7 (CH), 121.6 (CH), 116.6 (CH), 38.4 (CH2), 35.6 
(CH2), 35.1 (CH), 27.2 (CH2), 23.1 (CH3), 21.8 (CH3). 
IR (neat): ν͂ = 3354, 2930, 2861, 1704, 1668, 1521, 1482, 1394, 1049, 717 cm-1. 
MS (EI): m/z (relative intensity) 477 (34) [M+], 333 (39), 315 (32), 186 (20), 169 (66), 160 
(100), 130 (46). 
HR-MS (ESI): m/z calcd for C31H29N3O3 [M+H
+] 478.2131, found 478.2125. 
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Synthesis of 3-Cyclohexyl-2,2-dimethyl-N-(quinolin-8-yl)propanamide (101ad) 
 
The general procedure B was followed using 62a (228 mg, 1.00 mmol) and 80d (326 mg, 
2.00 mmol). After purification by column chromatography (n-hexane/EtOAc 2:1) followed by 
GPC 101ad (41 mg, 13%) was obtained as a brown oil. 
1H NMR (600 MHz, CDCl3): δ = 10.25 (s, 1H), 8.82 (dd, J = 4.2, 1.7 Hz, 1H), 8.78 (dd, J = 7.6, 
1.3 Hz, 1H), 8.16 (dd, J = 8.2, 1.7 Hz, 1H), 7.53 (dd, J = 7.9, 7.9 Hz, 1H), 7.48 (dd, J = 8.2, 1.3 Hz, 
1H), 7.45 (dd, J = 8.2, 4.2 Hz, 1H), 1.72 – 1.66 (m, 4H), 1.61 – 1.52 (m, 3H), 1.47 – 1.41 (m, 
1H), 1.40 (s, 6H), 1.16 (ttt, J = 12.6, 12.6, 3.2 Hz, 2H), 1.06 (ttt, J = 12.6, 12.6, 3.2 Hz, 1H), 0.96 
(ttd, J = 12.9, 12.9, 3.2  Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 177.0 (Cq), 148.2 (CH), 138.9 (Cq), 136.3 (CH), 134.8 (Cq), 
128.0 (Cq), 127.6 (CH), 121.6 (CH), 121.2 (CH), 116.3 (CH), 49.2 (CH), 43.6 (Cq), 35.0 (CH2), 
34.8 (CH2), 26.7 (CH3), 26.6 (CH2), 26.5 (CH2). 
IR (neat): ν͂ = 3365, 2920, 2849, 1678, 1521, 1485, 1382, 1324, 1131, 790, 678 cm-1. 
MS (EI): m/z (relative intensity) 310 (4) [M+], 253 (3), 214 (36), 171 (100), 144 (52), 116 (7). 
HR-MS (EI): m/z calcd for C20H26N2O [M




Reaction of 59a under primary alkylation conditions 
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Following the reported procedure,52 59a (262 mg, 1.0 mmol) was reacted with 80d (326 mg, 
2.0 mmol). At ambient temperature, CH2Cl2 (2.0 mL) was added. No conversion was 
observed through 1H NMR spectroscopic analysis of the crude reaction mixture. 
 
Intermolecular Competition Experiment between 59a and 80d 
 
Benzamide 59a (262 mg, 1.0 mmol), [Ni(OTf)2] (37 mg, 10 mol %), PPh3 (53 mg, 20 mol %) 
and Na2CO3 (212 mg, 2.0 mmol) were placed in a 25 mL sealed tube. The tube was evacuated 
and purged with Ar for three times. n-Butyl bromide (55a) (274 mg, 2.0 mmol), cyclohexyl 
bromide (80d) (326 mg, 2.0 mmol) and toluene (2.0 mL) were then added, and the mixture 
was stirred at 140 °C for 16 h. At ambient temperature, CH2Cl2 (2.0 mL) was added, and the 
reaction mixture was transferred into a round-bottom flask with CH2Cl2 and concentrated 
under reduced pressure. Analysis of the crude reaction mixture by GCMS gave 27% of 60ad 
as the sole product. 
 
Intermolecular Competition Experiment between 80k and 80m 
 
Benzamide 59a (262 mg, 1.0 mmol), [(DME)NiCl2] (22 mg, 10 mol %) and LiOtBu (160 mg, 
2.0 mmol) were placed in a 25 mL sealed tube. The tube was evacuated and purged with Ar 
for three times. BDMAE (76 µL, 40 mol %), 2-bromo-octane (80k) (386 mg, 2.0 mmol), 3-
bromo-octane (80m) (386 mg, 2.0 mmol) and PhMe (2.0 mL) were then added, and the 
mixture was stirred at 150 °C for 20 h. At ambient temperature, CH2Cl2 (2.0 mL) was added, 
and the reaction mixture was transferred into a round-bottom flask with CH2Cl2 and 
concentrated under reduced pressure. After purification by column chromatography (n-
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hexane/EtOAc 97:3) 81ak/am (55 mg, 32%) was isolated as a mixture. The ratio of products 
was determined by 1H NMR spectroscopy. 
 
 
5.4.3 Analytical Data for C–H Trifluoroethylation of benzamides 59 
 




The general procedure C was followed using 59b (133 mg, 0.50 mmol) and 82 (210 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 2:1), followed by 
GPC, 84b (41 mg, 23%) and 84b’ (16 mg, 7%) were obtained as yellow solids. 
84b: 
M.p.: 95–96 °C 
1H NMR (600 MHz, CDCl3): δ = 10.30 (s, 1H), 8.88 (dd, J = 7.1, 1.4 Hz, 1H), 8.79 (dd, J = 4.2, 
1.7 Hz, 1H), 8.19 (dd, J = 8.3, 1.6 Hz, 1H), 7.83 – 7.78 (m, 1H), 7.62 – 7.59 (m, 1H), 7.58 (dd, J 
= 8.3, 1.8 Hz, 1H), 7.47 (dd, J = 8.2, 4.2 Hz, 1H), 7.21 – 7.18 (m, 2H), 3.97 (q, J = 10.8 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 166.4 (Cq), 163.4 (Cq, d, 
1JC–F = 252.3 Hz), 148.4 (CH), 138.6 
(Cq), 136.5 (CH), 134.5 (Cq), 133.8 (Cq, d, 
4JC–F = 3.5 Hz), 132.6 (Cq, dq, 
3JC–F = 8.3, 2.9 Hz), 129.8 
(CH, d, 3JC–F = 9.2 Hz), 128.1 (Cq), 127.4 (CH), 125.7 (Cq, q, 
1JC–F = 276.4 Hz), 122.3 (CH), 121.9 
(CH), 119.7 (CH, d, 2JC–F = 21.9 Hz), 116.8 (CH), 115.5 (CH, d, 
2JC–F = 20.6 Hz), 36.4 (CH2, q, 
2JC–F 
= 30.7 Hz). 
19F NMR (283 MHz, CDCl3): δ = -64.95 (t, J = 10.8 Hz), -108.36 – -109.18 (m). 
IR (neat): ν͂ = 3326, 1663, 1527, 1485, 1251, 1142, 1067, 915, 788, 593 cm-1. 
MS (EI): m/z (relative intensity) 348 (99) [M+], 205 (100), 185 (98), 171 (15), 157 (25), 144 
(71), 127 (35). 
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HR-MS (EI): m/z calcd for C18H12F4N2O [M
+] 348.0886, found 348.0879. 
 
84b’: 
M.p.: 181–182 °C 
1H NMR (600 MHz, CDCl3): δ = 10.14 (s, 1H), 8.91 (dd, J = 6.3, 2.6 Hz, 1H), 8.75 (dd, J = 4.2, 
1.6 Hz, 1H), 8.20 (dd, J = 8.3, 1.6 Hz, 1H), 7.63 – 7.61 (m, 2H), 7.47 (dd, J = 8.3, 4.2 Hz, 1H), 
7.22 (d, J = 8.9 Hz, 2H), 3.60 (q, J = 9.1 Hz, 4H). 
13C NMR (125 MHz, CDCl3): δ = 165.4 (Cq), 163.2 (Cq, d, 
1JC–F = 249.1 Hz), 148.5 (CH), 138.5 
(Cq), 136.6 (Cq, d, 
4JC–F = 3.6 Hz), 136.2 (CH), 133.5 (Cq), 130.4 (Cq, dq, 
3JC–F = 8.3, 2.8 Hz), 127.9 
(Cq), 127.1 (CH), 125.1 (Cq, q, 
1JC–F = 276.8 Hz), 122.8 (CH), 121.8 (CH), 118.1 (CH, d, 
2JC–F = 
22.8 Hz), 117.1 (CH), 37.6 (CH2, q, 
2JC–F = 29.5 Hz). 
19F NMR (283 MHz, CDCl3): δ =  -64.60 (t, J = 10.4 Hz), -109.92 (t, J = 8.9 Hz). 
IR (neat): ν͂ = 3356, 2924, 1666, 1527, 1486, 1280, 1243, 1124, 1085, 788 cm-1. 
MS (EI): m/z (relative intensity) 430 (10) [M+], 287 (100), 267 (8), 247 (5), 144 (11). 
HR-MS (EI): m/z calcd for C20H13F7N2O [M
+] 430.0916, found 430.0922. 
 
 
Synthesis of N-(Quinolin-8-yl)-2-(2,2,2-trifluoroethyl)-5-(trifluoromethyl)benzamide (84e) 
 
The general procedure C was followed using 59e (158 mg, 0.50 mmol) and 82 (210 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/DCM 2:1) 84e (70 mg, 
35%) was obtained as a white solid. 
M.p.: 115–116 °C 
1H NMR (600 MHz, CDCl3): δ = 10.34 (s, 1H), 8.88 (dd, J = 5.1, 3.7 Hz, 1H), 8.81 (dd, J = 4.2, 
1.6 Hz, 1H), 8.21 (dd, J = 8.3, 1.6 Hz, 1H), 8.01 (s, 1H), 7.78 (dd, J = 7.9, 1.4 Hz, 1H), 7.64 – 
7.60 (m, 3H), 7.49 (dd, J = 8.3, 4.2 Hz, 1H), 3.99 (q, J = 10.7 Hz, 2H). 
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13C NMR (125 MHz, CDCl3): δ = 166.1 (Cq), 148.7 (CH), 138.7 (Cq), 138.6 (Cq), 136.6 (CH), 
134.3 (Cq), 133.5 (Cq), 133.2 (CH), 131.1 (Cq, q, 
2JC–F = 33.6 Hz), 128.2 (Cq), 127.4 (CH), 127.3 
(CH, q, 3JC–F = 3.4 Hz), 125.6 (Cq, q, 
1JC–F = 277.3 Hz), 124.5 (CH, q, 
3JC–F = 3.6 Hz), 123.6 (Cq, q, 
1JC–F = 270.8 Hz), 122.6 (CH),122.0 (CH), 117.1 (CH), 36.5 (CH2, q, 
2JC–F = 30.0 Hz). 
19F NMR (283 MHz, CDCl3): δ = -62.79 (s), -64.83 (t, J = 10.7 Hz). 
IR (neat): ν͂ = 3336, 1676, 1527, 1485, 1326, 1257, 1114, 1069, 785, 669 cm-1. 
MS (EI): m/z (relative intensity) 398 (86) [M+], 255 (40), 235 (79), 207 (34), 171 (57), 144 
(100), 130 (15). 
HR-MS (EI): m/z calcd for C19H12F6N2O [M
+] 398.0854, found 398.0853. 
 
Synthesis of 2-Fluoro-N-(quinolin-8-yl)-6-(2,2,2-trifluoroethyl)benzamide (84f) 
 
The general procedure C was followed using 59f (133 mg, 0.50 mmol) and 82 (210 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/DCM 2:1) 84f (51 mg, 
29%) was obtained as a white solid. 
M.p.: 155–156 °C 
1H NMR (600 MHz, CDCl3): δ = 10.32 (s, 1H), 8.93 (dd, J = 6.9, 1.9 Hz, 1H), 8.79 (dd, J = 4.2, 
1.6 Hz, 1H), 8.18 (dd, J = 8.3, 1.6 Hz, 1H), 7.63 – 7.57 (m, 2H), 7.49 – 7.44 (m, 2H), 7.27 (d, J = 
7.5 Hz, 1H), 7.23 (dd, J = 8.9, 8.7 Hz, 1H), 3.82 (q, J = 10.7 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 162.6 (Cq), 159.7 (Cq, d, 
1JC–F = 248.3 Hz), 148.6 (CH), 138.7 
(Cq), 136.5 (CH), 134.3 (Cq), 131.5 (CH, d, 
3JC–F = 8.3 Hz), 131.4 (Cq, d, 
3JC–F = 5.7 Hz), 128.1 (Cq), 
127.9 (CH, d, 4JC–F = 2.7 Hz), 127.9 (CH), 126.4 (Cq, d, 
2JC–F = 17.3 Hz), 125.7 (Cq, q, 
1JC–F = 
275.7 Hz), 122.5 (CH), 121.9 (CH), 117.1 (CH), 116.3 (CH, d, 2JC–F = 22.5 Hz), 36.6 (CH2, qd, 
2,4JC–F = 30.7, 2.2 Hz). 
19F NMR (283 MHz, CDCl3): δ = -65.00 (t, J = 10.9 Hz), -113.53 (ddd, J = 9.5, 5.7, 1.0 Hz). 
IR (neat): ν͂ = 3343, 1672, 1526, 1486, 1262, 1099, 1061, 910, 784, 686 cm-1. 
MS (EI): m/z (relative intensity) 348 (81) [M+], 261 (10), 205 (76), 185 (100), 171 (33), 144 
(75), 127 (19). 
5 Experimental 
- 83 - 
 
HR-MS (EI): m/z calcd for C18H12F4N2O [M
+] 348.0886, found 348.0884. 
 
Synthesis of N-(Quinolin-8-yl)-2-(2,2,2-trifluoroethyl)thiophene-3-carboxamide (84g) 
 
The general procedure C was followed using 59g (127 mg, 0.50 mmol) and 82 (210 mg, 
1.00 mmol). After purification by column chromatography (n-hexane/EtOAc 2:1) followed by 
GPC 84g (33 mg, 19%) was obtained as a yellow solid. 
M.p.: 128–129 °C 
1H NMR (600 MHz, CDCl3): δ = 10.48 (s, 1H), 8.86 (dd, J = 7.4, 1.3 Hz, 1H), 8.83 (dd, J = 4.2, 
1.6 Hz, 1H), 8.18 (dd, J = 8.2, 1.6 Hz, 1H), 7.60 – 7.54 (m, 3H), 7.48 (dd, J = 8.2, 4.2 Hz, 1H), 
7.41 (d, J = 5.3 Hz, 1H), 4.32 (q, J = 10.5 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 161.9 (Cq), 148.4 (CH), 138.7 (Cq), 136.70 (Cq, q, 
3JC–F = 3.6 Hz), 
136.5 (CH), 135.6 (Cq), 134.4 (Cq), 128.1 (Cq), 127.5 (CH), 126.3 (CH), 125.7 (CH), 125.1 (Cq, q, 
1JC–F = 275.8 Hz), 122.0 (CH), 121.8 (CH), 116.7 (CH), 32.9 (CH2, q, 
2JC–F = 32.3 Hz). 
19F NMR (283 MHz, CDCl3): δ = -65.70 (t, J = 10.5 Hz). 
IR (neat): ν͂ = 3363, 3096, 1661, 1540, 1524, 1355, 1248, 1137, 789, 654 cm-1. 
MS (EI): m/z (relative intensity) 336 (42) [M+], 296 (17), 193 (39), 173 (41), 144 (100), 115 (9). 
HR-MS (EI): m/z calcd for C16H11F3N2OS [M
+] 336.0544, found 336.0546. 
 
 
5.4.4 Analytical Data for C–H Secondary Alkylation of N-(2-Pyrimidyl)anilines 69 
 
Synthesis of N-(2-Cyclobutyl-6-fluorophenyl)pyrimidin-2-amine (86ab) 
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The general procedure D1 was followed using substrate 69a (95 mg, 0.5 mmol), bromide 80b 
(135 mg, 1.0 mmol), [(DME)NiCl2] (2.8 mg, 2.5 mol %) and DtBEDA (5.5 μL, 5.0 mol %) at 
100 °C. Isolation by column chromatography (n-hexane/EtOAc: 9/1) yielded 86ab (108 mg, 
89%) as a white solid. 
M.p.: 121–122 °C 
1H NMR (600 MHz, CDCl3): δ = 8.33 (d, J = 4.8 Hz, 2H), 7.24 (ddd, J = 8.0, 8.0, 5.6 Hz, 1H), 7.14 
(d, J = 7.8 Hz, 1H), 7.01 (ddd, J = 9.3, 7.8, 0.8 Hz, 1H), 6.94 (s, 1H), 6.65 (t, J = 4.8 Hz, 1H), 3.70 
(p, J = 8.9 Hz, 1H), 2.31–2.23 (m, 2H), 2.16–2.08 (m, 2H), 1.99–1.89 (m, 1H), 1.85–1.75 (m, 
1H). 
13C NMR (125 MHz, CDCl3): δ = 161.6 (Cq), 158.6 (Cq, 
1JC-F = 247.6 Hz), 158.3 (CH), 145.4 (Cq), 
127.5 (CH, 3JC-F = 8.6 Hz), 123.9 (Cq, 
2JC-F = 12.8 Hz), 122.2 (CH, 
4JC-F = 3.0 Hz), 113.6 (CH, d, 
2JC-F 
= 20.9 Hz), 112.2 (CH), 37.0 (CH, 4JC-F = 2.4 Hz), 29.3 (CH2), 18.6 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -120.6 (dd, J = 9.6, 5.5 Hz). 
IR (neat): ν͂ = 3328, 2974, 2934, 1582, 1471, 1446, 1268, 782, 644, 496 cm-1. 
MS (EI): m/z (relative intensity) 243 (54) [M+], 214 (80), 196 (100), 188 (35), 148(9), 135 (10), 
107 (11). 
HR-MS (EI): m/z calcd for C14H14FN3 [M
+] 243.1172, found 243.1166. 
 
Synthesis of N-(2-Cyclopentyl-6-fluorophenyl)pyrimidin-2-amine (86ac) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80c (298 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
9/1) yielded 86ac (230 mg, 90%) as a white solid. 
M.p.: 117–118 °C 
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1H NMR (600 MHz, CDCl3): δ = 8.33 (d, J = 4.8 Hz, 2H), 7.23 (ddd, J = 8.0, 8.0, 5.6 Hz, 1H), 7.15 
(d, J = 7.9 Hz, 1H), 6.99 (ddd, J = 9.5, 8.0, 1.4 Hz, 1H), 6.95 (s, 1H), 6.65 (t, J = 4.8 Hz, 1H), 3.27 
(p, J = 8.3 Hz, 1H), 2.05–1.98 (m, 2H), 1.82–1.74 (m, 2H), 1.66–1.53 (m, 4H). 
13C NMR (125 MHz, CDCl3): δ = 162.0 (Cq), 158.9 (Cq, 
1JC-F = 247.5 Hz), 158.4 (CH), 146.8 (Cq), 
128.0 (CH, 3JC-F = 9.0 Hz), 124.5 (Cq, 
2JC-F = 12.6 Hz), 122.0 (CH, d, 
4JC-F = 3.4 Hz), 113.3 (CH, 
2JC-F 
= 20.3 Hz), 112.2 (CH), 40.5 (CH, 4JC-F = 2.3 Hz), 34.2 (CH2), 25.8 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -119.3 (dd, J = 9.5, 5.5 Hz). 
IR (neat): ν͂ = 3216, 2953, 2865, 1578, 1444, 1405, 1247, 789, 641 cm-1. 
MS (EI): m/z (relative intensity) 257 (51) [M+], 241 (25), 188 (100), 107 (12). 
HR-MS (EI): m/z calcd for C15H16FN3 [M
+] 257.1328, found 257.1320. 
 
Synthesis of N-(2-Cyclohexyl-6-fluorophenyl)pyrimidin-2-amine (86ad) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80d (246 μL, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
10/1→8/1) yielded 86ad (270 mg, 98%) as a yellow solid. 
 
The general procedure D3 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80d (246 μL, 2.0 mmol) at 100 °C. Isolation by column chromatography (n-
hexane/EtOAc: 10/1→8/1) yielded 86ad (264 mg, 97%) as a yellow solid. 
 
M.p.: 93–94 °C.  
1H NMR (500 MHz, CDCl3) δ = 8.31 (d, J = 4.8 Hz, 2H), 7.21 (ddd, J = 8.0, 8.0, 4.0 Hz, 1H), 7.10 
(d, J = 7.9 Hz, 1H), 6.97 (ddd, J = 9.6, 8.2, 1.3 Hz, 1H), 6.85 (s, 1H), 6.63 (t, J = 4.8 Hz, 1H), 
2.85–2.78 (m, 1H), 1.83–1.73 (m, 4H), 1.72–1.65 (m, 1H), 1.43–1.33 (m, 2H), 1.33–1.15 (m, 
3H).  
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13C NMR (125 MHz, CDCl3) δ = 161.9 (Cq), 158.6 (Cq, 
1JC-F = 248.0 Hz), 158.2 (CH), 147.5 (Cq), 
127.8 (CH, 3JC-F = 8.6 Hz), 123.6 (Cq, 
2JC-F = 12.4 Hz), 122.0 (CH, 
4JC-F = 3.3 Hz), 113.2 (CH, 
2JC-F = 
20.8 Hz), 112.1 (CH), 38.8 (CH, 4JC-F = 2.1 Hz), 33.7 (CH2), 26.8 (CH2), 26.1 (CH2).  
19F NMR (282 MHz, CDCl3) δ = -118.83 (dd, J = 9.8, 5.4 Hz).  
IR (neat): ν͂ = 3224, 2935, 2851, 1582, 1523, 1446, 1413, 1256, 958, 776, 641 cm-1.  
MS (EI) m/z (relative intensity) 271 (60) [M+], 188 (100), 170 (5).  
HR-MS (EI) m/z calcd for C16H18FN3 [M
+] 271.1485, found 271.1486. 
 
Synthesis of N-(2-Cycloheptyl-6-fluorophenyl)pyrimidin-2-amine (86ae) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80e (354 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
9/1) yielded 86ae (273 mg, 96%) as a white solid. 
M.p.: 103–104 °C 
1H NMR (600 MHz, CDCl3): δ = 8.31 (d, J = 4.8 Hz, 2H), 7.48 (s, 1H), 7.22 (ddd, J = 8.2, 8.2, 
5.6 Hz, 1H), 7.11 (d, J = 7.9 Hz, 1H), 6.98 (ddd, J = 9.6, 8.2, 1.4 Hz, 1H), 6.62 (t, J = 4.8 Hz, 1H), 
3.02 (tt, J = 10.6, 3.4 Hz, 1H), 1.90–1.83 (m, 2H), 1.77–1.70 (m, 2H), 1.66–1.59 (m, 4H), 1.58–
1.51 (m, 2H), 1.46–1.37 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ = 162.1 (Cq), 158.8 (Cq, 
1JC-F = 249.9 Hz), 158.3 (CH), 149.8 (Cq), 
128.0 (CH, 3JC-F = 8.8 Hz), 123.3 (Cq, 
2JC-F = 12.5 Hz), 122.2 (CH, 
4JC-F = 3.0 Hz), 113.0 (CH, 
2JC-F = 
21.1 Hz), 112.0 (CH), 40.8 (CH, 4JC-F = 2.1 Hz), 36.0 (CH2), 27.9 (CH2), 27.5 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -119.0 (ddd, J = 9.4, 5.5, 1.0 Hz). 
IR (neat): ν͂ = 3227, 2923, 2850, 1580, 1527, 1446, 1408, 1261, 970, 784 cm-1. 
MS (EI): m/z (relative intensity) 285 (58) [M+], 242 (24), 228 (34), 201 (15), 188 (100), 148 
(15), 94 (12), 43 (31). 
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HR-MS (EI): m/z calcd for C17H20FN3 [M
+] 285.1641, found 285.1641. 
 
Synthesis of N-(2-Cyclooctyl-6-fluorophenyl)pyrimidin-2-amine (86as) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80s (382 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
9/1) yielded 86as (270 mg, 90%) as a white solid. 
M.p.: 111–112 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.33 (d, J = 4.8 Hz, 2H), 7.22 (ddd, J = 8.0, 8.0, 5.6 Hz, 1H), 7.09 
(d, J = 7.9 Hz, 1H), 6.97 (ddd, J = 9.5, 8.2, 1.3 Hz, 1H), 6.71 (s, 1H), 6.65 (t, J = 4.8 Hz, 1H), 3.10 
(tt, J = 9.6, 3.4 Hz, 1H), 1.81–1.75 (m, 2H), 1.74–1.67 (m, 4H), 1.62–1.56 (m, 1H), 1.55–1.51 
(m, 4H), 1.50–1.44 (m, 3H). 
13C NMR (125 MHz, CDCl3): δ = 162.0 (Cq), 158.8 (Cq, 
1JC-F = 247.7 Hz), 158.4 (CH), 150.5 (Cq), 
128.1 (CH, 3JC-F = 8.7 Hz), 123.2 (Cq, 
2JC-F = 12.3 Hz), 122.7 (CH, 
4JC-F = 3.5 Hz), 113.1 (CH, 
2JC-F = 
20.3 Hz), 112.2 (CH), 38.3 (CH, d, 4JC-F = 1.9 Hz), 34.3 (CH2), 26.8 (CH2), 26.7 (CH2), 26.3 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -119.2 (ddd, J = 9.4, 5.5, 1.1 Hz). 
IR (neat): ν͂ = 3225, 2915, 2844, 1580, 1445, 1409, 1266, 785, 641cm-1. 
MS (EI): m/z (relative intensity) 299 (63) [M+], 242 (31), 228 (46), 214 (39), 188 (100), 148 
(15), 94 (11). 
HR-MS (EI): m/z calcd for C18H22FN3 [M
+] 299.1798, found 299.1798. 
 
Synthesis of N-(2-Cyclododecyl-6-fluorophenyl)pyrimidin-2-amine (86at) 
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The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80t (494 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
85/15) yielded 86at (330 mg, 93%) as a white solid. 
M.p.: 166–167 °C 
1H NMR (600 MHz, CDCl3): δ = 8.31 (d, J = 4.8 Hz, 2H), 7.25 (ddd, J = 8.0, 8.0, 5.6 Hz, 1H), 7.12 
(d, J = 7.9 Hz, 1H), 7.00 (ddd, J = 9.3, 8.1, 1.0 Hz, 1H), 6.70 (s, 1H), 6.63 (t, J = 4.8 Hz, 1H), 3.16 
(tt, J = 6.6, 6.6 Hz, 1H), 1.79–1.71 (m, 2H), 1.48–1.42 (m, 2H), 1.39–1.29 (m, 6H), 1.29–1.16 
(m, 10H), 1.16–1.07 (m, 2H). 
13C NMR (125 MHz, CDCl3): δ = 162.1 (Cq), 159.0 (Cq, 
1JC-F = 247.0 Hz), 158.4 (CH), 148.4 (Cq), 
128.2 (CH, 3JC-F = 8.7 Hz), 124.5 (Cq, 
2JC-F = 12.5 Hz), 122.9 (CH, 
4JC-F = 3.2 Hz), 113.2 (CH, 
2JC-F = 
21.3 Hz), 112.1 (CH), 33.4 (CH, JC-F = 1.9 Hz), 31.4 (CH2), 24.1 (CH2), 24.0 (CH2), 23.2 (CH2), 
23.0 (CH2), 22.8 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -119.7 (dd, J = 9.5, 5.7 Hz). 
IR (neat): ν͂ = 3218, 2930, 2844, 1595, 1450, 1415, 796, 643, 511 cm-1. 
MS (EI): m/z (relative intensity) 355 (100) [M+], 242 (21), 228 (35), 214 (40), 201 (39), 188 
(98), 148 (12), 55 (21). 
HR-MS (EI): m/z calcd for C22H30FN3 [M
+] 355.2424, found 355.2419. 
 
Synthesis of N-(2-exo-Norbornyl-6-fluorophenyl)pyrimidin-2-amine (86af) 
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The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and exo-
norbornyl bromide (80f) (350 mg, 2.0 mmol). Isolation by column chromatography (n-
hexane/EtOAc: 85/15) yielded 86af (260 mg, 92%) as a white solid. 
M.p.: 128–129 °C. 
1H NMR (600 MHz, CDCl3): δ = 8.33 (d, J = 4.8 Hz, 2H), 7.21 (ddd, J = 8.1, 8.1, 5.6 Hz, 1H), 7.14 
(d, J = 7.9 Hz, 1H), 6.99 (ddd, J = 9.5, 8.2, 1.3 Hz, 1H), 6.94 (s, 1H), 6.64 (t, J = 4.8 Hz, 1H), 2.92 
(dd, J = 8.9, 5.8 Hz, 1H), 2.41 (d, J = 3.0 Hz, 1H), 2.30 (s, 1H), 1.76 (ddd, J = 11.7, 9.1, 2.2 Hz, 
1H), 1.59–1.52 (m, 3H), 1.51–1.45 (m, 1H), 1.28–1.18 (m, 3H). 
13C NMR (125 MHz, CDCl3): δ = 161.7 (Cq), 159.2 (Cq, 
1JC-F = 248.6 Hz), 158.3 (CH), 147.1 (Cq), 
127.6 (CH, 3JC-F = 8.6 Hz), 124.4 (Cq, 
2JC-F = 12.3 Hz), 121.3 (CH, 
4JC-F = 3.3 Hz), 113.3 (CH, 
2JC-F = 
20.7 Hz), 112.1 (CH), 42.7 (CH, 4JC-F = 2.2 Hz), 41.4 (CH2), 39.3 (CH), 37.0 (CH), 36.6 (CH2), 30.5 
(CH2), 28.9 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -118.2 (dd, J = 9.4, 5.5 Hz). 
IR (neat): ν͂ = 3217, 2950, 2867, 1582, 1524, 1410, 1262, 933, 784, 641cm-1. 
MS (EI): m/z (relative intensity) 283 (86) [M+], 254 (84), 214 (37), 201 (45), 188 (100), 148 
(20). 
HR-MS (EI): m/z calcd for C17H18FN3 [M
+] 283.1485, found 283.1487. 
 
Synthesis of N-(2-Adamantyl-6-fluorophenyl)pyrimidin-2-amine (86ag) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80g (430 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
85/15) yielded 86ag (284 mg, 87%) as a yellow solid. 
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The general procedure D3 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80g (430 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
85/15) yielded 86ag (159 mg, 49%) as a yellow solid. 
 
M.p.: 169–170 °C 
1H NMR (600 MHz, CDCl3): δ = 8.32 (dd, J = 4.8, 0.6 Hz, 2H), 7.43 (d, J = 8.0 Hz, 1H), 7.24 (ddd, 
J = 8.0, 8.0, 5.4 Hz, 1H), 7.03 (dd, J = 8.0, 8.0 Hz, 1H), 6.84 (s, 1H), 6.64 (td, J = 4.8, 0.6 Hz, 1H), 
3.27 (s, 1H), 2.23 (s, 2H), 2.07–2.02 (m, 2H), 1.93–1.81 (m, 6H), 1.75 (s, 2H), 1.63 (d, J = 
12.2 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 161.6 (Cq), 159.2 (Cq, 
1JC-F = 247.9 Hz), 158.3 (CH), 145.3 (Cq), 
127.3 (CH, d, 3JC-F = 8.7 Hz), 125.0 (Cq, 
2JC-F = 12.2 Hz), 123.3 (CH, 
4JC-F = 3.2 Hz), 113.6 (CH, 
2JC-F 
= 20.3 Hz), 112.1 (CH), 45.6 (CH, 4JC-F = 2.0 Hz), 40.3 (CH), 38.0 (CH2), 32.8 (CH), 32.0 (CH), 
28.1 (CH2), 27.7 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -118.3 (dd, J = 9.4, 5.6 Hz). 
IR (neat): ν͂ = 3210, 2897, 2849, 1584, 1445, 1411, 995, 789, 641, 492 cm-1. 
MS (EI): m/z (relative intensity) 323 (66) [M+], 295 (100), 266 (10), 201 (16), 188 (76), 170 (9). 
HR-MS (EI): m/z calcd for C20H22FN3 [M
+] 323.1798, found 323.1808. 
 
Synthesis of N-(2-Fluoro-6-isopropylphenyl)pyrimidin-2-amine (86ai) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80i (246 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
85/15) yielded 86ai (219 mg, 95%) as a white solid.  
M.p.: 131–132 °C 
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1H NMR (600 MHz, CDCl3): δ = 8.32 (d, J = 4.8 Hz, 2H), 7.26 (ddd, J = 8.1, 8.1, 5.6 Hz, 1H), 
7.17–7.12 (m, 2H), 7.00 (ddd, J = 9.5, 8.2, 1.3 Hz, 1H), 6.64 (t, J = 4.8 Hz, 1H), 3.26 (hept, J = 
6.9 Hz, 1H), 1.21 (d, J = 6.9 Hz, 6H).  
13C NMR (125 MHz, CDCl3): δ = 162.1 (Cq), 158.9 (Cq, 
1JC-F = 247.5 Hz), 158.4 (CH), 148.8 (Cq), 
128.1 (CH, 3JC-F = 8.5 Hz), 123.8 (Cq, 
2JC-F = 12.7 Hz), 121.4 (CH, 
4JC-F = 3.4 Hz), 113.4 (CH, 
2JC-F = 
20.8 Hz), 112.2 (CH), 28.6 (CH, 4JC-F = 2.3 Hz), 23.4 (CH3).  
19F NMR (283 MHz, CDCl3): δ = -119.3 (dd, J = 9.6, 5.4 Hz).  
IR (neat): ν͂ = 3217, 2969, 2928, 1575, 1445, 1410, 1245, 954, 787, 638 cm-1.  
MS (EI): m/z (relative intensity) 231 (43) [M+], 215 (22), 196 (10), 188 (100), 170 (6).  
HR-MS (EI): m/z calcd for C13H14FN3 [M
+] 231.1172, found 231.1171. 
 
Synthesis of N-[2-Fluoro-6-(pentan-2-yl)phenyl]pyrimidin-2-amine (86am) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80m (302 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
85/15) yielded 86am (245 mg, 94%) as a white solid. 
M.p.: 122–123 °C 
1H NMR (600 MHz, CDCl3): δ = 8.32 (d, J = 4.8 Hz, 2H), 7.25 (ddd, J = 8.0, 8.0, 5.4 Hz, 1H), 7.10 
(d, J = 7.9 Hz, 1H), 6.99 (ddd, J = 9.5, 8.2, 1.4 Hz, 1H), 6.97 (s, 1H), 6.64 (t, J = 4.8 Hz, 1H), 3.09 
(qt, J = 7.1, 7.1 Hz, 1H), 1.59–1.54 (m, 1H), 1.53–1.46 (m, 1H), 1.27–1.20 (m, 1H), 1.19 (d, J = 
7.1 Hz, 3H), 1.17–1.10 (m, 1H), 0.79 (t, J = 7.4 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 162.0 (Cq), 158.9 (Cq, 
1JC-F = 247.3 Hz), 158.3 (CH), 148.2 (Cq), 
128.1 (CH, 3JC-F = 8.4 Hz), 124.2 (Cq, 
2JC-F =12.7 Hz), 121.9 (CH, 
4JC-F =3.5 Hz), 113.3 (CH, 
2JC-F 
=20.8 Hz), 112.2 (CH), 40.3 (CH2), 33.5 (CH, 
4JC-F =2.1 Hz), 21.6 (CH3), 20.9 (CH2), 14.2 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -119.2 (dd, J = 9.4, 5.5 Hz). 
IR (neat): ν͂ = 3211, 2963, 2864, 1582, 1527, 1446, 1267, 957, 786, 641cm-1. 
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MS (EI): m/z (relative intensity) 259 (22) [M+], 240 (8), 230 (100), 217 (13), 202 (15), 188 (40). 
HR-MS (EI): m/z calcd for C15H18FN3 [M
+] 259.1485, found 259.1480. 
 
Synthesis of N-[2-Fluoro-6-(octan-2-yl)phenyl]pyrimidin-2-amine (86as) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80s (386 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
85/15) yielded 86as (284 mg, 94%) as a white solid. 
M.p.: 85–86 °C 
1H NMR (600 MHz, CDCl3) δ = 8.31 (d, J = 4.8 Hz, 2H), 7.27–7.23 (m, 2H), 7.10 (d, J = 7.9 Hz, 
1H), 7.00 (ddd, J = 9.5, 8.2, 1.3 Hz, 1H), 6.63 (t, J = 4.8 Hz, 1H), 3.08 (qt, J = 7.0, 7.0 Hz, 1H), 
1.61–1.53 (m, 1H), 1.54–1.46 (m, 1H), 1.19 (d, J = 6.9 Hz, 3H), 1.21–1.07 (m, 8H), 0.82 (t, J = 
7.1 Hz, 3H). 
13C NMR (125 MHz, CDCl3) δ = 162.1 (Cq), 158.9 (Cq, 
1JC-F = 247.7 Hz), 158.3 (CH), 148.2 (Cq), 
128.1 (CH, 3 JC-F = 8.7 Hz), 124.3 (Cq, 
2JC-F = 12.8 Hz), 121.9 (CH, 
4JC-F = 3.4 Hz), 113.2 (CH, 
2JC-F = 
21.0 Hz), 112.1 (CH), 38.1 (CH2), 33.8 (CH, 
4JC-F = 2.3 Hz), 31.8 (CH2), 29.5 (CH2), 27.7 (CH2), 
22.7 (CH2), 21.7 (CH3), 14.2 (CH3). 
19F NMR (283 MHz, CDCl3) δ = -119.1 (dd, J = 9.4, 5.4 Hz). 
IR (neat): ν͂ = 3202, 2921, 2855, 1580, 1518, 1448, 1414, 943, 787, 640 cm-1. 
MS (EI): m/z (relative intensity) 301 (65) [M+], 230 (100), 217 (40), 202 (41), 188 (93), 146 
(15). 
HR-MS (EI): m/z calcd for C15H18FN3 [M
+] 301.1954, found 301.1960. 
 
Synthesis of N-[2-Fluoro-6-(nonan-5-yl)phenyl]pyrimidin-2-amine (86at) 
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The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80t (414 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
8/2) yielded 86at (270 mg, 85%) as a yellow solid. 
M.p.: 77–78 °C 
1H NMR (600 MHz, CDCl3): δ = 8.30 (d, J = 4.8 Hz, 2H), 7.24 (dd, J = 8.1, 5.5 Hz, 1H), 7.05 (d, J 
= 7.9 Hz, 1H), 6.99 (dd, J = 7.5, 9.2 Hz, 1H), 6.81 (br s, 1H), 6.62 (t, J = 4.8 Hz, 1H), 2.96 (tt, J = 
8.6, 5.9 Hz, 1H), 1.65–1.57 (m, 2H), 1.57–1.50 (m, 2H), 1.24–1.02 (m, 8H), 0.77 (t, J = 7.2 Hz, 
6H).  
13C NMR (125 MHz, CDCl3): δ = 161.8 (Cq), 158.9 (Cq, 
1JC-F = 248.7 Hz), 158.1 (CH), 146.8 (Cq), 
127.9 (CH, 3JC-F = 8.2 Hz), 124.8 (Cq, 
2JC-F = 12.7 Hz), 122.1 (CH, 
4JC-F = 3.9 Hz), 113.0 (CH, 
2JC-F = 
21.4 Hz), 111.8 (CH), 39.3 (CH), 36.2 (CH2), 29.8 (CH2), 22.8 (CH2), 13.9 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -118.5 (dd, J = 9.57, 5.59 Hz). 
IR (neat): ν͂ = 3211, 2951, 2921, 1591, 1521, 1413, 1258, 912, 797, 617 cm-1. 
MS (EI): m/z (relative intensity) 315 (53) [M+], 272 (100), 259 (31), 244 (40), 216 (24), 202 
(31), 188 (53). 
HR-MS (EI): m/z calcd for C19H26FN3 [M
+] 315.2111, found 315.2117. 
 
Synthesis of tert-Butyl-5-[3-fluoro-2-(pyrimidin-2-ylamino)phenyl]hexanoate (86au’) 
 
The general procedure D1 was followed using 69a (189 mg, 1.00 mmol) and 80u (418 mg, 
2.0 mmol). After purification by column chromatography (n-hexane/EtOAc 90:10) side 
product 86au’ (24 mg, 7%) was obtained as a white solid. 
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86au’: 
M.p.: 118–119 °C 
1H NMR (600 MHz, CDCl3): δ = 8.33 (d, J = 4.8 Hz, 2H), 7.28 – 7.23 (m, 1H), 7.09 (d, J = 7.9 Hz, 
1H), 6.99 (ddd, J = 9.5, 8.2, 1.3 Hz, 1H), 6.66 (t, J = 4.8 Hz, 1H), 6.54 (s, 1H), 3.08 (tq, J = 6.9, 
6.9 Hz, 1H), 2.12 (t, J = 7.3 Hz, 2H), 1.65 – 1.47 (m, 3H), 1.45 – 1.42 (m, 1H), 1.41 (s, 9H), 1.20 
(d, J = 6.9 Hz, 3H). 
13C NMR (125 MHz, CDCl3): δ = 172.9 (Cq), 161.9 (Cq), 158.8 (Cq, d, 
1JC–F = 247.0 Hz), 158.3 
(CH), 147.6 (Cq), 128.2 (CH, d, 
3JC–F = 8.6 Hz), 124.2 (Cq, d, 
2JC–F = 13.2 Hz), 121.8 (CH, d, 
4JC–F = 
3.5 Hz), 113.4 (CH, d, 2JC–F = 20.6 Hz), 112.3 (CH), 80.2 (Cq), 37.3 (CH2), 35.7 (CH2), 33.7 (CH, d, 
4JC–F = 2.1 Hz), 28.3 (CH3), 23.4 (CH2), 21.8 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -119.12 (dd, J = 9.5, 5.7 Hz). 
IR (neat): ν͂ = 3198, 2977, 2927, 2865, 1719, 1581, 1446, 1392, 1154, 787 cm-1. 
MS (EI): m/z (relative intensity) 359 (19) [M+], 303 (12), 286 (25), 230 (33), 217 (23), 188 
(100). 
HR-MS (ESI): m/z calcd for C20H27FN3O2 [M+H
+] 360.2087, found 360.2084. 
 
Synthesis of 2-{4-[3-fluoro-2-(pyrimidin-2-ylamino)phenyl]pentyl}isoindoline-1,3-dione 
(86ap) 
 
The general procedure D1 was followed using 69a (189 mg, 1.0 mmol) and 80p (592 mg, 
2.0 mmol). After purification by column chromatography (n-hexane/EtOAc 2:1) 86ap 
(324 mg, 80%) was obtained as a white solid. 
M.p.: 61–62 °C 
1H NMR (600 MHz, CDCl3): δ = 8.29 (d, J = 4.8 Hz, 2H), 7.80 (dd, J = 5.5, 3.1 Hz, 2H), 7.67 (dd, J 
= 5.5, 3.1 Hz, 2H), 7.23 (td, J = 8.0, 5.6 Hz, 1H), 7.12 (s, 1H), 7.07 (d, J = 7.9 Hz, 1H), 6.97 (dd, J 
= 8.9, 8.7 Hz, 1H), 6.61 (t, J = 4.8 Hz, 1H), 3.64 (dt, J = 14.3, 7.3 Hz, 1H), 3.56 (dt, J = 14.3, 
7.3 Hz, 1H), 3.17 (tq, J = 6.9, 6.7 Hz, 1H), 1.67 – 1.51 (m, 4H), 1.20 (d, J = 6.9 Hz, 3H). 
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13C NMR (125 MHz, CDCl3): δ = 168.4 (Cq), 162.0 (Cq), 158.8 (Cq, d, 
1JC–F = 247.3 Hz), 158.2 
(CH), 147.5 (Cq), 133.9 (CH), 132.1 (Cq), 128.2 (CH, d, 
3JC–F = 9.1 Hz), 124.5 (Cq, d, 
2JC–F = 
11.2 Hz), 123.2 (CH), 121.8 (CH, d, 4JC–F = 3.4 Hz), 113.4 (CH, d, 
2JC–F = 21.5 Hz), 112.1 (CH), 
37.9 (CH2), 34.9 (CH2), 32.9 (CH, d, 
4JC–F = 1.4 Hz), 26.7 (CH2), 21.9 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -119.16 (dd, J = 9.4, 5.6 Hz). 
IR (neat): ν͂ = 3342, 3216, 2960, 2931, 1704, 1581, 1444, 1394, 788, 717 cm-1. 
MS (EI): m/z (relative intensity) 404 (25) [M+], 244 (12), 230 (42), 217 (18), 188 (100), 160 
(20). 
HR-MS (EI): m/z calcd for C23H21FN4O2 [M
+] 404.1649, found 404.1647. 
 
 
Synthesis of N-(2-Fluorophenyl)-N-(1-phenylethyl)pyrimidin-2-amine (86av’’) 
 
The general procedure D1 was followed using substrate 69a (189 mg, 1.0 mmol) and 
bromide 80v (370 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 
95/5) yielded 86av’’ (246 mg, 84%) as a white solid.  
M.p.: 96–97 °C.  
1H NMR (600 MHz, CDCl3): δ =
 8.33 (d, J = 4.7 Hz, 2H), 7.29 (d, J = 7.0 Hz, 1H), 7.27 – 7.19 (m, 
5H), 7.06 (t, J = 8.8 Hz, 1H), 6.97 (dd, J = 6.8, 6.8 Hz, 1H), 6.68 (bs, 1H), 6.57 (t, J = 4.7 Hz, 1H), 
6.48 (q, J = 6.5 Hz, 1H), 1.53 (d, J = 6.5 Hz, 3H).  
13C NMR (126 MHz, CDCl3): δ = 161.7 (Cq), 160.0 (Cq, d, 
1JC-F = 247.9 Hz), 157.8 (CH), 142.2 (Cq) 
131.8 (CH, 
4JC-F = 1.6 Hz), 128.8 (CH, d, 
3JC-F = 7.5 Hz), 128.1 (CH), 128.0 (Cq), 127.8 (CH), 127.2 
(CH), 124.0 (CH, d, 3JC-F = 4.9 Hz), 116.0 (CH, d, 
2JC-F = 23.5 Hz), 111.1 (CH), 54.2 (CH), 17.0 
(CH3).  
19F NMR (283 MHz, CDCl3): δ = -117.2 (bs).  
IR (neat): ν͂ = 3088, 2982, 2936, 1578, 1495, 1433, 1067, 798, 750, 593 cm-1.  
MS (EI) m/z (relative intensity) 293 (43) [M+], 214 (9), 189 (28), 170 (100), 136 (4), 105 (45).  
HR-MS (EI) m/z calcd for C18H16FN3 [M
+] 293.1328, found 293.1332. 
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Synthesis of N-Benzhydryl-N-(2-fluorophenyl)pyrimidin-2-amine (86ao’’) 
 
The general procedure D1 was followed using substrate 69 (189 mg, 1.0 mmol) and bromide 
80o (494 mg, 2.0 mmol). Isolation by column chromatography (n-hexane/EtOAc: 9/1) yielded 
86ao’’ (275 mg, 77%) as a yellow solid.  
M.p.: 180–181 °C.  
1H NMR (300 MHz, CDCl3): δ = 8.33 (d, J = 4.8 Hz, 2H), 7.40 (s, 1H), 7.39 – 7.29 (m, 1H), 7.26 – 
7.15 (m, 10H), 7.14 – 7.03 (m, 1H), 6.93 (ddd, J = 7.7, 7.7, 1.4 Hz, 1H), 6.82 (dd, J = 9.9, 8.1 Hz, 
1H), 6.61 (t, J = 4.8 Hz, 1H).  
13C NMR (126 MHz, CDCl3): δ = 161.8 (Cq), 159.4 (Cq, d, JC-F = 247.7 Hz), 157.8 (CH), 140.8 (Cq), 
130.8 (CH, d, JC-F = 1.5 Hz), 129.6 (Cq, d, JC-F = 12.6 Hz), 129.4 (CH), 128.5 (CH, d, JC-F = 7.2 Hz), 
128.5 (CH), 127.8 (CH), 127.5 (Cq), 127.0 (CH), 126.5 (CH), 123.9 (CH), 111.6 (CH), 66.5 (CH).  
19F NMR (283 MHz, CDCl3): δ = -116.0 (ddd, J = 10.2, 7.6, 5.0 Hz).  
IR (neat): ν ͂= 3290, 3056, 2922, 1582, 1523, 1430, 1292, 1201, 1025, 736 cm-1.  
MS (EI) m/z (relative intensity) 355 (51) [M+], 276 (6), 185 (9), 167 (100), 152 (19).  
HR-MS (EI) m/z calcd for C23H18FN3 [M
+] 355.1485, found 355.1479. 
 
Synthesis of N-Phenyl-N-(1-phenylethyl)pyrimidin-2-amine (86hv’’) 
 
The general procedure D1 was followed using 69a (128 mg, 0.75 mmol) and 80v (153 mg, 
1.5 mmol). After purification by column chromatography (n-hexane/EtOAc 9:1) 86hv’’ 
(118 mg, 57%) was obtained as a white solid. 
M.p.: 92–93 °C 
1H NMR (600 MHz, CDCl3): δ = 8.30 (d, J = 4.8 Hz, 2H), 7.30 – 7.19 (m, 8H), 6.84 – 6.79 (m, 
2H), 6.54 – 6.47 (m, 2H), 1.51 (d, J = 7.2 Hz, 3H). 
5 Experimental 
- 97 - 
 
13C NMR (125 MHz, CDCl3): δ = 162.3 (Cq), 157.7 (CH), 142.2 (Cq), 140.1 (Cq), 130.7 (CH), 
128.8 (CH), 127.9 (CH), 127.8 (CH), 127.1 (CH), 127.0 (CH), 110.5 (CH), 53.7 (CH), 17.7 (CH3). 
IR (neat): ν͂ = 2978, 2931, 1597, 1547, 1431, 1064, 962, 795, 698, 589 cm-1. 
MS (EI): m/z (relative intensity) 275 (38) [M+], 260 (10), 196 (11), 170 (100), 105 (36), 77 (31). 
HR-MS (ESI): m/z calcd for C18H18N3 [M+H
+] 276.1501, found 276.1500. 
 
Synthesis of N-(2-Cyclohexylphenyl)pyrimidin-2-amine (86hd) and N-(2,6-
Dicyclohexylphenyl)pyrimidin-2-amine (86hd’) 
 
The general procedure D2 was followed using 69h (599 mg, 3.5 mmol) and 80d (628 mg, 
3.85 mmol). After purification by column chromatography (n-hexane/EtOAc 95:15) 86hd 
(362 mg, 54%) and 86hd’ (150 mg, 13%) were obtained as a white solids. 
86hd: 
M.p.: 93–94 °C 
1H NMR (600 MHz, CDCl3): δ = 8.36 (d, J = 4.8 Hz, 2H), 7.73 (d, J = 8.0 Hz, 1H), 7.31 (dd, J = 7.8, 
1.5 Hz, 1H), 7.23 (ddd, J = 7.8, 7.7, 1.5 Hz, 1H), 7.16 (ddd, J = 7.8, 7.7, 1.2 Hz, 1H), 6.98 (s, 1H), 
6.66 (t, J = 4.8 Hz, 1H), 2.76 (tt, J = 11.8, 3.0 Hz, 1H), 1.88 – 1.80 (m, 4H), 1.75 (d, J = 12.8 Hz, 
1H), 1.49 – 1.33 (m, 4H), 1.27 (dtt, J = 12.9, 12.7, 3.4 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ = 161.2 (Cq), 158.0 (CH), 140.1 (Cq), 135.5 (Cq), 126.4 (CH), 
126.1 (CH), 125.1 (CH), 124.4 (CH), 112.0 (CH), 38.6 (CH), 33.6 (CH2), 27.0 (CH2), 26.3 (CH2). 
IR (neat): ν͂ = 3224, 2922, 2848, 1571, 1516, 1442, 1402, 1253, 799, 752 cm-1. 
MS (EI): m/z (relative intensity) 253 (23) [M+], 237 (8), 210 (6), 196 (12), 170 (100), 93 (9). 
HR-MS (EI): m/z calcd for C16H19N3 [M
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M.p.: 205–206 °C 
1H NMR (600 MHz, CDCl3): δ = 8.27 (d, J = 4.8 Hz, 2H), 7.31 (t, J = 7.7 Hz, 1H), 7.21 (d, J = 7.7 
Hz, 2H), 6.85 (s, 1H), 6.57 (t, J = 4.8 Hz, 1H), 2.77 (t, J = 11.7 Hz, 2H), 1.84 – 1.68 (m, 5H), 1.45 
– 1.12 (m, 5H). 
13C NMR (125 MHz, CDCl3): δ = 162.8 (Cq), 158.3 (CH), 146.0 (Cq), 132.9 (Cq), 128.0 (CH), 
124.4 (CH), 111.2 (CH), 39.7 (CH), 34.2 (CH2), 27.2 (CH2), 26.4 (CH2). 
IR (neat): ν͂ = 3222, 2921, 2847, 1601, 1578, 1527, 1445, 1412, 777 cm-1. 
MS (EI): m/z (relative intensity) 335 (4) [M+], 280 (2), 252 (100), 208 (3), 196 (6). 
HR-MS (EI): m/z calcd for C22H29N3 [M
+] 335.2361, found 335.2348. 
 
 
Synthesis of N-(2-Cyclohexyl-4-methylphenyl)pyrimidin-2-amine (86ld) 
 
The general procedure D3 was followed using 69l (185 mg, 1.0 mmol) and 80d (179 mg, 
1.1 mmol). After purification by column chromatography (n-hexane/EtOAc 95:5) 86ld (92 mg, 
34%) was obtained as a white solid. 
M.p.: 122–123 °C 
1H NMR (600 MHz, CDCl3): δ = 8.34 (d, J = 4.8 Hz, 2H), 7.49 (d, J = 8.1 Hz, 1H), 7.11 (s, 1H), 
7.03 (d, J = 8.1 Hz, 1H), 6.83 (s, 1H), 6.63 (t, J = 4.8 Hz, 1H), 2.73 (tt, J = 11.9, 2.7 Hz, 1H), 2.34 
(s, 3H), 1.81 (d, J = 10.9 Hz, 4H), 1.76 – 1.71 (m, 1H), 1.47 – 1.40 (m, 2H), 1.39 – 1.30 (m, 2H), 
1.30 – 1.21 (m, 1H). 
13C NMR (125 MHz, CDCl3): δ = 161.8 (Cq), 158.2 (CH), 141.2 (Cq), 135.3 (Cq), 132.9 (Cq), 127.3 
(CH), 127.0 (CH), 125.5 (CH), 111.9 (CH), 38.8 (CH), 33.9 (CH2), 27.2 (CH2), 26.5 (CH2), 21.5 
(CH3). 
IR (neat): ν͂ = 3223, 2927, 2848, 1597, 1520, 1447, 1410, 797, 639 cm-1. 
MS (EI): m/z (relative intensity) 267 (18) [M+], 251 (5), 210 (6), 184 (100), 144 (3), 107 (8). 
HR-MS (EI): m/z calcd for C17H21N3 [M
+] 267.1735, found 267.1731. 
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Synthesis of N-(2-Cyclohexyl-4-fluorophenyl)pyrimidin-2-amine (86kd) 
 
The general procedure D3 was followed using 69k (189 mg, 1.0 mmol) and 80d (179 mg, 
1.1 mmol). After purification by column chromatography (n-hexane/EtOAc 95:5) 86kd 
(162 mg, 60%) was obtained as a white solid. 
M.p.: 119–120 °C 
1H NMR (600 MHz, CDCl3): δ = 8.32 (d, J = 4.8 Hz, 2H), 7.54 (dd, J = 8.8, 5.6 Hz, 1H), 6.98 (dd, J 
= 10.2, 3.0 Hz, 1H), 6.89 (td, J = 8.3, 3.0 Hz, 1H), 6.83 (s, 1H), 6.64 (t, J = 4.8 Hz, 1H), 2.72 (t, J 
= 10.3 Hz, 1H), 1.84 – 1.76 (m, 4H), 1.75 – 1.69 (m, 1H), 1.40 – 1.18 (m, 5H). 
13C NMR (125 MHz, CDCl3): δ = 161.6 (Cq), 160.5 (Cq, 
1JC–F = 243.2 Hz), 158.2 (CH), 144.1 (Cq, 
3JC–F = 6.6 Hz), 131.5 (Cq, 
4JC–F = 2.2 Hz), 127.2 (Cq, 
3JC–F = 7.8 Hz), 113.4 (CH, 
2JC–F = 22.4 Hz), 
113.0 (CH, 2JC–F = 21.5 Hz), 112.2 (CH), 39.0 (CH, 
4JC–F = 1.5 Hz), 33.7 (CH2), 27.0 (CH2), 26.3 
(CH2). 
19F NMR (376 MHz, CDCl3): δ = -116.51 (ddd, J = 10.2, 5.6, 1.5 Hz). 
IR (neat): ν͂ = 3232, 2924, 2850, 1575, 1518, 1445, 1403, 1259, 1191, 799 cm-1. 
MS (EI): m/z (relative intensity) 271 (24) [M+], 255 (8), 243 (5), 214 (11), 201 (6), 188 (100), 
161 (6). 
HR-MS (EI): m/z calcd for C16H18FN3 [M
+] 271.1485, found 271.1496. 
 
Synthesis of N-(2-Cyclohexyl-3,4,5-trifluorophenyl)pyrimidin-2-amine (86id) 
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The general procedure D2 was followed using 69i (225 mg, 1.0 mmol) and 80d (179 mg, 
1.1 mmol). After purification by column chromatography (n-hexane/EtOAc 9:1) 86id (19 mg, 
6%) was obtained as a white solid. 
M.p.: 92–93 °C 
1H NMR (600 MHz, CDCl3): δ = 8.39 (d, J = 4.7 Hz, 2H), 7.45 (ddd, J = 11.6, 7.0, 2.0 Hz, 1H), 
6.88 (s, 1H), 6.75 (t, J = 4.7 Hz, 1H), 2.80 (t, J = 12.2 Hz, 1H), 1.89 – 1.79 (m, 4H), 1.76 – 1.70 
(m, 3H), 1.32 – 1.24 (m, 3H). 
13C NMR (125 MHz, CDCl3): δ = 160.8 (Cq), 158.3 (CH), 125.4 (Cq, JC–F = 10.9, 3.9, 1.2 Hz), 
113.1 (CH), 108.8 (CH, JC–F = 20.2, 3.0 Hz), 38.0 (CH), 31.0 (CH2, JC–F = 3.6 Hz), 27.2 (CH2), 26.0 
(CH2). [4 Cq not observed] 
19F NMR (283 MHz, CDCl3): δ = -135.47 (d, J = 20.0 Hz), -138.02 (ddd, J = 21.8, 11.8, 6.3 Hz), -
164.35 (ddd, J = 21.2, 21.0 7.1 Hz). 
IR (neat): ν͂ = 3225, 2937, 2848, 1585, 1505, 1443, 1409, 1117, 939, 625 cm-1. 
MS (EI): m/z (relative intensity) 307 (18) [M+], 291 (4), 250 (8), 237 (5), 224 (100), 161 (8). 
HR-MS (EI): m/z calcd for C16H16F3N3 [M
+] 307.1296, found 307.1289. 
 
Synthesis of N-(2-Cyclohexyl-5-fluorophenyl)pyrimidin-2-amine (86jd) and N-(2,6-
Dicyclohexyl-3-fluorophenyl)pyrimidin-2-amine (86jd’) 
 
The general procedure D2 was followed using 69j (95 mg, 0.5 mmol) and 80d (90 mg, 
0.55 mmol). After purification by column chromatography (n-hexane/EtOAc 95:5) 86jd 
(33 mg, 26%) was obtained as a clear oil and 86jd’ (63 mg, 18%) was obtained as a white 
solid. 
86la: 
1H NMR (600 MHz, CDCl3): δ = 8.42 (d, J = 4.8 Hz, 2H), 7.84 (dd, J = 11.3, 2.7 Hz, 1H), 7.20 (dd, 
J = 8.7, 6.5 Hz, 1H), 6.98 (s, 1H), 6.80 (ddd, J = 8.3, 8.3, 2.7 Hz, 1H), 6.74 (t, J = 4.8 Hz, 1H), 
2.66 (t, J = 9.0 Hz, 1H), 1.88 – 1.83 (m, 4H), 1.77 (dd, J = 13.3, 3.4 Hz, 1H), 1.45 – 1.39 (m, 4H), 
1.31 – 1.24 (m, 1H). 
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13C NMR (125 MHz, CDCl3): δ = 161.0 (Cq, 
1JC–F = 241.6 Hz), 160.5 (Cq), 158.2 (CH), 137.1 (Cq, 
3JC–F = 10.1 Hz), 133.5 (Cq, 
4JC–F = 3.4 Hz), 127.3 (CH, 
3JC–F = 9.3 Hz), 112.9 (CH), 110.7 (CH, 
2JC–F 
= 21.4 Hz), 109.5 (CH, 2JC–F = 25.1 Hz), 38.4 (CH), 33.9 (CH2), 27.2 (CH2), 26.4 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -116.08 (ddd, J = 11.8,, 11.0, 7.2 Hz). 
IR (neat): ν͂ = 3444, 2924, 2851, 1577, 1519, 1445, 1401, 1161, 992, 797 cm-1. 
MS (EI): m/z (relative intensity) 271 (48) [M+], 255 (11), 242 (9), 228 (10), 214 (23), 201 (12), 
188 (100), 161 (27). 
HR-MS (EI): m/z calcd for C16H18FN3 [M
+] 271.1485, found 271.1490. 
 
86la’ 
M.p.: 210–211 °C 
1H NMR (600 MHz, CDCl3): δ = 8.32 (s, 2H), 7.13 (dd, J = 8.7, 5.9 Hz, 1H), 6.98 (dd, J = 11.0, 
8.8 Hz, 1H), 6.62 (t, J = 4.8 Hz, 1H), 6.47 (s, 1H), 2.80 (t, J = 12.2 Hz, 1H), 2.70 (t, J = 11.4 Hz, 
1H), 1.89 – 1.63 (m, 12H), 1.39 – 1.11 (m, 7H), 1.06 – 0.94 (m, 1H). 
13C NMR (125 MHz, CDCl3): δ = 162.7 (Cq), 160.6 (Cq, 
1JC–F = 241.5 Hz), 158.4 (CH), 141.8 (Cq, 
4JC–F = 2.9 Hz), 134.3 (Cq, 
3JC–F = 7.7 Hz), 132.9 (Cq, 
2JC–F = 13.2 Hz), 125.1 (CH, 
3JC–F = 10.2 Hz), 
115.8 (CH, 2JC–F = 23.5 Hz), 111.7 (CH), 39.5 (CH), 39.2 (CH), 34.3 (CH2), 30.9 (CH2), 27.3 (CH2), 
27.2 (CH2), 26.4 (CH2), 26.2 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -115.62 (d, J = 6.3 Hz). 
IR (neat): ν͂ = 3217, 2919, 2848, 1579, 1446, 1260, 1226, 1042, 811, 641 cm-1. 
MS (EI): m/z (relative intensity) 353 (5) [M+], 298 (2), 270 (100), 226 (3), 214 (6), 200 (5). 
HR-MS (EI): m/z calcd for C22H28FN3 [M
+] 353.2267, found 353.2280. 
 
Synthesis of N-[2-(Nonan-5-yl)phenyl]pyrimidin-2-amine (86ht) 
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The general procedure D2 was followed using 69h (128 mg, 0.75 mmol) and 80t (171 mg, 
0.83 mmol). After purification by column chromatography (n-hexane/EtOAc 9:1) 86ht 
(134 mg, 60%) was obtained as a white solid. 
M.p.: 68–69 °C 
1H NMR (400 MHz, CDCl3): δ = 8.33 (d, J = 4.8 Hz, 2H), 7.67 (d, J = 7.7 Hz, 1H), 7.23 – 7.13 (m, 
3H), 6.76 (s, 1H), 6.63 (t, J = 4.8 Hz, 1H), 2.84 (tt, J = 8.7, 5.8 Hz, 1H), 1.67 – 1.49 (m, 4H), 1.25 
– 1.04 (m, 8H), 0.76 (t, J = 7.1 Hz, 6H). 
13C NMR (75 MHz, CDCl3): δ = 161.5 (Cq), 158.4 (CH), 139.7 (Cq), 136.7 (Cq), 127.1 (CH), 126.2 
(CH), 125.6 (CH), 125.2 (CH), 112.2 (CH), 39.2 (CH), 36.3 (CH2), 29.9 (CH2), 23.0 (CH2), 14.1 
(CH3). 
IR (neat): ν͂ = 3205, 2922, 2855, 1591, 1521, 1447, 1355, 995, 800, 641 cm-1. 
MS (EI): m/z (relative intensity) 297 (63) [M+], 254 (92), 240 (63), 226 (44), 196 (27), 184 (66), 
170 (100). 
HR-MS (EI): m/z calcd for C19H27N3 [M
+] 297.2205, found 297.2196. 
 
Synthesis of N-[2-(2-Adamantyll)phenyl]pyrimidin-2-amine (86hg) 
 
The general procedure D2 was followed using 69h (128 mg, 0.75 mmol) and 80g (177 mg, 
0.83 mmol). After purification by column chromatography (n-hexane/EtOAc 95:5) 86hg 
(126 mg, 55%) was obtained as a white solid. 
M.p.: 130–131 °C 
1H NMR (400 MHz, CDCl3): δ = 8.37 (d, J = 4.8 Hz, 2H), 7.87 (dd, J = 8.0, 1.2 Hz, 1H), 7.58 (d, J 
= 7.7 Hz, 1H), 7.28 – 7.23 (m, 1H), 7.14 (ddd, J = 7.9, 7.8, 1.3 Hz, 1H), 6.79 (s, 1H), 6.67 (t, J = 
4.8 Hz, 1H), 3.16 (s, 1H), 2.27 (s, 2H), 2.09 (s, 1H), 2.05 (s, 1H), 2.01 – 1.93 (m, 4H), 1.92 – 
1.87 (m, 1H), 1.78 (s, 2H), 1.67 (s, 1H), 1.63 (s, 2H). 
13C NMR (125 MHz, CDCl3): δ = 160.8 (Cq), 158.2 (CH), 137.0 (Cq), 136.8 (Cq), 127.6 (CH), 
126.2 (CH), 124.1 (CH), 123.8 (CH), 112.2 (CH), 45.2 (CH), 40.2 (CH2), 37.9 (CH2), 32.7 (CH2), 
31.5 (CH), 28.0 (CH), 27.5 (CH). 
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IR (neat): ν͂ = 3224, 2899, 2845, 1579, 1519, 1443, 1407, 993, 798, 641 cm-1. 
MS (EI): m/z (relative intensity) 305 (53) [M+], 289 (28), 277 (100), 248 (8), 208 (10), 184 (16), 
170 (90). 
HR-MS (EI): m/z calcd for C20H23N3 [M
+] 305.1892, found 305.1879. 
 
Synthesis of N-(2-Cyclohexyl-6-fluorophenyl)pyridin-2-amine (131) 
 
The general procedure D2 was followed using 123 (94 mg, 0.5 mmol) and 80d (163 mg, 
1.0 mmol). After purification by column chromatography (n-hexane/EtOAc 2:1), followed by 
GPC, 131 (6 mg, 5%) was obtained as a brown oil. 
1H NMR (300 MHz, CDCl3): δ = 8.16 (s, 1H), 7.42 (ddd, J = 8.0, 7.7, 1.7 Hz, 1H), 7.25 – 7.18 (m, 
1H), 7.12 (d, J = 7.5 Hz, 1H), 6.99 (ddd, J = 9.6, 8.0, 1.5 Hz, 1H), 6.70 – 6.65 (m, 1H), 6.24 (d, J 
= 6.8 Hz, 1H), 6.14 (s, 1H), 2.91 – 2.79 (m, 1H), 1.85 – 1.66 (m, 5H), 1.48 – 1.22 (m, 5H). 
13C NMR (125 MHz, CDCl3): δ = 158.8 (Cq, 
1JC–F = 246.6 Hz), 157.9 (Cq), 148.1 (CH), 147.9 (Cq), 
137.9 (CH), 127.5 (CH, 3JC–F = 9.1 Hz), 124.8 (Cq, 
2JC–F = 12.2 Hz), 122.4 (CH, 
4JC–F = 3.5 Hz), 
114.6 (CH), 113.6 (CH, 2JC–F = 20.7 Hz), 106.7 (CH), 38.9 (CH, 
4JC–F = 2.2 Hz), 34.1 (CH2), 27.0 
(CH2), 26.3 (CH2). 
19F NMR (283 MHz, CDCl3): δ = -119.06 (ddd, J = 9.7, 5.5, 1.8 Hz). 
IR (neat): ν͂ = 3206, 2926, 2852, 1599, 1523, 1446, 1325, 1259, 958, 770 cm-1. 
MS (ESI): m/z (relative intensity) 271 (100) [M+], 236 (9), 201 (1), 159 (3), 130 (2). 
HR-MS (ESI): m/z calcd for C17H20FN2 [M
+] 271.1610, found 271.1606. 
 
Synthesis of N-(2-Cyclohexyl-6-fluorophenyl)-4-(p-tolyl)pyrimidin-2-amine (129) and 4-(2-
Cyclohexyl-4-methylphenyl)-N-(2-cyclohexyl-6-fluorophenyl)pyrimidin-2-amine (129’) 
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The general procedure D1 was followed using 121 (279 mg, 1.0 mmol) and 80d (326 mg, 
2.0 mmol). After purification by column chromatography (n-hexane/EtOAc 95:5) 129 
(262 mg, 72%) and 129’ (50 mg, 11%) were obtained as white solids. 
129: 
M.p.: 70–71 °C 
1H NMR (600 MHz, CDCl3): δ = 8.36 (d, J = 5.2 Hz, 1H), 7.89 (d, J = 8.1 Hz, 2H), 7.26 – 7.22 (m, 
3H), 7.12 (d, J = 7.9 Hz, 1H), 7.08 (d, J = 5.3 Hz, 1H), 7.00 (ddd, J = 9.6, 8.1, 1.4 Hz, 1H), 6.57 (s, 
1H), 2.89 (tt, J = 11.9, 3.2 Hz, 1H), 2.40 (s, 3H), 1.86 – 1.80 (m, 2H), 1.80 – 1.74 (m, 2H), 1.73 – 
1.67 (m, 1H), 1.45 – 1.36 (m, 2H), 1.35 – 1.21 (m, 3H). 
13C NMR (76 MHz, CDCl3): δ = 165.2 (Cq), 162.1 (Cq), 158.9 (Cq, 
1JC–F = 246.3 Hz), 158.7 (CH), 
147.7 (Cq), 141.1 (Cq), 134.5 (Cq), 129.6 (CH), 127.7 (CH, 
1JC–F = 8.8 Hz), 127.1 (CH), 124.2 (Cq, 
1JC–F = 12.5 Hz), 122.0 (CH, 
1JC–F = 3.7 Hz), 113.3 (CH, 
1JC–F = 20.7 Hz), 108.0 (CH), 39.0 (CH, 
1JC–F 
= 2.4 Hz), 33.9 (CH2), 26.9 (CH2), 26.3 (CH2), 21.6 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -118.69 (dd, J = 9.6, 5.5 Hz). 
IR (neat): ν͂ = 3219, 2923, 2850, 1575, 1549, 1443, 1280, 958, 801, 702 cm-1. 
MS (EI): m/z (relative intensity) 361 (63) [M+], 342 (14), 304 (13), 278 (100), 251 (14), 237 
(12), 184 (16). 
HR-MS (EI): m/z calcd for C23H24FN3 [M
+] 361.1954, found 361.1966. 
 
129’ 
M.p.: 162–163 °C 
1H NMR (600 MHz, CDCl3): δ = 8.34 (d, J = 5.0 Hz, 1H), 7.21 (d, J = 7.8 Hz, 1H), 7.20 – 7.17 (m, 
1H), 7.15 (s, 1H), 7.07 (d, J = 7.8 Hz, 1H), 7.03 (d, J = 6.8 Hz, 1H), 6.95 (dd, J = 8.9, 8.7 Hz, 1H), 
6.72 (d, J = 5.0 Hz, 1H), 6.49 (s, 1H), 2.89 – 2.80 (m, 2H), 2.35 (s, 3H), 1.81 – 1.62 (m, 10H), 
1.43 – 1.16 (m, 10H). 
13C NMR (76 MHz, CDCl3): δ = 169.2 (Cq), 161.6 (Cq), 158.9 (Cq, 
1JC–F = 247.3 Hz), 158.0 (CH), 
147.5 (Cq), 145.8 (Cq), 139.1 (Cq), 135.2 (Cq), 129.3 (CH), 127.7 (CH, 
3JC–F = 8.2 Hz), 127.5 (CH), 
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126.5 (CH), 124.0 (Cq, 
2JC–F = 11.7 Hz), 122.0 (Cq, 
3JC–F = 3.6 Hz), 113.3 (CH, 
2JC–F = 20.2 Hz), 
112.7 (CH), 39.8 (CH), 39.1 (CH, 4JC–F = 2.3 Hz), 34.6 (CH2), 33.8 (CH2), 27.0 (CH2), 26.9 (CH2), 
26.4 (CH2), 26.3 (CH2), 21.6 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -118.56 (dd, J = 9.7, 5.5 Hz). 
IR (neat): ν͂ = 3219, 2921, 2849, 1576, 1556, 1415, 961, 783, 708, 648 cm-1. 
MS (EI): m/z (relative intensity) 443 (100) [M+], 400 (6), 388 (6), 360 (67), 319 (6), 226 (15), 
208 (6). 
HR-MS (EI): m/z calcd for C29H34FN3 [M
+] 443.2737, found 443.2723. 
 
Synthesis of Cyclohexyl-N-phenylmorpholine-4-carbimidothioate (133’) 
 
The general procedure D1 was followed using 125 (222 mg, 1.0 mmol) and 80d (326 mg, 
2.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1) 133’ (169 mg, 
55%) was obtained as a yellow oil. 
1H NMR (600 MHz, CDCl3): δ = 7.25 – 7.21 (m, 2H), 6.97 (t, J = 7.4 Hz, 1H), 6.85 (d, J = 7.4 Hz, 
2H), 3.73 – 3.70 (m, 4H), 3.66 – 3.63 (m, 4H), 2.55 (tt, J = 10.7, 3.6 Hz, 1H), 1.74 – 1.68 (m, 
2H), 1.65 – 1.57 (m, 3H), 1.52 – 1.45 (m, 1H), 1.20 – 1.00 (m, 5H). 
13C NMR (125 MHz, CDCl3): δ = 154.7 (Cq), 150.0 (Cq), 128.6 (CH), 122.3 (CH), 121.6 (CH), 67.0 
(CH2), 49.0 (CH2), 45.1 (CH), 33.7 (CH2), 26.1 (CH2), 25.7 (CH2). 
IR (neat): ν͂ = 2926, 2851, 1577, 1447, 1194, 1111, 1022, 853, 763, 694 cm-1. 
MS (ESI): m/z (relative intensity) 327 (6), 305 (100) [M+H+], 271 (3), 236 (11), 169 (3). 
HR-MS (ESI): m/z calcd for C17H25N2OS [M+H
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H/D exchange experiments with [D]5-69h as the substrate: 
 
 
Following the general procedure D1 [D]5-69h (38 mg, 0.22 mmol) was reacted without alkyl 
halide 80. After 12 h, the reaction was cooled to 0 °C, filtered through a silica pad and 
concentrated in vacuo, giving [D]n-69h (36 mg, 98%). 
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Following the general procedure D1 69h (86 mg, 0.5 mmol) was reacted with D4-MeOH 
(0.2 mL, 5.0 mmol). After 12 h, the reaction was cooled to 0 °C, filtered through a silica pad 
and concentrated in vacuo, giving [D]n-69h (86 mg, 98%). 
 
 
H/D exchange experiments with [D]5-69h and 80d as the substrates: 
 
Following the general procedure D2 [D]5-69h (88 mg, 0.5 mmol) was reacted with 80d 
(90 mg, 0.55 mmol). After 3.5 h, the reaction was cooled with an ice bath, filtered through a 
silica pad and concentrated in vacuo. The residue was analyzed by 1H NMR spectroscopy. 









KIE experiments with 69h and [D]5-69h as the substrates 
 
Parallel independent reactions with 69h and [D]5-69h were performed for different reaction 
times. Following general procedure D1 69h (86 mg, 0.5 mmol) or [D]5-69h (88 mg, 0.5 mmol) 
were reacted with 80d (90 mg, 0.55 mmol). After the reaction times indicated below, each 
reaction was cooled with an ice bath, filtered through a silica pad and concentrated in vacuo. 
The residue was analyzed by 1H NMR spectroscopy. Yields of products were determined 
using CH2Br2 (49.5 mg, 0.28 mmol) as internal standard. For each reaction time the average 
of two reactions was obtained. 
 
 
t [h] 1.5 2.0 2.5 3.0 3.5 4.0 
86hd 3 10 17 34 39 53 
[D]n-86hd 0 7 13 17 20 33 
5 Experimental 






Reaction of aniline 69a with cyclohexene 138 
 
Following the general procedure D1 69a (189 mg, 1.0 mmol) was reacted with 138 (164 mg, 
2.0 mmol). After cooling to ambient temperature, CH2Cl2 (2.0 mL) was added. No conversion 
was observed through 19F NMR analysis of the crude reaction mixture. 
 
Reaction of aniline 69a with styrene 139 
 
Following the general procedure D1 69a (189 mg, 1.0 mmol) was reacted with 139 (208 mg, 
2.0 mmol). After cooling to ambient temperature, CH2Cl2 (2.0 mL) was added. No conversion 
was observed through 19F NMR analysis of the crude reaction mixture. 
y = 19,943x - 29,01 
R² = 0,9804 
y = 11,886x - 17,686 
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Reaction of aniline 69a with (S)-2-Bromooctane (80k) 
 
The general procedure D2 was followed using substrate 69a (189 mg, 1.0 mmol) and (S)-2-
Bromooctane (S)-80k (193 mg, 1.0 mmol). Isolation by filtration through a silica pad (n-
hexane/EtOAc: 85/15) yielded the mixture of 69a and 86ak as a white solid. Analysis by HPLC 









retention time area area % 
5.81 28300 85.2 
8.09 2452 7.4 
9.56 2445 7.4 
retention time area area % 
7.91 7921 50.1 
9.30 7894 49.9 
retention time area area % 
5.84 13400 100 
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Hammett plot correlation for anilines 69 
 
The general procedure D2 was followed using anilines 69 (0.50 mmol) and 
cyclohexylbromide (80d) (90 mg, 0.55 mmol). After 3 h, the reaction mixture was cooled in 
an ice bath. The crude mixture was filtered through a celite pad and concentrated in vacuo. 
The residue was analyzed by 1H NMR spectroscopy. Yields of products were determined 
using CH2Br2 (49.5 mg, 0.28 mmol) as the internal standard. For each substrate the average 
of two reactions was obtained. 
 
R P σp Log (ratio (R/H) 
OMe 6 - 0.27 -0.76 
Me 13 - 0.17 -0.43 
H 35 0.00 0 
F 37 0.06 0.03 
Cl 24 0.23 -0.16 









y = 2,4517x - 0,0571 
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5.4.5 Analytical Data for C–H Fluoroalkylation of N-(2-Pyrimidyl)anilines 69 
 
Synthesis of N-[2-Fluoro-6-(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87a) 
 
The general procedure E1 was followed using 69a (189 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87a (147 mg, 54%) was obtained as a white solid. 
 
The general procedure E2 was followed using 69a (189 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87a (188 mg, 69%) was obtained as a white solid. 
 
The general procedure E3 was followed using 69a (189 mg, 1.0 mmol) and 82 (420 mg, 
2.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87a (218 mg, 80%) was obtained as a white solid. 
 
M.p.: 105–106 °C 
1H NMR (600 MHz, CDCl3): δ = 8.35 (d, J = 4.8 Hz, 2H), 7.30 (ddd, J = 8.3, 7.8, 5.4 Hz, 1H), 7.23 
(d, J = 7.8 Hz, 1H), 7.17 (ddd, J = 9.6, 8.3, 1.4 Hz, 1H), 6.88 (s, 1H), 6.71 (t, J = 4.8 Hz, 1H), 3.52 
(q, J = 10.7 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 161.4 (Cq), 159.0 (Cq, d, 
1JC–F = 247.6 Hz), 158.3 (CH), 130.8 (Cq, 
q, 3JC–F = 2.7 Hz), 128.1 (CH, d, 
3JC–F = 7.4 Hz), 126.8 (CH, q, 
3JC–F = 2.7 Hz), 126.4 (Cq, q, 
2JC–F = 
13.0 Hz), 125.9 (Cq, q, 
1JC–F = 277.1 Hz), 116.3 (CH, d, 
2JC–F = 20.9 Hz), 112.9 (CH), 36.1 (CH2, qd, 
2,4JC–F = 30.4, 2.6 Hz). 
19F NMR (283 MHz, CDCl3): δ = -64.99 (t, J = 10.7 Hz), -117.63 (dd, J = 9.6, 5.0 Hz). 
IR (neat): ν͂ = 3234, 2963, 2921, 1576, 1449, 1407, 1258, 1096, 787, 638 cm-1. 
MS (EI): m/z (relative intensity) 271 (12) [M+], 252 (27), 232 (17), 201 (8), 188 (100), 182 (3). 
HR-MS (EI): m/z calcd for C12H9F4N3 [M
+] 271.0733, found 271.0743. 
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Synthesis of N-[2-Methyl-6-(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87b) 
 
The general procedure E1 was followed using 69b (185 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87b (181 mg, 68%) was obtained as a pale brown solid. 
 
The general procedure E2 was followed using 69b (185 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87b (184 mg, 69%) was obtained as a pale brown solid. 
 
The general procedure E3 was followed using 69b (185 mg, 1.0 mmol) and 82 (420 mg, 
2.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87b (190 mg, 71%) was obtained as a pale brown solid. 
 
M.p.: 104–105 °C 
1H NMR (600 MHz, CDCl3): δ = 8.32 (t, J = 4.8 Hz, 2H), 7.31 – 7.27 (m, 2H), 7.26 – 7.23 (m, 1H), 
7.09 (s, 1H), 6.63 (t, J = 4.8 Hz, 1H), 3.45 (q, J = 10.3 Hz, 2H), 2.24 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 161.5 (Cq), 158.5 (CH), 137.7 (Cq), 136.4 (Cq), 131.0 (CH), 
129.3 (CH), 129.1 (Cq, q, 
3JC–F = 2.2 Hz), 127.6 (CH), 126.2 (Cq, q, 
1JC–F = 277.6 Hz), 112.0 (CH), 
36.5 (CH2, q, 
2JC–F = 29.4 Hz), 18.93 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -65.09 (t, J = 10.3 Hz). 
IR (neat): ν͂ = 3193, 2971, 2921, 1577, 1446, 1358, 1258, 1128, 791,639 cm-1. 
MS (EI): m/z (relative intensity) 267 (34) [M+], 252 (38), 232 (18), 197 (7), 184 (100). 
HR-MS (EI): m/z calcd for C13H12F3N3 [M
+] 267.0983, found 267.0993. 
 
Synthesis of N-[2-Methoxy-6-(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87c) 
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The general procedure E1 was followed using 69c (201 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87c (94 mg, 33%) was obtained as a white solid. 
 
The general procedure E2 was followed using 69c (201 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87c (226 mg, 78%) was obtained as a white solid. 
 
The general procedure E3 was followed using 69c (201 mg, 1.0 mmol) and 82 (420 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87c (140 mg, 50%) was obtained as a white solid. 
 
M.p.: 118–119 °C 
1H NMR (600 MHz, CDCl3): δ = 8.33 (d, J = 4.8 Hz, 2H), 7.29 – 7.26 (m, 1H), 7.06 (d, J = 7.8 Hz, 
1H), 6.95 (d, J = 8.3 Hz, 1H), 6.71 (s, 1H), 6.66 (t, J = 4.8 Hz, 1H), 3.78 (s, 3H), 3.49 (q, J = 
11.0 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 162.0 (Cq), 158.3 (CH), 155.4 (Cq), 140.5 (Cq) 130.2 (Cq, q, 
3JC–F 
= 2.6 Hz), 127.6 (CH), 126.2 (Cq, q, 
1JC–F = 275.4 Hz), 122.8 (CH), 112.4 (CH), 111.2 (CH), 55.9 
(CH3), 36.2 (CH2, q, 
2JC–F = 29.9 Hz). 
19F NMR (283 MHz, CDCl3): δ = -64.60 (t, J = 10.9 Hz). 
IR (neat): ν͂ = 3212, 3009, 2938, 2841, 1580, 1450, 1410, 1262, 1105, 795 cm-1. 
MS (EI): m/z (relative intensity) 283 (4) [M+], 260 (52), 252 (100), 232 (54), 200 (32), 182 (25). 
HR-MS (ESI): m/z calcd for C13H13F3N3O [M+H
+] 284.1013, found 284.1007. 
 
Synthesis of N-[3-(2,2,2-trifluoroethyl)-[1,1'-biphenyl]-2-yl]pyrimidin-2-amine (87e) 
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The general procedure E2 was followed using 69e (247 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87e (257 mg, 77%) was obtained as a white solid. 
 
The general procedure E3 was followed using 69e (247 mg, 1.0 mmol) and 82 (420 mg, 
2.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87e (270 mg, 82%) was obtained as a white solid. 
 
M.p.: 159–160 °C 
1H NMR (600 MHz, CDCl3): δ = 8.21 (d, J = 4.8 Hz, 2H), 7.49 – 7.47 (m, 1H), 7.41 – 7.39 (m, 
2H), 7.29 – 7.23 (m, 5H), 6.78 (s, 1H), 6.55 (t, J = 4.8 Hz, 1H), 3.51 (q, J = 10.9 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 161.5 (Cq), 158.2 (CH), 140.9 (Cq), 139.4 (Cq), 135.3 (Cq), 130.9 
(CH), 130.6 (CH), 129.7 (Cq, q, 
3JC–F = 2.8 Hz), 128.9 (CH), 128.2 (CH), 127.4 (CH), 127.4 (CH), 
126.2 (Cq, q, 
1JC–F = 276.9 Hz), 112.0 (CH), 36.5 (CH2, q, 
2JC–F = 27.8 Hz). 
19F NMR (283 MHz, CDCl3): δ = -64.62 (t, J = 10.9 Hz). 
IR (neat): ν͂ = 3194, 3026, 2916, 1578, 1442, 1410, 1244, 1109, 1066, 759 cm-1. 
MS (EI): m/z (relative intensity) 329 (23) [M+], 289 (6), 259 (9), 246 (100), 232 (10), 182 (5). 
HR-MS (EI): m/z calcd for C18H14F3N3 [M
+] 329.1140, found 329.1138. 
 
Synthesis of N-[5-Chloro-2-(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87m) 
 
The general procedure E2 was followed using 69m (206 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87m (75 mg, 26%) was obtained as a white solid. 
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M.p.: 104–105 °C 
1H NMR (600 MHz, CDCl3): δ = 8.41 (d, J = 4.8 Hz, 2H), 7.89 (d, J = 2.2 Hz, 1H), 7.27 (d, J = 
8.3 Hz, 1H), 7.17 (dd, J = 8.3, 2.2 Hz, 1H), 7.01 (s, 1H), 6.77 (t, J = 4.8 Hz, 1H), 3.45 (q, J = 
10.7 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 160.5 (Cq), 158.3 (CH), 139.2 (Cq), 134.8 (Cq), 132.9 (CH), 
125.9 (Cq, q, 
1JC–F = 275.1 Hz), 125.3 (CH), 125.2 (CH), 121.8 (Cq, q, 
3JC–F = 2.6 Hz), 113.4 (CH), 
36.0 (CH2, q, 
2JC–F = 30.7 Hz). 
19F NMR (283 MHz, CDCl3): δ = -65.05 (t, J = 10.7 Hz). 
IR (neat): ν͂ = 3237, 3085, 1571, 1445, 1357, 1229, 1122, 1068, 798, 633 cm-1. 
MS (EI): m/z (relative intensity) 287 (10) [M+], 266 (3), 247 (10), 217 (7), 204 (100), 182 (3). 
HR-MS (EI): m/z calcd for C12H9ClF3N3 [M
+] 287.0437, found 287.0442. 
 
Synthesis of N-[5-Methyl-2-(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87n) 
 
The general procedure E2 was followed using 69n (185 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87n (85 mg, 32%) was obtained as a white solid. 
M.p.: 99–100 °C 
1H NMR (600 MHz, CDCl3): δ = 8.36 (d, J = 4.8 Hz, 2H), 7.46 (s, 1H), 7.26 (d, J = 7.8 Hz, 1H), 
7.06 – 7.02 (m, 2H), 6.69 (t, J = 4.8 Hz, 1H), 3.44 (q, J = 10.9 Hz, 2H), 2.37 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 161.2 (Cq), 158.3 (CH), 139.2 (Cq), 137.7 (Cq), 131.7 (CH), 
126.9 (CH), 126.9 (CH), 126.2 (Cq, q, 
1JC–F = 278.7 Hz), 122.1 (Cq, q, 
3JC–F = 2.7 Hz), 112.5 (CH), 
36.0 (CH2, q, 
2JC–F = 27.9 Hz), 21.5 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -65.19 (t, J = 10.9 Hz). 
IR (neat): ν͂ = 3239, 3010, 1576, 1527, 1448, 1411, 1244, 1136, 1070, 789 cm-1. 
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MS (EI): m/z (relative intensity) 267 (7) [M+], 246 (2), 227 (4), 197 (4), 184 (100), 148 (2). 
HR-MS (EI): m/z calcd for C13H12F3N3 [M
+] 267.0983, found 267.0984. 
 
Synthesis of N-[5-Methoxy-2-(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87o) 
 
The general procedure E2 was followed using 69o (201 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87o (85 mg, 30%) was obtained as a brown solid. 
M.p.: 88–89 °C 
1H NMR (600 MHz, CDCl3): δ = 8.41 (d, J = 4.8 Hz, 2H), 7.38 (d, J = 2.7 Hz, 1H), 7.25 (d, J = 
7.2 Hz, 1H), 6.89 (s, 1H), 6.79 – 6.70 (m, 2H), 3.82 (s, 3H), 3.41 (q, J = 10.9 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 161.1 (Cq), 160.0 (Cq), 158.2 (CH), 139.0 (Cq), 132.6 (CH), 
126.2 (Cq, q, 
1JC–F = 277.1 Hz), 116.2 (Cq), 112.8 (CH), 111.3 (CH), 111.2 (CH), 55.5 (CH3), 35.7 
(CH2, q, 
2JC–F = 29.3 Hz). 
19F NMR (283 MHz, CDCl3): δ = -65.42 (t, J = 10.8 Hz). 
IR (neat): ν͂ = 3227, 3095, 3009, 1575, 1443, 1401, 1257, 1119, 1059, 798 cm-1. 
MS (ESI): m/z (relative intensity) 306 (22), 284 (100) [M+H+], 257 (2), 227 (4), 159 (2). 
HR-MS (ESI): m/z calcd for C13H13F3N3O [M+H
+] 284.1010, found 284.1006. 
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The general procedure E2 was followed using 69h (171 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87h (138 mg, 55%) and 87h’ (54 mg, 16%) were obtained as white solids. 
87h 
M.p.: 123–124 °C 
1H NMR (600 MHz, CDCl3): δ = 8.38 (d, J = 4.8 Hz, 2H), 7.69 (d, J = 8.1 Hz, 1H), 7.42 – 7.35 (m, 
2H), 7.22 (dd, J = 7.6, 7.6, 1.1 Hz, 1H), 7.05 (s, 1H), 6.71 (t, J = 4.8 Hz, 1H), 3.49 (q, J = 10.8 Hz, 
2H). 
13C NMR (125 MHz, CDCl3): δ = 161.1 (Cq), 158.3 (CH), 138.0 (Cq), 132.0 (CH), 129.2 (CH), 
126.2 (CH), 126.1 (Cq, q, 
1JC–F = 276.3 Hz), 125.8 (CH), 124.8 (Cq, q, 
3JC–F = 2.3 Hz), 112.8 (CH), 
36.3 (CH2, q, 
2JC–F = 29.6 Hz). 
19F NMR (283 MHz, CDCl3): δ = -65.02 (t, J = 10.8 Hz). 
IR (neat): ν͂ = 3251, 1580, 1518, 1444, 1356, 1245, 1135, 1068, 756, 653 cm-1. 
MS (EI): m/z (relative intensity) 253 (8) [M+], 232 (3), 213 (5), 183 (4), 170 (100), 168 (3). 
HR-MS (EI): m/z calcd for C12H10F3N3 [M
+] 253.0827, found 253.0826. 
 
87h’ 
M.p.: 142–143 °C 
1H NMR (600 MHz, CDCl3): δ = 8.32 (d, J = 4.7 Hz, 2H), 7.46 (d, J = 7.7 Hz, 2H), 7.38 (t, J = 
7.7 Hz, 1H), 6.93 (s, 1H), 6.68 (t, J = 4.7 Hz, 1H), 3.42 (br s, 4H). 
13C NMR (125 MHz, CDCl3): δ = 161.3 (Cq), 158.7 (CH), 137.3 (Cq), 131.9 (CH), 130.5 (Cq, q, 
3JC–
F = 2.5 Hz), 128.1 (CH), 125.9 (Cq, q, 
1JC–F = 277.1 Hz), 112.5 (CH), 36.6 (CH2, q, 
2JC–F = 30.5 Hz). 
19F NMR (283 MHz, CDCl3): δ = -65.01 (t, J = 10.7 Hz). 
IR (neat): ν͂ = 3206, 2927, 1580, 1449, 1354, 1252, 1128, 1062, 777, 600 cm-1. 
MS (EI): m/z (relative intensity) 335 (13) [M+], 295 (4), 275 (6), 265 (6), 252 (100), 232 (44), 
226 (4), 182 (8). 
HR-MS (EI): m/z calcd for C14H11F6N3 [M
+] 335.0857, found 335.0851. 
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Synthesis of N-[4-Fluoro-2-(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87k) 
 
The general procedure E2 was followed using 69k (189 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87k (43 mg, 16%) was obtained as a white solid. 
M.p.: 101–102 °C 
1H NMR (600 MHz, CDCl3): δ = 8.35 (d, J = 4.8 Hz, 2H), 7.56 (dd, J = 8.5, 5.3 Hz, 1H), 7.12 – 
7.08 (m, 2H), 6.89 (s, 1H), 6.71 (t, J = 4.8 Hz, 1H), 3.46 (q, J = 10.7 Hz, 2H). 
13C NMR (125 MHz, CDCl3): δ = 161.3 (Cq), 160.2 (Cq, d, 
1JC–F = 245.7 Hz), 158.3 (CH), 134.0 (Cq, 
d, 4JC–F = 2.9 Hz), 128.8 (CH, d, 
3JC–F = 9.2 Hz), 127.8 (Cq, dq, 
3,3JC–F = 7.8, 2.6 Hz), 125.9 (Cq, q, 
1JC–F = 277.1 Hz), 118.3 (CH, d, 
2JC–F = 24.0 Hz), 116.3 (CH, d, 
2JC–F = 21.3 Hz), 112.8 (CH), 36.3 
(CH2, qd, 
2,4JC–F = 30.3, 1.3 Hz). 
19F NMR (283 MHz, CDCl3): δ = -64.98 (t, J = 10.7 Hz), -115.71 (ddd, J = 8.4, 8.4, 5.3 Hz). 
IR (neat): ν͂ = 3206, 2928, 1581, 1412, 1255, 1209, 1129, 1070, 802, 541 cm-1. 
MS (EI): m/z (relative intensity) 271 (13) [M+], 250 (4), 231 (9), 201 (5), 188 (100), 178 (2), 
100 (2). 
HR-MS (EI): m/z calcd for C12H9F4N3 [M
+] 271.0733, found 271.0735. 
 
Synthesis of N-[4-Methyl-2-(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87l) and N-[4-
Methyl-2,6-bis(2,2,2-trifluoroethyl)phenyl]pyrimidin-2-amine (87l’) 
 
The general procedure E2 was followed using 69l (185 mg, 1.0 mmol) and 146 (326 mg, 
2.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87l (114 mg, 43%) and 87l’ (19 mg, 6%) were obtained as white solids. 
87l: 
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M.p.: 114–115 °C 
1H NMR (600 MHz, CDCl3): δ = 8.34 (d, J = 4.8 Hz, 2H), 7.47 (d, J = 8.0 Hz, 1H), 7.21 – 7.18 (m, 
2H), 6.99 (s, 1H), 6.67 (t, J = 4.8 Hz, 1H), 3.44 (q, J = 10.9 Hz, 2H), 2.36 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 161.5 (Cq), 158.3 (CH), 136.0 (Cq), 135.3 (Cq), 132.4 (CH), 
130.0 (CH), 126.9 (CH), 126.2 (Cq, q, 
1JC–F = 276.3 Hz), 125.4 (Cq, q, 
3JC–F = 2.5 Hz), 112.4 (CH), 
36.2 (CH2, q, 
2JC–F = 29.8 Hz), 21.2 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -65.03 (t, J = 10.9 Hz). 
IR (neat): ν͂ = 3292, 1581, 1513, 1445, 1399, 1245, 1124, 1069, 795, 608 cm-1. 
MS (EI): m/z (relative intensity) 267 (9) [M+], 246 (3), 227 (4), 197 (3), 184 (100), 148 (2). 
HR-MS (EI): m/z calcd for C13H12F3N3 [M
+] 267.0983, found 267.0980. 
 
87l’: 
M.p.: 126–127 °C 
1H NMR (600 MHz, CDCl3): δ = 8.30 (d, J = 4.8 Hz, 2H), 7.26 (s, 2H), 7.10 (s, 1H), 6.65 (t, J = 
4.8 Hz, 1H), 3.37 (br s, 4H), 2.39 (s, 3H). 
13C NMR (125 MHz, CDCl3): δ = 161.4 (Cq), 158.7 (CH), 138.1 (Cq), 134.6 (Cq), 132.6 (CH), 
130.1 (Cq, q, 
3JC–F = 1.9 Hz), 126.0 (Cq, q, 
1JC–F = 276.5 Hz), 112.4 (CH), 36.5 (CH2, q, 
2JC–F = 
29.9 Hz), 21.3 (CH3). 
19F NMR (283 MHz, CDCl3): δ = -64.99 (t, J = 10.8 Hz). 
IR (neat): ν͂ = 3223, 2922, 1585, 1517, 1256, 1234, 1139, 1079, 801, 639 cm-1. 
MS (EI): m/z (relative intensity) 349 (5) [M+], 309 (2), 279 (2), 266 (100), 246 (11), 196 (3). 
HR-MS (EI): m/z calcd for C15H13F6N3 [M
+] 349.1014, found 349.1019. 
 
Synthesis of N-[2-(2,2,2-trifluoroethyl)naphthalen-1-yl]pyrimidin-2-amine (87g) 
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The general procedure E2 was followed using 69g (221 mg, 1.0 mmol) and 146 (489 mg, 
3.0 mmol). After purification by column chromatography (n-hexane/EtOAc 3:1), followed by 
GPC purification, 87g (135 mg, 45%) was obtained as a white solid. 
M.p.: 149–150 °C 
1H NMR (600 MHz, CDCl3): δ = 8.26 (d, J = 4.8 Hz, 2H), 8.03 (d, J = 8.4 Hz, 1H), 7.93 (s, 1H), 
7.90 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 8.5 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.55 – 7.48 (m, 2H), 
6.61 (t, J = 4.8 Hz, 1H), 3.66 (s, 2H). 
13C NMR (125 MHz, CDCl3): δ = 162.3 (Cq), 158.5 (CH), 134.4 (Cq), 134.1 (Cq), 131.7 (Cq), 128.4 
(CH), 128.2 (CH), 128.1 (CH), 127.0 (CH), 126.7 (Cq, q, 
3JC–F = 2.2 Hz), 126.6 (CH), 126.3 (Cq, q, 
1JC–F = 277.1 Hz), 123.6 (CH), 112.1 (CH), 36.7 (CH2, q, 
2JC–F = 30.2 Hz). 
19F NMR (283 MHz, CDCl3): δ = -64.59 (t, J = 10.8 Hz). 
IR (neat): ν͂ = 3206, 3008, 2929, 1589, 1448, 1265, 1140, 1064, 812, 516 cm-1. 
MS (EI): m/z (relative intensity) 303 (17) [M+], 282 (2), 263 (9), 232 (5), 220 (100), 192 (2). 
HR-MS (EI): m/z calcd for C16H12F3N3 [M
+] 303.0983, found 303.0974. 
 
Synthesis of 1-[(Difluoromethyl)sulfonyl]-N-(2-fluorophenyl)pyrimidin-2(1H)-imine (157a) 
 
The general procedure E2 was followed using 69a (57 mg, 0.3 mmol) and Langlois’ reagent 
(94 mg, 0.6 mmol). After purification by column chromatography (n-hexane/EtOAc 85:18), 
157a (4 mg, 4%) was obtained as a yellow solid. 
M.p.: 130–132 °C 
1H NMR (300 MHz, CDCl3): δ = 8.20 (dd, J = 3.6, 2.5 Hz, 1H), 7.70 (t, J = 60.2 Hz, 1H), 7.56 (dd, 
J = 7.2, 2.5 Hz, 1H), 7.12 – 6.92 (m, 4H), 6.01 (dd, J = 7.2, 3.6 Hz, 1H). 
13C NMR (125 MHz, CDCl3): δ = 163.7 (CH), 154.7 (Cq, d, 
1JC–F = 244.4 Hz), 147.4 (Cq), 138.1 
(CH, t, 4JC–F = 2.6 Hz), 135.3 (Cq, d, 
2JC–F = 11.5 Hz), 124.6 (CH, d, 
4JC–F = 2.4 Hz), 124.1 (CH, d, 
3JC–F = 3.8 Hz), 124.0 (CH, d, 
3JC–F = 7.4 Hz), 115.8 (CH, d, 
4JC–F = 20.5 Hz), 108.6 (CH, t, 
1JC–F = 
255.6 Hz), 102.4 (CH). 
19F NMR (283 MHz, CDCl3): δ = -104.02 (d, J = 60.2 Hz), -124.96 – -125.11 (m). 
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IR (neat): ν͂ = 3503, 3094, 1678, 1568, 1499, 1411, 1310, 1075, 746, 693 cm-1. 
MS (EI): m/z (relative intensity) 217 (3), 188 (40), 170 (100), 136 (5), 109 (4), 85 (11). 
HR-MS (EI): m/z calcd for C10H9FN3 [M+2H-SO2CHF2





H/D exchange experiments with [D]5-69h as the substrate: 
 
Following the general procedure E2 [D]5-69h (176 mg, 1.0 mmol) was reacted with 146 (245 
mg, 1.5 mmol). After 3 h, the reaction was cooled to 0 °C, filtered through a silica pad and 
concentrated in vacuo. Purification by GPC yielded 69h (85 mg, 48%) and 87h (99 mg, 39%). 
87h was isolated as a mixture with a benzylated side-product from reaction with PhMe and 
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Intermolecular KIE Experiment between 69h and [D5]-69h 
 
69h (86 mg, 0.5 mmol), [D5]-69h (88 mg, 0.5 mmol), [(DME)NiCl2] (22 mg, 10 mol %) and 
LiOtBu (160 mg, 2.0 mmol) were placed in a 25 mL sealed tube. The tube was evacuated and 
purged with Ar three times. BDMAE (76 µL, 40 mol %), trifluoroethylbromide 146 (245 mg, 
1.5 mmol) and PhMe (2.0 mL) were added, and the mixture was stirred at 150 °C for 3 h. At 
ambient temperature, CH2Cl2 (2.0 mL) was added and concentrated under reduced pressure. 
Purification of the crude reaction mixture by flash column chromatography and GPC yielded 








Reaction with TEMPO 
 
N-(2-Fluorophenyl)pyrimidin-2-amine (69a) (95 mg, 0.5 mmol), [(DME)NiCl2] (11 mg, 
10 mol %), TEMPO (78 mg, 0.5 mmol) and LiOtBu (80 mg, 1.0 mmol) were placed in a 25 mL 
Schlenk tube. The tube was evacuated and purged with Ar three times. BDMAE (38 µL, 
40 mol %), trifluoroethyl bromide (146) (245 mg, 1.5 mmol) and PhMe (1.5 mL) were then 
added, and the mixture was stirred at 150 °C for 16 h. After cooling to ambient temperature, 
CH2Cl2 (2.0 mL) was added. No conversion was observed through 
19F NMR analysis of the 
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Intermolecular Competition Experiment between 69k and 69l 
 
69k (223 mg, 1.2 mmol), 69l (227 mg, 1.2 mmol), [(DME)NiCl2] (22 mg, 10 mol %) and LiOtBu 
(160 mg, 2.0 mmol) were placed in a 25 mL sealed tube. The tube was evacuated and purged 
with Ar three times. BDMAE (76 µL, 40 mol %), trifluoroethylbromide (146) (163 mg, 
1.0 mmol) and PhMe (2.0 mL) were then added, and the mixture was stirred at 150 °C for 
16 h. At ambient temperature, CH2Cl2 (2.0 mL) was added, and the reaction mixture was 
concentrated under reduced pressure. Analysis of the crude reaction mixture by 19F NMR 
with 29 μL C6F6 as internal standard gave 3% of 87l and 1% of 87k. 
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6 List of Abbreviations 
 

















CPME cyclopentyl methyl ether 
 chemical shift 
d doublet 
DABCO 1,4-diazabicyclo[2.2.2]octane 






ee enantiomeric excess 
EI electron ionization 
ESI electronspray ionization 
Et ethyl 





HR high resolution 
Hz Hertz 
IES internal electrophilic substitution 
IR infrared (spectroscopy) 
J coupling constant 
L ligand 
LDL-C low-density lipoprotein - cholesterol 
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MEM methoxy ethoxyl 
M.p. melting point 
Mes mesityl 
MS mass spectrometry 
MTHP tetrahydro-3-methyl-2H-pyran 
m/z mass-to-charge ratio 
n. d. not determined 
NHC N-heterocyclic carbene 








RRMS relapsing-remitting multiple sclerosis 
s singlet 
SEM [2-(trimethylsilyl)ethoxy]methyl acetal 
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